<SEC-DOCUMENT>0001683168-26-002663.txt : 20260403
<SEC-HEADER>0001683168-26-002663.hdr.sgml : 20260403
<ACCEPTANCE-DATETIME>20260403165843
ACCESSION NUMBER:		0001683168-26-002663
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20260403
DATE AS OF CHANGE:		20260403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AUDDIA INC.
		CENTRAL INDEX KEY:			0001554818
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
		ORGANIZATION NAME:           	06 Technology
		EIN:				454257218
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-294887
		FILM NUMBER:		26838812

	BUSINESS ADDRESS:	
		STREET 1:		1680 38TH STREET
		STREET 2:		SUITE 130
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-219-9771

	MAIL ADDRESS:	
		STREET 1:		1680 38TH STREET
		STREET 2:		SUITE 130
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Clip Interactive, LLC
		DATE OF NAME CHANGE:	20120724
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>auddia_s1.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-roles="http://fasb.org/us-roles/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:AUUD="http://auddia.com/20260402">
<head>
     <title>Auddia Inc. S-1</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_AUUD_auddia.com_20260402 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20260402_20260402 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001554818 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000004" name="dei:EntityCentralIndexKey">0001554818</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="auud-20260402.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-04-02</xbrli:startDate>
        <xbrli:endDate>2026-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 7pt"><a href="#toc">Table
of Contents</a></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange Commission
on April 3, 2026.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_906_edei--DocumentType_c20260402__20260402_zgOEc93CdeRl"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000009" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT<br/>
<i>UNDER</i><br/>
<i>THE SECURITIES ACT OF 1933</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20260402__20260402_zpFseOkzU6Dd"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000010" name="dei:EntityRegistrantName">Auddia Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20260402__20260402_zimJ3dcFgIAb"><ix:nonNumeric contextRef="AsOf2026-04-02" format="ixt-sec:stateprovnameen" id="Fact000011" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</p></td>
    <td style="vertical-align: bottom; width: 34%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>7371</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</p></td>
    <td style="vertical-align: top; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20260402__20260402_zdA6S3ijIz1j"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000012" name="dei:EntityTaxIdentificationNumber">45-4257218</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer Identification Number)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20260402__20260402_zwp3yvoKmU1i"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000013" name="dei:EntityAddressAddressLine1">1680 38th Street, Suite 130</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20260402__20260402_zfKwElNAH16b"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000014" name="dei:EntityAddressCityOrTown">Boulder</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20260402__20260402_zNALFLlU0CD6"><ix:nonNumeric contextRef="AsOf2026-04-02" format="ixt-sec:stateprovnameen" id="Fact000015" name="dei:EntityAddressStateOrProvince">Colorado</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20260402__20260402_zN6f0FOIc2ld"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000016" name="dei:EntityAddressPostalZipCode">80301</ix:nonNumeric></span></b><br/>
<b>(<span id="xdx_90B_edei--CityAreaCode_c20260402__20260402_zggflw0bymu7"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000017" name="dei:CityAreaCode">303</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20260402__20260402_zMzjBpJyC3qd"><ix:nonNumeric contextRef="AsOf2026-04-02" id="Fact000018" name="dei:LocalPhoneNumber">219-9771</ix:nonNumeric></span></b><br/>
(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Jeffrey Thramann</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Executive Officer</b><br/>
<b>Auddia Inc.</b><br/>
<b>1680 38<sup>th</sup> Street, Suite 130</b><br/>
<b>Boulder, Colorado 80301</b><br/>
<b>(303) 219-9771</b><br/>
(Name, address, including zip code, and telephone number, including area code, of agent for service)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: center; font-size: 10pt; width: 33%">&#160;</td>
    <td style="text-align: center; font-size: 10pt; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer L. Porter, Esq.</span></td>
    <td style="text-align: center; width: 33%">Rick Werner</td></tr>
  <tr>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James H. Carroll, Esq.</span></td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin Platt, Esq.</span></td>
    <td style="text-align: center">Alla Digilova</td></tr>
  <tr>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carroll Legal LLC</span></td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwin Procter LLP</span></td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haynes and Boone, LLP</p></td></tr>
  <tr>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1449 Wynkoop Street, Suite 507</span></td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3025 John F. Kennedy Boulevard</span></td>
    <td style="text-align: center">30 Rockefeller Plaza, 26th Floor</td></tr>
  <tr>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver, CO 80202</span></td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</span></td>
    <td style="text-align: center">New York, New York 10112</td></tr>
  <tr>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(303) 888-4859</span></td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(445) 207-7806</span></td>
    <td style="text-align: center">(212) 659-7300</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approximate date of commencement of the proposed
sale to the public: As soon as practicable after the effective date of this Registration Statement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20260402__20260402_z029KdqnPFkb"><ix:nonNumeric contextRef="AsOf2026-04-02" format="ixt-sec:entityfilercategoryen" id="Fact000019" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntitySmallBusiness_c20260402__20260402_zoZkQgVK4iz6"><ix:nonNumeric contextRef="AsOf2026-04-02" format="ixt:booleantrue" id="Fact000020" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20260402__20260402_zITwKr3UGsK1"><ix:nonNumeric contextRef="AsOf2026-04-02" format="ixt:booleantrue" id="Fact000021" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(b) of the Securities Act. <span id="xdx_90A_edei--EntityExTransitionPeriod_c20260402__20260402_zWci70ZS9O8b"><ix:nonNumeric contextRef="AsOf2026-04-02" format="ixt:booleanfalse" id="Fact000022" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section 8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red"><b>The information in this preliminary prospectus
is not complete and may be changed. We may not sell the securities until the Registration Statement filed with the Securities and Exchange
Commission, of which this prospectus is a part, is effective. This preliminary prospectus is not an offer to sell these securities and
is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Preliminary
    Prospectus</b></span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>Subject to
    Completion, dated April 3, 2026</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AUDDIA INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 2,201,834 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 2,201,834 Pre-Funded Warrants to Purchase
Shares of Up to 2,201,834 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 2,201,834 Common Warrants to Purchase
Up to 2,201,834 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 4,403,668 Shares of Common Stock underlying
Pre-Funded Warrants and Common Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering up to 2,201,834 shares of our
common stock, par value $0.001 per share (&#8220;common stock&#8221;), or up to 2,201,834 pre-funded warrants to purchase up to 2,201,834
shares of common stock (&#8220;Pre-Funded Warrants&#8221;) in lieu thereof, and up to 2,201,834 accompanying common warrants to purchase
up to 2,201,834 shares of our common stock (&#8220;Common Warrants&#8221;). Each share of common stock (or a pre-funded warrant in lieu
thereof) is being offered and sold together with an accompanying Common Warrant to purchase one share of common stock at an assumed combined
public offering price of $5.45. This prospectus also relates to the offering of the shares of our common stock issuable upon the exercise
of such Pre-Funded Warrants and Common Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Common Warrant will have an assumed exercise
price of $5.45 per share (which will be no less than 100% of the assumed combined public offering price per share and common warrants
to be sold in this offering), be immediately exercisable and will expire upon the earlier of: (i) the 5-year anniversary of the date of
issuance; or (ii) the consummation of the transactions contemplated by certain Agreement and Plan of Merger, as may be amended, dated
as of February 17, 2026, by and among, McCarthy Finney, Inc., Auddia Merger Sub, Inc., Thramann Merger Sub LLC, and us (the &#8220;Merger&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock and the accompanying
Common Warrants are immediately separable and will be issued separately, but can only be purchased together in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;AUUD.&#8221; On April 1, 2026, the last reported sale price of our shares of common
stock on the Nasdaq Capital Market was $5.45 per share. All share, Common Warrant and Pre-Funded Warrant numbers are based on an assumed
combined public offering price of $5.45 per share and the accompanying Common Warrants and $5.45 per Pre-Funded Warrant and the accompanying
Common Warrants, based on the closing price of the Company&#8217;s Common Stock on April 1, 2026 as reported on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading market
for the Pre-Funded Warrants or the Common Warrants, and we do not expect a market to develop. We do not intend to list the Pre-Funded
Warrants or the Common Warrants on The Nasdaq Capital Market or any other national securities exchange or nationally recognized trading
system. Without an active trading market, the liquidity of the Pre-Funded Warrants or the Common Warrants will be limited. We anticipate
that the shares of our Common Stock to be issued upon exercise of the Common Warrants and the Pre- Funded Warrants will trade on The Nasdaq
Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also offering to certain purchasers whose
purchase of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties,
beneficially owning more than 4.99% of our outstanding shares of common stock immediately following the consummation of this offering,
the opportunity to purchase, if any such purchaser so chooses, Pre-Funded Warrants in lieu of common stock that otherwise would result
in such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares
of common stock. The assumed combined public offering price of each Pre-Funded Warrant with an accompanying Common Warrant is $5.45, the
closing price of the Company&#8217;s Common Stock on April 1, 2026 as reported on the Nasdaq Capital Market, minus $0.001, and the exercise
price of each Pre-Funded Warrant will be $0.001 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at
any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell, the number of shares of common
stock we are offering will be decreased on a one-for-one basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumed combined public offering price used throughout
this prospectus has been included for illustration purposes only and may not be indicative of the final offering price. The actual public
offering price for our securities in this offering will be determined at the time of pricing and may be at a discount to the then-current
market price. The final public offering price will be determined through negotiation between us and investors based upon a number of factors,
including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience
of our executive officers and the general condition of the securities markets at the time of this offering. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, together with
additional information described under the heading &#8220;<a href="#s_016">Where You Can Find More Information</a>&#8221; carefully before you invest in any
of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INVESTING IN OUR SECURITIES INVOLVES RISKS.
SEE THE &#8220;<a href="#s_004">RISK FACTORS</a>&#8221; ON PAGE 12 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN ANY DOCUMENT
INCORPORATED BY REFERENCE HEREIN CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company&#8221;
and a &#8220;smaller reporting company&#8221; under the federal securities laws and are subject to reduced public company reporting requirements.
See &#8220;<a href="#s_001">Prospectus Summary</a>&#8211;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This offering <span>will terminate on May 15,
                                                                                                  2026</span>, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will
                                                                                                  have one closing for all the securities purchased in this offering. There is no minimum number of securities or minimum aggregate
                                                                                                  amount of proceeds for this offering to close.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no arrangement for funds to be received
in escrow, trust or similar arrangement. Because there is no escrow account and no minimum offering amount, investors could be in a position
where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in
this offering. Further, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty
about whether we would be able to use such funds to effectively implement our business plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged Dawson James Securities, Inc.
(the &#8220;Placement Agent&#8221;) as our exclusive placement agent in connection with this offering. The Placement Agent is not purchasing
or selling the securities offered by us, and is not required to arrange for the purchase or sale of any specific number or dollar amount
of our securities, but will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus.
We have agreed to pay to the Placement Agent the Placement Agent fees set forth in the table, which assumes that we sell all of the securities
offered by this prospectus. Because there is no minimum offering amount required as a condition to closing in this offering, the actual
aggregate public offering price, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be substantially
less than the total maximum offering amounts set forth below and throughout this prospectus. See &#8220;<a href="#s_012">Plan of Distribution</a>&#8221; beginning
on page 32 of this prospectus for more information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share of Common Stock and Accompanying Common Warrant</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Pre-Funded<br/>
Warrant and Accompanying Common Warrant</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent fees<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before expenses)<sup>(2)(3)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#160;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">We have agreed to pay the Placement Agent a cash fee equal to&#8239;7.0% of the aggregate gross proceeds raised in this offering. We also have agreed to reimburse the Placement Agent for certain of its offering-related expenses. See &#8220;</span><span style="font-size: 10pt"><a href="#s_012">Plan of Distribution</a></span><span style="font-size: 10pt">&#8221; for a complete description of the compensation to be received by the Placement Agent.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We estimate the total expenses of this offering payable by us, excluding the Placement Agent fees, will be approximately $250,000. Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">Does not include proceeds from the cash exercise of the Pre-Funded Warrants or Common Warrants, if any.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of the securities is expected to be made
on or about&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;,
2026, subject to satisfaction of certain conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Placement Agent</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 14pt"><b>Dawson
James Securities, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Prospectus dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="toc"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="text-decoration: underline">Page</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 98%"><a href="#s_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: right">10</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market and Industry Data</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_007">Dilution</a></span></td>
    <td style="text-align: right">19</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</span></a></td>
    <td style="text-align: right">20</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters</span></a></td>
    <td style="text-align: right">21</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</span></a></td>
    <td style="text-align: right">22</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities We
    Are Offering</span></a></td>
    <td style="text-align: right">28</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: right">32</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><a href="#s_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material United States Federal Income Tax Considerations</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: right">35</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: right">41</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_015">Experts</a></span></td>
    <td style="text-align: right">42</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</span></a></td>
    <td style="text-align: right">43</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Information by Reference</span></a></td>
    <td style="text-align: right">44</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABOUT THIS PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement we filed with the
Securities and Exchange Commission (the &#8220;SEC&#8221;) includes exhibits that provide more detail of the matters discussed in this
prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein
before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated
by reference herein or any amendment thereto. You should not assume that the information contained in this prospectus or any related
free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information
we have incorporated by reference herein is correct on any date subsequent to the date of the document incorporated by reference, even
though this prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus
contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed or have been incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the
heading &#8220;<a href="#s_016">Where You Can Find More Information</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information that we
have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided
to you. We have not, and the Placement Agent has not, authorized any dealer, salesman or other person to give any information or to make
any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus that
we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference
in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus do not constitute an
offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does
this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in
any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All references to shares of our common stock and
per share information in this prospectus refer to the number of shares of common stock after giving effect to the Reverse Stock Split
(defined below) effectuated on April 1, 2026, unless otherwise stated or the context otherwise requires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the information incorporated
by reference into this prospectus contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience,
trademarks and trade names referred to in this prospectus and the information incorporated by reference into this prospectus, including
logos, artwork, and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to
these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship
with, or endorsement or sponsorship of us by, any other company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span id="s_001"></span><b>Prospectus
Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following summary highlights information
contained elsewhere in this prospectus. This summary is not complete and may not contain all the information you should consider before
investing in our common stock. You should read the entire prospectus, the registration statement of which this prospectus is a part,
and the information incorporated by reference into this prospectus in their entirety, including the &#8220;Risk Factors&#8221; and our
financial statements and the related notes incorporated by reference into this prospectus, before purchasing our securities in this offering.
Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus and the documents incorporated
by reference in this prospectus to &#8220;Auddia,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;
refer to Auddia Inc. This prospectus includes forward-looking statements that involve risks and uncertainties. See &#8220;<a href="#s_003">Information Regarding Forward-Looking Statements.</a>&#8221;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This prospectus includes trademarks, service
marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus are the
property of their respective owners.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an artificial intelligence (&#8220;AI&#8221;)
technology company headquartered in Boulder, CO that is reinventing how consumers engage with audio through the development of our faidr
app, an industry-first audio platform, which utilizes proprietary AI technology to personalize and customize both radio and podcast listening
experiences-and the Discovr Radio platform, a web-based portal that allows artists and record labels to promote songs on radio streams,
through an integration with faidr.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">faidr historically allowed users to listen to
AM/FM radio stations without unwanted commercial breaks. The app replaces these ad breaks in real time with songs supplied by Discovr
Radio, giving artists exposure on mainstream airwaves. The faidr app represents the first-time consumers can combine the local content
uniquely provided by AM/FM radio with commercial-free and personalized listening many consumers demand from digital-media consumption
and preference-based new music discovery. In addition to commercial-free AM/FM, faidr includes podcasts with its Forward+ ad skipping
technology on iOS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combination of AM/FM streaming and new-music
distribution, with our unique, AI technology-driven differentiators, addresses large (radio streamers) and rapidly growing (independent
and emerging artists) audiences and customer bases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have developed our AI platform on top of Google&#8217;s
TensorFlow open-source library that is being &#8220;taught&#8221; to know the difference between all types of audio content on the radio.
For instance, the platform recognizes the difference between a commercial and a song and DJ conversation. Not only does the technology
learn the differences between the various types of audio segments, but it also identifies the beginning and end of each piece of content.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The faidr app with its advanced features allow
users to skip any content heard on the station and request audio content on-demand. We believe the faidr app represents a significant
differentiated audio streaming product, the first to give audio streamers a more personalized middle ground between passive content like
broadcast radio and fully on-demand content like Spotify. No other audio streaming app available today, including category leaders like
TuneIn, iHeart, and Audacy, can compete with faidr&#8217;s full product offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We launched an MVP version of faidr through several
consumer trials in 2021 to measure consumer interest and engagement with the app. The full app launched on February 15, 2022, and included
all major U.S. radio stations in the US. In February 2023, we added faidrRadio, our exclusive content offerings, to the app. Podcasts
were added to the app for the iOS version before the end of Q1 2023 and added to the Android app in May of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We initially launched faidr with a B2C subscription
model in February of 2022 and transitioned to a B2B subscription model in Q1 of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2025, we announced a new B2B business
model with a strategic shift to AI driven music discovery. We are targeting artists and labels for SaaS subscription access to ad-free
AM/FM streaming listeners on the faidr app, while faidr users will enjoy free access to AI driven ad-free AM/FM streams on all music stations.
Consumer subscriptions will no longer be required to enjoy faidr&#8217;s ad-free and content personalization listening experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New music platforms like Bandcamp and SoundCloud
are integral tools for artists to connect with new fans and even monetize their content, but those platforms only cater to a subset of
the total addressable market for an artist. We believe the largest group of potential fans for most artists remains on commercial radio,
listening to music passively and not searching for new artists even though Company surveys and research indicate radio listeners are interested
in hearing new music when listening to their favorite radio stations. Our new Discovr Radio platform delivers the experience of passively
listening to commercial AM/FM radio streams while being exposed to new music instead of radio ads.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unlike other new music discovery platforms, which
allow artists to upload songs in the hopes that new listeners will find them among the other songs available, Discovr Radio delivers guaranteed
plays to artists, leveraging AI to place their songs into radio feeds as part of a custom programming experience and as unique content
during what would typically be an ad break. This gives artists opportunities to be heard by the many millions of streaming radio listeners
worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new Discovr Radio platform consists of a new
AI Placement Engine and Artist Portal. The AI Placement Engine aims to put the right new song in front of the right listener, on the right
station, adjacent to the right artist, to optimize music discovery and the connection between artists and fans. The Artist Portal gives
artists performance analytics on number of total plays, likes and dislikes, demographic data, and facilitate the connection of artists
to their new fans. In addition to streaming songs on live radio streams, the Discovr Radio offering will eventually allow artists and
labels to launch campaigns on streaming apps to promote new songs, albums, and tours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Auddia is evolving its business model from direct-to-consumer
to business-to-business, shifting its focus from individual radio-streaming subscribers to artists and labels as subscribers. Through
a modest monthly subscription, artist and label customers gain guaranteed radio plays-offering a new channel for music promotion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The faidr mobile App is available today through
the iOS and Android App stores and the MVP version of the Discovr Radio platform was released on January 20, 2026. The MVP is expected
to be supported by a pilot program of participating customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the release of Discovr Radio, participating
artists are seeing an average of 116 plays over radio per week. In addition to plays and likes, faidr users have been engaging with artists
through visits to artists pages and clicking on outbound links. As of February 12, 2026, artist pages are seeing an average 30% clickthrough
rate, meaning nearly a third of all artist-page visits results in a user clicking to listen to the artist&#8217;s full library elsewhere,
or following them on socials, or buying the artist&#8217;s merch, tickets, or music.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reverse Stock Split </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2026, our common stock began trading
on a split-adjusted basis on Nasdaq as a result of a reverse stock split of our common stock at a ratio of 1-for-7.7 (the &#8220;Reverse
Stock Split&#8221;). Such split was approved by our Board of Directors (the &#8220;Board&#8221;) and our stockholders. The Reverse Stock
Split was legally effective at 5:00 p.m.  Eastern Time on March 31, 2026. Trading of our common stock on the Nasdaq Stock Market commenced
on a split-adjusted basis at market open on April 1, 2026, under the existing trading symbol &#8220;AUUD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Reverse Stock Split, every
7.7 shares of our common stock issued or outstanding was automatically reclassified into one validly issued, fully-paid and non-assessable
new share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fractional shares were issued in connection
with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock
Split will automatically be entitled to receive an additional fraction of a share of our common stock to round up to the next whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proportional adjustments will also be made to the number of shares
of common stock awarded and available for issuance under our equity incentive plans, as well as the exercise price and the number of shares
issuable upon the exercise or conversion of our outstanding convertible preferred stock, stock options, restricted stock units and other
equity securities under our equity incentive plans. All outstanding warrants will also be adjusted in accordance with their terms, which,
among other changes to the warrant terms, resulted in proportionate adjustments being made to the number of shares issuable upon exercise
of such warrants and to the exercise and redemption prices of such warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proposed Business Combination</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2025, we issued a press release announcing
that we had entered into a non-binding letter of intent (&#8220;LOI&#8221;) for a proposed business combination with Thramann Holdings,
LLC (&#8220;Holdings&#8221;). Holdings is a privately held holding company that controls LT350, Influence Healthcare, and Voyex, three
early stage AI-native companies founded by Jeff Thramann, Auddia&#8217;s founder, Chief Executive Officer and Executive Chairman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established a special committee of independent
directors to evaluate the related party transaction. The special committee has engaged its own counsel and financial advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2026, acting upon the recommendation
of its special committee of independent directors, we entered into a definitive merger agreement for a business combination with Holdings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon closing of the proposed transaction, the
Company would be renamed &#8220;McCarthy Finney&#8221; and would trade under its new &#8220;MCFN&#8221; ticker symbol. Auddia would become
a wholly owned subsidiary of McCarthy Finney, and each of the three Holdings entities would also be wholly owned by McCarthy Finney. Jeff
Thramann would remain as CEO of McCarthy Finney and John Mahoney would remain as CFO. Auddia&#8217;s current board members are expected
to continue as members of the board of the combined company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Auddia shareholders at the time of closing are
expected to own a 20% economic interest of McCarthy Finney, with an 80% economic interest of the combined company expected to be owned
at closing by Jeff Thramann. Under certain circumstances, these ownership percentages may be adjusted upward or downward based on the
level of Auddia&#8217;s cash at closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consideration to be paid to Thramann Holdings
in the proposed transaction will consist of (i) shares of McCarthy Finney convertible preferred stock and (ii) $3.5 million aggregate
principal amount of McCarthy Finney notes with a two year maturity date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The closing of the merger will be conditioned,
among other customary closing conditions, on Auddia having at least $12 million cash on hand at closing in order to provide cash runway
to fund McCarthy Finney to key future business milestones. There can be no assurances as to Auddia&#8217;s level of cash at closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction has been unanimously approved
by the board of directors of both companies. In connection with the approval of the merger agreement, Houlihan Capital provided a fairness
opinion to Auddia&#8217;s special committee and board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed transaction is expected to close
in the second quarter of 2026, subject to customary closing conditions, including approvals by the Auddia stockholders, the effectiveness
of the S-4 registration statement to be filed with the SEC to register the shares of McCarthy Finney stock to be issued in connection
with the merger, and the continued listing of the combined company&#8217;s common stock on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed business combination is subject to
a number of known and unknown risks and uncertainties. There can be no assurances that such business combination will be approved by stockholders
or will ultimately be consummated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information about the business combination
transaction, please see Auddia&#8217;s Current Report on Form 8-K filed with the SEC on February 17, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Mergers and Acquisitions
Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exploring various merger and acquisition
options as part of a broader strategy which aims to scale our business more rapidly; accelerate user adoption and subscriber growth; enter
new markets (international); and open new pathways toward raising capital. The overall strategy focuses on three areas: (1) acquiring
retained customers of the Discovr Radio platform to generate significant subscription revenue, (2) acquiring retained users of faidr to
supply the audience to Discovr Radio customers and (3) scaling the faidr userbase and the Discovr Radio customer base once we&#8217;ve
achieved product-market fit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Deficiency Notices</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2022, 2023 and 2024, the Company received
notices from Nasdaq indicating that the Company was not in compliance with (i) Nasdaq Listing Rule 5550(b)(1), which requires companies
listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders&#8217; equity for continued listing or (ii) Nasdaq
Listing Rule 5550(a)(2) which requires companies listed on The Nasdaq Stock Market to maintain a minimum of a $1.00 bid price for continued
listing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2024, we received a letter from Nasdaq
indicating that we had regained compliance with the equity requirement in Listing Rule 5550(b) (1). We will be subject to a Mandatory
Panel Monitor for a period of one year from the date of the letter in accordance with application of Listing Rule 5815(d)(4)(B).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2024, we received a written notice
from Nasdaq indicating that we were not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)
for continued listing. The bid price notice does not result in the immediate delisting of our common stock from the Nasdaq Capital Market.
The bid price notice indicated that we have 180 calendar days (or until April 14, 2025) in which to regain compliance. If at any time
during this 180 calendar day period the bid price of our common stock closes at or above $1.00 per share for a minimum of ten consecutive
business days, the Nasdaq staff will provide us with a written confirmation of compliance and the matter will be closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2025, Nasdaq notified us that we
were in compliance with the $1.00 minimum bid price requirement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reverse Stock Splits</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the Reverse Stock Split, on February
27, 2024, we effectuated a 1-for-25 reverse stock split and on March 28, 2025, we effectuated a 1-for-17 reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reverse stock splits did not change the authorized
number of shares of our common stock. No fractional shares were issued and any fractional shares resulting from the reverse stock splits
were rounded up to the nearest whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reverse stock splits applied to our outstanding
warrants, stock options and restricted stock units. The number of shares of common stock into which these outstanding securities are convertible
or exercisable were adjusted proportionately as a result of the reverse stock splits. The exercise prices of any outstanding warrants
or stock options were also proportionately adjusted in accordance with the terms of those securities and our equity incentive plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Associated with Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves a high
degree of risk. You should carefully consider the risks described in &#8220;<a href="#s_004">Risk Factors</a>&#8221; beginning on
page 12 before making a decision to invest in our common stock. If any of these risks actually occurs, our business, financial
condition, results of operations and prospects would likely be materially, adversely affected. In that event, the trading price of
our common stock could decline, and you could lose part or all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our working capital deficiency, stockholders&#8217;
deficit, and recurring losses from operations raise substantial doubt about our ability to continue as a going concern. As a result, our
independent registered public accounting firm included an explanatory paragraph in its report on our financial statements for the year
ended December 31, 2025 with respect to this uncertainty. Our ability to continue as a going concern will require us to obtain additional
funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our existing cash was $3,186,985 at December 31,
2025. We secured approximately $7.1 million in additional financing in 2025 and $0.9 million year-to-date through March 30, 2026,
which will only be sufficient to fund our current operating plans into the second quarter of 2026. We have based these estimates, however,
on assumptions that may prove to be wrong. We will need additional funding to complete the development of our full product line and scale
products with a demonstrated market fit. Management has plans to secure such additional funding. If we are unable to raise capital when
needed or on acceptable terms, we would be forced to delay, reduce, or eliminate our technology development and commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our recurring losses from operations,
and the need for additional financing to fund our operating and capital requirements, there is uncertainty regarding our ability to maintain
liquidity sufficient to operate its business effectively, which raises substantial doubt as to our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an &#8220;emerging growth company&#8221;
as defined in the Jumpstart our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). An emerging growth company may take advantage
of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inclusion of only two years, as compared to three years, of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;) requiring mandatory audit firm rotation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure about executive compensation arrangements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these provisions until
we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal
year (a) following the fifth anniversary of the completion of our February 2021 initial public offering, (b) in which we have total annual
gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of
our common stock that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal year&#8217;s second fiscal quarter,
and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on these criteria, our emerging growth company
status is currently expected to expire on December 31, 2026, unless it earlier meets one of the disqualifying conditions described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have taken advantage of the reduced reporting
requirements in this prospectus and in the documents incorporated by reference into this prospectus. Accordingly, the information contained
herein may be different from the information you receive from other public companies that are not emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JOBS Act permits an emerging growth company
such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public
companies until those standards would otherwise apply to private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, we are a &#8220;smaller reporting
company&#8221; as defined in Item 10(f)(1) of Regulation S-K. We will remain a smaller reporting company until the last day of the fiscal
year in which either (i) the market value of the shares of our common stock held by non-affiliates exceeds $250 million as of the last
business day of our most recently completed second fiscal quarter and (ii) our annual revenue exceeded $100 million during such completed
fiscal year or the market value of the shares of our common stock held by non-affiliates exceeds $700 million as of as of the last business
day of our most recently completed second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging
growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements
in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations
regarding executive compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were originally formed as Clip Interactive,
LLC in January 2012, as a limited liability company under the laws of the State of Colorado. Immediately prior to our initial public offering
in February 2021, we converted into a Delaware corporation pursuant to a statutory conversion and were renamed Auddia Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
1680 38<sup>th</sup> Street, Suite 130, Boulder, CO 80301. Our main telephone number is (303) 219-9771. Our internet website is www.auddia.com.
The information contained in, or that can be accessed through, our website is not incorporated by reference and is not a part of this
prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trademarks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hold the trademark for &#8220;AUDDIA&#8221;
which is used as the corporate brand name, as well as &#8220;FAIDR&#8221; which is used as the name of the consumer-facing mobile application
that delivers our commercial free radio service. We have omitted the <sup>&#174;</sup> and &#8482; designations, as applicable, for the
trademarks used in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_002"></span><span style="text-transform: uppercase"><b>The
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-size: 10pt">Securities Offered by Us</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 79%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Up to 2,201,834 shares of common stock in the
    aggregate, represented by up to 2,201,834 shares of common stock, or up to 2,201,834 Pre-Funded Warrants to purchase up to&#8239;2,201,834
    shares of common stock, and up to 2,201,834 accompanying Common Warrants to purchase up to 2,201,834 shares of our common stock.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Common Warrant will have an assumed
    exercise price of $5.45 per share (which will be no less than 100% of the assumed combined public offering price per share and common
    warrants to be sold in this offering), be immediately exercisable and will expire upon the earlier of: (i) the 5-year anniversary of
    the date of the date of issuance; or (ii) the consummation of the Merger.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus also relates to the offering of
    shares of common stock issuable upon exercise of the Common Warrants issued in this offering. The shares of common stock and the accompanying
    Common Warrants, can only be purchased together in this offering but will be issued separately and will be immediately separable upon
    issuance.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Common Stock Outstanding Prior to this Offering</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">500,876 shares of common stock issued and outstanding as of April 1, 2026.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Assumed Combined Public Offering Price</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The assumed combined public offering price for each share of common stock and accompanying Common Warrant is $5.45, assuming the offering price is equal to the closing price of our common stock on April 1, 2026. The assumed combined public offering price of each Pre-Funded Warrant with an accompanying Common Warrant is $5.45, the closing price of the Company&#8217;s Common Stock on April 1, 2026 as reported on the Nasdaq Capital Market, minus $0.001.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Pre-Funded Warrants</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">We are offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding shares of common stock immediately following the closing of this offering, the opportunity to purchase, if such purchasers so choose, Pre-Funded Warrants, in lieu of shares of common stock that would otherwise result in any such purchaser&#8217;s beneficial ownership, together with its affiliates and certain related parties, exceeding 4.99% (or, at the election of such purchaser, 9.99%) of our outstanding shares of common stock immediately following the consummation of this offering.&#8239;&#8239;The assumed combined public offering price of each Pre-Funded Warrant with an accompanying Common Warrant is $5.45, the closing price of our common stock on April 1, 2026 as reported on the Nasdaq Capital Market, minus $0.001, the exercise price of each Pre-Funded Warrant.&#8239;&#8239;Each Pre-Funded Warrant is immediately exercisable and may be exercised at any time until it has been exercised in full.&#8239;&#8239;For each Pre-Funded Warrant we sell, the number of shares of common stock that we are offering will be decreased on a one-for-one basis.&#8239;&#8239;This offering also relates to the shares of common stock issuable upon exercise of any Pre-Funded Warrants sold in this offering..</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Common Stock to be Outstanding After this Offering</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Up to 2,702,710 shares of common stock, assuming no exercise of the Common Warrants included in this offering, and also assuming no sales of Pre-Funded Warrants which, if sold, would reduce the number of shares of common stock to be outstanding after this offering on a one-for-one basis.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Reasonable Best Efforts Offering</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have agreed to issue and sell the securities offered hereby to the purchasers through the Placement Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;</span><span style="font-size: 10pt"><a href="#s_012">Plan of Distribution</a></span><span style="font-size: 10pt">&#8221; beginning on page 32 of this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 7; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate
    that the net proceeds to us from this offering will be approximately $11.2 million, based on an assumed public offering price of
    $5.45 per share and accompanying Common Warrant, which is the last reported sales price of our common stock on Nasdaq on April 1, 2026, and after deducting
    estimated Placement Agent fees and estimated offering expenses payable by us, assuming no sale of Pre-Funded Warrants and assuming
    the maximum number of shares are sold in this offering and excluding the proceeds, if any, from the exercise of the Common Warrants.
    We intend to use the net proceeds from this offering to fund working capital and general corporate purposes. Because this is a
    reasonable best efforts offering with no minimum amount as a condition to closing, we may not sell all or any of the securities
    offered hereby. As a result, we may receive significantly less in net proceeds than we currently estimate. See &#8220;<a href="#s_006">Use
    of Proceeds</a>&#8221; beginning on page 18 of this prospectus.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Capital Market Symbol</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock &#8220;AUUD&#8221;. Currently, there
    is no public market for the Pre-Funded Warrants or the Common Warrants. We do not intend to list the Pre-Funded Warrants or the Common
    Warrants on Nasdaq or any other national securities exchange or nationally recognized trading system.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without an active trading market, the liquidity
    of the warrants will be limited. See &#8220;<a href="#s_011">Description of Securities We Are Offering.</a>&#8221;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves a high
    degree of risk. See &#8220;<a href="#s_004">Risk Factors</a>&#8221; beginning on page 12 of this prospectus for a discussion of
    factors you should carefully consider before deciding to invest in our securities.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading market
    for the Common Warrants, and we do not expect a market to develop. We do not intend to list the Common Warrants on The Nasdaq Capital
    Market or any other national securities exchange or nationally recognized trading system.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares outstanding after this offering
is based on 500,876 shares of our common stock outstanding as of April 1, 2026, and excludes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32 shares of our common stock reserved for issuance under outstanding stock options granted under our 2013 Equity Incentive Plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,421 shares of our common stock reserved for issuance under outstanding stock options granted under our 2020 Equity Incentive Plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,472 shares of our common stock reserved for future grant under our 2020 Equity Incentive Plan;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify; width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">187 shares of our common stock reserved for issuance under outstanding stock options granted as employment inducement awards to current executives outside of our 2013 Equity Incentive Plan and 2020 Equity Incentive Plan;</span></td></tr>
</table>



<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify; width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,306 shares of common stock reserved for issuance upon the exercise of outstanding common stock warrants;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,214 shares of common stock reserved for issuance upon the conversion of our Series C convertible Preferred Stock including accrued capitalized dividends;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,393 shares of common stock reserved for issuance upon the exercise of warrants sold in private placements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">up to 672,918 shares of common stock registered for issuance that may be sold in the future by the Company to White Lion Capital pursuant to the Common Stock Purchase Agreement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated, all information contained in this prospectus
assumes or gives effect to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<tr style="vertical-align: top">
  <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
  <td style="width: 98%">no exercise of the options or warrants described above;</td></tr>

<tr style="vertical-align: top">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
  <td style="text-align: justify">no sale of any Pre-Funded Warrants in this offering, which, if sold, would reduce the number of shares of common stock that we are offering
on a one-for-one basis; and</td></tr>

<tr style="vertical-align: top">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
  <td>no exercise of any Common Warrants issued in this offering.</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_003"></span><span style="text-transform: uppercase"><b>Information
Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This prospectus and the
documents incorporated by reference in this prospectus contain forward-looking statements that involve risks and uncertainties. We make
such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other
federal securities laws. All statements other than statements of historical facts contained in this prospectus and the documents incorporated
by reference in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;,
&#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221;
or the negative of these terms or other comparable terminology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.8pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Forward-looking statements
are neither historical facts nor assurances of future performance, and are based only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future
conditions. Forward-looking statements appear in a number of places throughout this prospectus and the documents incorporated by reference
in this prospectus, and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our
commercialization objectives, prospects, strategies, the industry in which we operate and potential collaborations. We derive many of
our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to
predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Important
factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements
include, among others, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.8pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sufficiency of our existing cash to meet our working capital and capital expenditure needs over the next 12 months and our need to raise additional capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to generate revenue from new software services;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our limited operating history;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain proper and effective internal financial controls;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue to operate as a going concern;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws, government regulations and policies and interpretations thereof;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain protection for our intellectual property;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk of errors, failures or bugs in our platform or products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract and retain qualified employees and key personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manage our rapid growth and organizational change effectively;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of security vulnerabilities, cyberattacks and network disruptions, including breaches of data security and privacy leaks, data loss, and business interruptions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our compliance with data privacy laws and regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to develop and maintain our brand cost-effectively; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to complete the proposed business combination;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain the listing of our common stock on the Nasdaq Stock Market;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our use of proceeds from this offering; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the other factors set forth elsewhere in (i) this prospectus, (ii) Part I, Item 1A, &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2025 and (iii) the other documents incorporated by reference in this prospectus.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements speak only as
of the date of the document in which they are made and are subject to business and economic risks. We do not undertake any obligation
to update or revise the forward-looking statements to reflect events that occur or circumstances that exist after the date on which such
statements were made, except to the extent required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, the documents
incorporated by reference in this prospectus, and the documents that we reference in this prospectus and have filed with the SEC as exhibits
to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity,
performance and other events and circumstances may be materially different from what we expect. In addition, even if our results of operations,
financial condition, business and prospects are consistent with the forward-looking statements contained in this prospectus, those results
may not be indicative of results in subsequent periods.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read and consider the information set
forth in the section titled &#8220;Risk Factors,&#8221; together with all of the other information included in or incorporated by reference
in this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_004"></span><span style="text-transform: uppercase"><b>Risk
Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investing in our securities involves a high
degree of risk. You should carefully consider the risks and uncertainties described below, together with the risks set forth under the
section titled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2025, which is incorporated
by reference herein. You should also refer to the other information contained in this prospectus, and the documents incorporated by reference
herein including our financial statements and the related notes, and the section titled &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2025,
before deciding to invest in our securities. The risks and uncertainties described below are not the only risks or uncertainties that
we face. Other sections of this prospectus may include additional factors which could adversely affect our business, results of operations
and financial performance. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may
also become important factors that affect us. If any of the following risks actually occurs, our business, financial condition, results
of operations and prospects could be materially and adversely affected, the trading price of our common stock could decline and you could
lose all or part of your investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to this Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>You will experience immediate dilution as a result of this offering.
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You will incur immediate dilution as a result of this
offering. Based on the assumed public offering price of $5.45 per share and accompanying Common Warrant, which is the last reported sales
price of our common stock on Nasdaq on April 1, 2026 (and assuming (1) no exercise of the Common Warrants being offered in this offering
and that the Common Warrants are classified as and accounted for as equity and (2) no sale of any pre-funded warrants), purchasers of
common stock (or pre-funded warrants in lieu of common stock) in this offering will experience immediate dilution of $0.22 per share in
net tangible book value of the common stock. See the section titled &#8220;<a href="#s_007">Dilution</a>&#8221; for a more detailed description of the dilution
to new investors in the offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>This is a reasonable best efforts offering,
in which no minimum number or dollar amount of securities is required to be sold, and we may not raise the amount of capital we believe
is required for our business plans.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent has agreed to use its reasonable
best efforts to solicit offers to purchase the securities in this offering. The Placement Agent has no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum
number of securities that must be sold as a condition to completion of this offering, and there can be no assurance that the offering
contemplated hereby will ultimately be consummated. Even if we sell securities offered hereby, because there is no minimum offering amount
required as a condition to the closing of this offering, the actual offering amount is not presently determinable and may be substantially
less than the maximum amount set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce
the amount of proceeds received by us. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term
and may need to raise additional funds, which may not be available at all or on terms acceptable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future offerings of debt or equity securities,
which could rank senior to our common stock, may materially and adversely affect the market price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we decide to issue debt or equity securities
in the future, which could rank senior to our common stock, it is likely that such securities will be governed by an indenture or other
instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that we
issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in dilution
to owners of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future issuances and sales of debt or equity securities,
or the perception that such issuances and sales could occur, may cause prevailing market prices for our common stock to decline and may
adversely affect our ability to raise additional capital in the financial markets at times and prices favorable to us. We and, indirectly,
our stockholders will bear the cost of issuing and servicing such securities. Since our decision to issue debt or equity securities in
any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing
or nature of our future offerings. Therefore, holders of our common stock will bear the risk of our future offerings reducing the market
price of our common stock and diluting the value of their stock holdings in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience future dilution as a
result of future equity offerings.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to raise additional capital, we may in
the future offer additional shares of common stock or other securities convertible into or exchangeable for our shares of common stock
that could result in further dilution to investors purchasing our shares in this offering or result in downward pressure on the price
of our shares of common stock. We may sell shares of common stock or other securities in any other offering at prices that are higher
or lower than the prices paid by investors in this offering, and investors purchasing shares or other securities in the future could have
rights superior to existing shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Pre-Funded Warrants and Common Warrants
being issued in this offering will be exercisable for common stock, the exercise of which would increase the number of shares eligible
for future resale in the public market and result in dilution to our stockholders. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering to each purchaser whose purchase
of shares of our common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related
parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of common stock immediately
following consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-Funded Warrants to purchase shares
of common stock in lieu of shares of common stock. Each Pre-Funded Warrant will be exercisable for one share of our common stock. The
purchase price of each Pre-Funded Warrant will equal the price per share of common stock being sold to the public in this offering, minus
$0.001, and the exercise price of each Pre-Funded Warrant will be $0.001 per share. Additionally, we are offering up to 2,201,834 accompanying
Common Warrants to purchase up to 2,201,834 shares of our common stock. To the extent such Pre-Funded Warrants and Common Warrants are
exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and
increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market
could adversely affect the market price of our common stock, the impact of which increases as our stock price increases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is no public market for the Pre-Funded
Warrants or Common Warrants being offered in this offering.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading market
for the Pre-Funded Warrants or Common Warrants being offered in this offering, and we do not expect a market to develop. In addition,
we do not intend to list the Pre-Funded Warrants or Common Warrants on The Nasdaq Capital Market or any other national securities exchange
or nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants or the Common Warrants
will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of the Pre-Funded Warrants and/or
the Common Warrants, as applicable, will have no rights as common stockholders unless and until such holders exercise their Pre-Funded
Warrants and/or Common Warrants, as applicable, for shares of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless and until holders of the Pre-Funded Warrants
or the Common Warrants exercise such Pre-Funded Warrants and Common Warrants, respectively, and acquire shares of our common stock, such
holders will have no rights with respect to the shares of our common stock underlying such Pre-Funded Warrants and Common Warrants, except
for the right to participate in certain dividends and distributions. Upon exercise of the Pre-Funded Warrants and/or Common Warrants,
the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after
the exercise date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Common Warrants are speculative in nature.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Common Warrants may exercise
their right to acquire the common stock and pay an assumed exercise price per share equal to $5.45, subject to certain adjustments, prior
to three years from the date of issuance, after which date any such unexercised Common Warrants will expire and have no further value.
Moreover, following this offering, the market value of the Common Warrants, if any, is uncertain and there can be no assurance that the
market value of such Common Warrants will equal or exceed their imputed offering price. There can be no assurance that the market price
of the common stock will ever equal or exceed the exercise price of the Common Warrants, and consequently, it may not ever be profitable
for holders of such warrant to exercise them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive any additional funds
upon the exercise of the Common Warrants.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant may be exercised by way of a cashless
exercise if at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein
is not available for the issuance of, the shares underlying the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Resales of our common stock in the public
market by our stockholders as a result of this offering may cause the market price of our common stock to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of a significant number of shares of our
common stock could occur at any time. The issuance of new shares of our common stock could result in resales of our common stock by our
current stockholders concerned about the potential dilution of their holdings. In turn, these resales could have the effect of depressing
the market price for our common stock and the value of the Pre-Funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>This offering may cause the trading price
of our common stock to decrease.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The price per share of common stock, together
with the number of shares of common stock we propose to issue and ultimately will issue if this offering is completed, may result in an
immediate decrease in the market price of our common stock. This decrease may continue after the completion of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Significant holders or beneficial owners
of our common stock may not be permitted to exercise the Pre-Funded Warrants that they hold.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A holder of the Pre-Funded Warrants will not be
entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause the aggregate number
of shares of our common stock beneficially owned by such holder, together with its affiliates and certain related parties, to exceed 4.99%
(or, at the election of the purchaser, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect
to the exercise. As a result, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock at a time when it
would be financially beneficial for you to do so. In such a circumstance, you could seek to sell your Pre-Funded Warrants to realize value,
but you may be unable to do so in the absence of an established trading market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will not receive any meaningful amount
of additional funds upon the exercise of the Pre-Funded Warrants.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Pre-Funded Warrant will be exercisable until
it is fully exercised and by means of payment of the nominal cash purchase price upon exercise or by means of a &#8220;cashless exercise&#8221;
according to a formula set forth in the Pre-Funded Warrant. Accordingly, we will not receive any meaningful additional funds upon the
exercise of the Pre-Funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have broad discretion in the use of the
net proceeds from this offering and may not use them effectively, which could affect our results of operations and cause our stock price
to decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion as to
the use of the net proceeds from this offering, including for any of the purposes described in the section titled &#8220;Use of Proceeds&#8221;.
Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have
the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that
the proceeds will be invested in a way that does not yield a favorable, or any, return for us. In addition, pending their use, we may
invest the net proceeds from this offering in a manner that does not produce income or that loses value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Industry Regulatory Authority
(&#8220;FINRA&#8221;) sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our securities.&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 30, 2020, the SEC implemented Regulation
Best Interest requiring that &#8220;a broker, dealer, or a natural person who is an associated person of a broker or dealer, when making
a recommendation of any securities transaction or investment strategy involving securities (including account recommendations) to a retail
customer, shall act in the best interest of the retail customer at the time the recommendation is made, without placing the financial
or other interest of the broker, dealer, or natural person who is an associated person of a broker or dealer making the recommendation
ahead of the interest of the retail customer.&#8221; This is a significantly higher standard for broker-dealers to recommend securities
to retail customers than before under FINRA &#8220;suitability rules.&#8221; FINRA suitability rules do still apply to institutional investors
and require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment
is suitable for that customer. Prior to recommending securities to their customers, broker-dealers must make reasonable efforts to obtain
information about the customer&#8217;s financial status, tax status, investment objectives and other information, and for retail customers
determine the investment is in the customer&#8217;s &#8220;best interest&#8221; and meet other SEC requirements. Both SEC Regulation Best
Interest and FINRA&#8217;s suitability requirements may make it more difficult for broker-dealers to recommend that their customers buy
speculative, low-priced securities. They may affect investing in our Common Stock, which may have the effect of reducing the level of
trading activity in our securities. As a result, fewer broker-dealers may be willing to make a market in our Common Stock, reducing a
stockholder&#8217;s ability to resell our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Purchasers who purchase our securities in
this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit
of a securities purchase agreement.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to rights and remedies available to
all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement
will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those
investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not
limited to: (i) timely delivery of shares and (ii) indemnification for breach of contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Financial Position and
Need For Additional Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our auditors have expressed substantial
doubt about our ability to continue as a going concern, which may hinder our ability to obtain further financing.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our past working capital deficiency, stockholders&#8217;
deficit and recurring losses from operations raised substantial doubt about our ability to continue as a going concern. As a result, our
independent registered public accounting firm has included an explanatory paragraph in its report on our financial statements for the
year ended December 31, 2025 with respect to this uncertainty. We had existing cash of $3,186,985 at December 31, 2025. We secured
approximately $7.1 million in additional financing in 2025 and $0.9 million year-to-date through April 1, 2026, which will only be sufficient
to fund our current operating plans into the second quarter of 2026. We will need additional funding to complete the development of our
full product line and scale products with a demonstrated market fit. Management has plans to secure such additional funding. If we are
unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce, or eliminate our technology development
and commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to continue our current
listing of our common stock on the Nasdaq Capital Market. A delisting of our common stock from Nasdaq could limit the liquidity of our
stock, increase its volatility and hinder our ability to raise capital.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to satisfy the requirements
for the continued listing of our common stock on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2022, 2023 and 2024, the Company received
notices from Nasdaq indicating that the Company was not in compliance with (i) Nasdaq Listing Rule 5550(b)(1), which requires companies
listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders&#8217; equity for continued listing (the &#8220;Equity Requirement&#8221;)
or (ii) Nasdaq Listing Rule 5550(a)(2) which requires companies listed on Nasdaq to maintain a minimum of a $1.00 bid price for continued
listing (the &#8220;Minimum Bid Price Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2024, we received a letter from Nasdaq
indicating that we had regained compliance with the Equity Requirement. We were subject to a Mandatory Panel Monitor for a period of one
year from the date of the letter in accordance with application of Listing Rule 5815(d)(4)(B).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2024, we received a written notice
from Nasdaq indicating that we were not in compliance with the Minimum Bid Price Requirement. The bid price notice does not result in
the immediate delisting of our common stock from the Nasdaq Capital Market. The bid price notice indicated that we have 180 calendar days
(or until April 14, 2025) in which to regain compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2025, we received a letter from Nasdaq
indicating that we had regained compliance with the Minimum Bid Price Requirement in Listing Rule 5550(a) (2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event we are not able to maintain compliance
with the Equity Requirement or the Minimum Bid Price Requirement in the future or cure any future deficiencies, or if we are not otherwise
eligible, the staff of the SEC will provide us with written notification that its securities are subject to delisting from Nasdaq. At
that time, we may appeal the delisting determination to a Nasdaq listing hearings panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our common stock is delisted by Nasdaq, our
common stock may be eligible for quotation on an over-the-counter quotation system or on the pink sheets. Upon any such delisting, our
common stock would become subject to the regulations of the SEC relating to the market for penny stocks. A penny stock is any equity security
not traded on a national securities exchange that has a market price of less than $5.00 per share. The regulations applicable to penny
stocks may severely affect the market liquidity for our common stock and could limit the ability of shareholders to sell securities in
the secondary market. In such a case, an investor may find it more difficult to dispose of or obtain accurate quotations as to the market
value of our common stock, and there can be no assurance that our common stock will be eligible for trading or quotation on any alternative
exchanges or markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delisting from Nasdaq could adversely affect our
ability to raise additional financing through public or private sales of equity securities, would significantly affect the ability of
investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other
negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business
development opportunities.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="s_005"></span>Market
and Industry Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, information contained
(or incorporated by reference) in this prospectus concerning our industry and the markets in which we operate is based on information
from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived
from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal
research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets which we believe
to be reasonable. Although we believe the data from these third-party sources is reliable, we have not independently verified any third-party
information. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our
future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those set forth under the section
titled &#8220;Risk Factors&#8221; included in this prospectus and the section titled &#8220;Risk Factors&#8221; included in our Annual
Report on Form 10-K for the year ended December 31, 2025. These and other factors could cause results to differ materially from those
expressed in the estimates made by the independent parties and by us and subsequent filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_006"></span><span style="text-transform: uppercase"><b>Use
of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds to us from the
issuance and sale of shares of our common stock (or Pre-Funded Warrants in lieu of common stock) and accompanying Common Warrants in this
offering, as applicable, will be approximately $11.2 million, based on the assumed public offering price of $5.45 per share, which is
the last reported sales price of our common stock on Nasdaq on April 1, 2026, (1) excluding the proceeds, if any, from the exercise of
the Common Warrants sold in this offering, (2) assuming no sale of any Pre-Funded Warrants, (3) assuming the maximum number of shares
are sold in this offering and after deducting estimated Placement Agent fees and estimated offering expenses payable by us. However, because
this is a reasonable best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering,
the actual offering amount, and net proceeds to us, are not presently determinable and may be substantially less than the maximum amounts
set forth on the cover page of this prospectus. Based on the assumed public offering price set forth above, we estimate that our net proceeds
from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $8.1 million, $5.3 million, and $2.5
million, respectively, assuming no sale of any Pre-Funded Warrants, no exercise of the accompanying Common Warrants, and after deducting
the estimated Placement Agent fees and estimated offering expenses payable by us. If all of the Common Warrants sold in this offering
were to be exercised in cash at their exercise price, we would receive additional gross proceeds of approximately $12.0 million, based
on assumed exercise price of $5.45.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to use the net proceeds from
this offering, together with our existing cash and cash equivalents, for working capital and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our expected use of net proceeds from this offering
and our existing cash and cash equivalents represents our intentions based upon our current plans and business conditions, which could
change in the future as our plans and business conditions evolve. As a result, we cannot predict with any certainty our use of the net
proceeds from this offering or the amounts that we will actually spend on each area of use set forth above. Our management will retain
broad discretion over the allocation of the net proceeds from this offering. Accordingly, we will have discretion in the application
of the net proceeds, and investors will be relying on our judgment regarding the application of the proceeds of this offering. See the
subsection titled &#8220;<a href="#s_004">Risk Factors</a>&#8211;Risks Related to This Offering and Ownership of Our Securities&#8211;We have broad discretion
in the use of the net proceeds from this offering and may not use them effectively, which could affect our results of operations and
cause our stock price to decline.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each $1.00 increase (decrease) in the assumed public
offering price of $5.45 per share would increase (decrease) the net proceeds to us from this offering by approximately $2 million, assuming
that the number of shares offered by us, as set forth on the cover of this prospectus remains the same, assuming no sale of any Pre-Funded
Warrants, no exercise of the Common Warrants and after deducting the estimated Placement Agent fees and estimated offering expenses payable
by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Similarly, each 1.0 million share increase (decrease)
in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to
us by approximately $5.1 million, assuming the public offering price of $5.45 per share, remains the same, assuming no sale of any Pre-Funded
Warrants, no exercise of the Common Warrants and after deducting the estimated Placement Agent fees and estimated offering expenses payable
by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_007"></span><span style="text-transform: uppercase"><b>DILUTION
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If you invest in our shares
of common stock in this offering, your ownership interest will be diluted to the extent of the difference between the assumed public offering
price per share of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately
after the closing of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As of December 31, 2025, our
historical net tangible book value was approximately $2.3 million, or $5.80 per share of common stock. Our historical net tangible book
value per share is equal to our total tangible assets, less total liabilities, divided by the number of outstanding shares of common stock
as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">After giving effect to the
issuance of 98,043 shares under the At-The-Market Issuance Sales Agreement, dated August 22, 2025, with Ascendiant Capital Markets LLC
subsequent to December 31, 2025 (the &#8220;Pro Forma Adjustments&#8221;), our pro forma net tangible book value as of December 31, 2025
would have been approximately $3.2 million, or $6.45 per share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving further effect to the sale of shares
of our common stock and accompanying Common Warrants in this offering at an assumed public offering price of $5.45 per share, the last
reported sale price of our common stock on the Nasdaq Capital Market on April 1, 2026, and after deducting commissions and estimated offering
expenses payable by us, our as adjusted net tangible book value as of December 31, 2025 would have been approximately $14.1 million, or
$5.23 per share of common stock. This amount represents an immediate increase (decrease) in as adjusted net tangible book value of $(1.21)
per share to our existing stockholders and an immediate dilution of $0.22 per share to investors participating in this offering. We determine
dilution per share to investors participating in this offering by subtracting as adjusted net tangible book value per share after this
offering from the assumed public offering price per share paid by investors participating in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following table illustrates this per share
dilution to new investors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; font-size: 10pt">Assumed public offering price per share</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">5.45</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Historical Net tangible book value per share as of December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5.80</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">Increase in net tangible book value per share attributable to the Pro Forma Adjustments</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.65</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Pro forma net tangible book value per share as of December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6.45</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">Increase (decrease) in net tangible book value per share attributable to this offering</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1.20</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Pro forma net tangible book value per share after giving effect to this offering as of December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5.23</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net dilution in net tangible book value per share to new investors participating in this offering</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.22</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">To the extent that outstanding
options, restricted stock units or warrants are exercised or shares of preferred stock are converted, or any additional options, restricted
stock units, warrants or other equity awards are granted and exercised or become vested or other issuances of shares of our common stock
are made, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic
considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital
is raised through the sale of common stock or securities exercisable, convertible or exchangeable into common stock, such issuance could
result in further dilution to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The above discussion and table
are based on 402,833 shares of our common stock outstanding as of December 31, 2025, and excludes as of such date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 95%; text-align: justify"><span style="font-size: 10pt">32 shares of our common stock reserved for issuance under outstanding stock options granted under our 2013 Equity Incentive Plan;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">17,421 shares of our common stock reserved for issuance under outstanding stock options granted under our 2020 Equity Incentive Plan;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">333 shares of our common stock reserved for future grant under our 2020 Equity Incentive Plan;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">187 shares of our common stock reserved for issuance under outstanding stock options and outstanding restricted stock units granted as employment inducement awards to current executives outside of our 2013 and 2020 Equity Incentive Plans;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">5,473 shares of common stock reserved for issuance upon the exercise of outstanding common stock warrants;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">47,379 shares of common stock reserved for issuance upon the conversion of our Series C convertible Preferred Stock including accrued capitalized dividends;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">50,393 shares of common stock reserved for issuance upon the exercise of warrants sold in a private placements; </span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Up to 672,918 shares of common stock that may be sold in the future by the Company to White Lion Capital pursuant to the Equity Line Purchase Agreement; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon exercise of warrants sold in this offering.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="s_008"></span>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not declared or paid any cash dividends
on our capital stock since our inception. We currently intend to retain all available funds and any future earnings for use in the operation
and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future
determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition,
operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="s_009"></span>Market
for Registrant&#8217;s Common Equity AND Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock has been traded on Nasdaq under the
symbol &#8220;AUUD&#8221; since our initial public offering in February 2021. As of April 1, 2026, there were approximately 79 holders
of record of our common stock. These numbers are based on the actual number of holders registered at such date and does not include holders
whose shares are held in &#8220;street name&#8221; by brokers and other nominees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span id="s_010"></span><b>Description
of Capital Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following description is intended as a
summary of our certificate of incorporation (which we refer to as our &#8220;charter&#8221;) and our bylaws, each previously filed with
the SEC and incorporated by reference as an exhibit to the registration statement of which this prospectus forms a part, and to the applicable
provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Because the following is only a summary, it does not contain
all of the information that may be important to you. For a complete description, you should refer to our charter and bylaws.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have one class of securities registered under
Section 12 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Our shares of common stock are listed
on Nasdaq under the trading symbol &#8220;AUUD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Authorized Capital Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of 100,000,000
shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our common stock are entitled to
one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative
voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds
legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has
no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of our liquidation, dissolution or
winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other
liabilities and any liquidation preference of any outstanding preferred stock. Each outstanding share of common stock is duly and validly
issued, fully paid and non-assessable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board will have the authority, without further
action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting
rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of,
such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect
the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control
of our company or other corporate action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series C Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2025, we entered into a securities
purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with accredited investors, pursuant to which we issued and sold 750
shares of our newly designated Series C Convertible Preferred Stock (the &#8220;Series C Convertible Preferred Stock&#8221;) for an aggregate
purchase price of $750,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of the Series C Convertible Preferred
Stock will be entitled to dividends in the amount of 15% per annum, payable quarterly. We have the option to pay dividends on the Series
C Convertible Preferred Stock in additional shares of common stock. If we elect to pay in the form of common stock, the number of dividend
shares to be issued shall be calculated by using a &#8220;Dividend Conversion Price&#8221; equal to the lower of (i) the then applicable
Series C Conversion Price (as defined in the Certificate of Designations for the Series C Convertible Preferred Stock (the &#8220;Certificate
of Designations&#8221;)) as in effect on the applicable dividend date, or (ii) 90% of the lowest volume-weighted average price (&#8220;VWAP&#8221;)
of the common stock during the five consecutive trading day period ending and including the trading day immediately preceding the applicable
dividend date. We also have the option to cumulate or &#8220;capitalize&#8221; the dividends, in which case the accrued dividend amount
shall be added to the stated value of each share of Series C Convertible Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stated value of each share of Series C Convertible
Preferred Stock (including all the unpaid dividends and other amounts payable on the Series C Convertible Preferred Stock) will be convertible
into common stock at an initial fixed Conversion Price of $36.73 per share of common stock. The Series C Convertible Preferred Stock may
be converted into shares of common stock at any time at the option of the holder. The Series C Convertible Preferred Stock may also be
converted into shares of common stock at our option if the closing price of the common stock exceeds 300% of the Conversion Price for
20 consecutive trading days, subject to certain conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Conversion Price of the Series C Convertible
Preferred Stock is subject to certain anti-dilution adjustments, including in the event of any stock splits or combinations, certain dividends
and distributions, reclassification, exchange or substitution of our common stock or in the event that we grant, issue or sell (or enters
into any agreement to grant, issue or sell), or are deemed to have granted, issued or sold, any shares of common stock for a consideration
per share (the &#8220;New Issuance Price&#8221;) less than a price equal to the Conversion Price in effect immediately prior to such granting,
issuance or sale or deemed granting, issuance or sale (the foregoing, a &#8220;Dilutive Issuance&#8221;); provided, that any Conversion
Price adjustment due to a Dilutive Issuance may not be effected until after stockholder approval of the issuance of all of the securities
under the Securities Purchase Agreement in compliance with the rules and regulations of Nasdaq has been obtained. Immediately after such
Dilutive Issuance, the Conversion Price then in effect shall be reduced to an amount equal to the New Issuance Price. The conversion price
has been subsequently adjusted to $9.0976.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Convertible Preferred Stock has no
voting rights, except as may otherwise be required by the DGCL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Certificate of Designations contains customary
events of default (&#8220;Triggering Events&#8221;), including, among others, (i) certain events of bankruptcy, insolvency or reorganization;
(ii) failure to comply with the listing rules of Nasdaq; (iii) certain breaches of the transaction agreements related to the Series C
Convertible Preferred Stock financing; and (iv) any of the shares of the Series C Convertible Preferred Stock remaining outstanding on
or after June 30, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the occurrence of a Triggering Event, (i)
the dividend rate on the Series C Convertible Preferred Stock will increase by 18%, and (ii) the Conversion Price then in effect will
be adjusted to an &#8220;Alternate Conversion Price&#8221; equal to the lowest of (i) the applicable Conversion Price as then in effect
and (ii) the greater of (x) the &#8220;Floor Price&#8221; of $7.3458 and (y) 80% of the lowest VWAP of the common stock during the five
consecutive trading day period immediately preceding the delivery or deemed delivery of the applicable conversion notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time, we shall have the right to redeem
all, but not less than all, of the Series C Convertible Preferred Stock then outstanding in cash at a 25% redemption premium to the greater
of (i) the face value of our common stock underlying the Series C Convertible Preferred Stock and (ii) the equity value of our common
stock underlying the Series C Convertible Preferred Stock. The equity value of our common stock underlying the Series C Convertible Preferred
Stock is calculated using the greatest closing sale price of our common stock on any trading day immediately preceding the date we notify
the holders of our election to redeem and the date we make the entire payment required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon our liquidation, dissolution or winding up,
holders of Series C Convertible Preferred Stock shall be entitled to receive in cash out of our assets, before any amount shall be paid
to the holders of any of shares of common stock, an amount per shares of Series C Convertible Preferred Stock equal to the sum of (i)
the Black Scholes Value (as defined in the warrants issued pursuant to the Securities Purchase Agreement (the &#8220;Warrants&#8221;))
with respect to the outstanding portion of all Warrants held by such holder (without regard to any limitations on the exercise thereof)
as of the date of such event and (ii) the greater of (A) 125% of the applicable liquidation value and (B) the amount per share such holder
would receive if such holder converted such share of Series C Convertible Preferred Stock into common stock immediately prior to the date
of such payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of April 1, 2026, there were 750 shares of Series
C Convertible Preferred Stock outstanding.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no other shares of preferred stock that
are currently outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-Takeover Effects of Delaware Law and Provisions
of Our Charter and Our Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain provisions of the DGCL and of our charter
and our bylaws could have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons
considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
non-negotiated takeover attempts. These provisions include the items described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Delaware Anti-Takeover Statute</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the provisions of Section 203
of the DGCL (&#8220;Section 203&#8221;). In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business
combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes
an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination
between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 203 defines a business combination to
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger or consolidation involving the corporation and the interested stockholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, Section 203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity
or person affiliated with or controlling or controlled by the entity or person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Board Composition and Filling Vacancies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our charter provides that stockholders may remove
directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding common stock. Our charter
and bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number
of directors constituting our board of directors may only be set by a resolution adopted by a majority vote of our entire board of directors.
These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board
of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board
of directors but promotes continuity of management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>No Written Consent of Stockholders</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our charter and bylaws provide that all stockholder
actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any
action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would
prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Meetings of Stockholders</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our charter and bylaws provide that only a majority
of the members of our board of directors then in office, our Executive Chairman or our Chief Executive Officer may call special meetings
of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting
of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Advance Notice Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our bylaws provide advance notice procedures for
stockholders seeking to bring matters before our annual meeting of stockholders or to nominate candidates for election as directors at
our annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s
notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making
nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions
might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate
of directors or otherwise attempting to obtain control of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Amendment to Our Charter and Bylaws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DGCL, provides, generally, that the affirmative
vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation
or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our
bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least two-thirds
of the votes that all our stockholders would be entitled to cast in an annual election of directors. In addition, the affirmative vote
of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast in an election of directors is
required to amend or repeal or to adopt certain provisions of our charter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Undesignated Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our charter provides for 10,000,000 authorized
shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board to discourage an attempt
to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary
obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board
could cause shares of convertible preferred stock to be issued without stockholder approval in one or more private offerings or other
transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this
regard, our charter grants our board broad power to establish the rights and preferences of authorized and unissued shares of preferred
stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders
of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and
may have the effect of delaying, deterring or preventing a change in control of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Choice of Forum</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our charter provides that the Court of Chancery
of the State of Delaware is the exclusive forum for the following types of actions or proceedings: any derivative action or proceeding
brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the
Company to us or our stockholders, any action asserting a claim against us arising pursuant to any provision of the DGCL or our charter
or bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. Our charter also provides that unless
we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the
exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the
&#8220;Securities Act&#8221;). Despite the fact that the charter provides for this exclusive forum provision to be applicable to the fullest
extent permitted by applicable law, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce
any duty or liability created by the Exchange Act or the rules and regulations thereunder and Section 22 of the Securities Act creates
concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities
Act or the rules and regulations thereunder. As a result, this provision of our charter would not apply to claims brought to enforce a
duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. However, there
is uncertainty as to whether a Delaware court would enforce the exclusive federal forum provisions for Securities Act claims and investors
cannot waive compliance with the federal securities laws and rules and regulations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we consent in writing to the selection
of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of
any complaint asserting a cause of action arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent, Registrar, Warrant Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our common
stock is VStock Transfer LLC, 18 Lafayette Place, Woodmere, NY 11598.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of April 1, 2026 there were 500,876 shares of our
common stock outstanding, and approximately 79 stockholders of record.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At April 1, 2026, we had 64,699 other outstanding
common stock warrants with a weighted-average exercise price of $9.0976 and a weighted average remaining contractual life of approximately
3.9 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These warrants have a net exercise provision under
which its holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based
on the fair market value of the underlying shares at the time of exercise of the warrant after deduction of a number of shares equal in
value to the aggregate exercise price. The warrants contain provisions for the adjustment of the exercise price and the number of shares
issuable upon the exercise of the warrant in the event of certain stock dividends, stock splits, reorganizations, reclassifications and
consolidations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2013 Equity Incentive Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of April 1, 2026, we had 32 outstanding common
stock options, with a weighted-average exercise price of $38,034, which were granted under the Clip Interactive, LLC 2013 Equity Incentive
Plan. We ceased granting awards under the 2013 Equity Incentive Plan upon the implementation of the 2020 Equity Incentive Plan described
below.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2020 Equity Incentive Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s 2020 Equity Incentive Plan,
which became effective upon the completion of our initial public offering in February 2021, serves as the successor equity incentive plan
to the 2013 Equity Incentive Plan. As of April 1, 2026, the 2020 Equity Incentive Plan had an aggregate of 57,893 shares of common stock
authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Equity Incentive Plan contains an &#8220;evergreen&#8221;
provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased
on the first day of each year beginning January 1, 2022 and ending January 1, 2030 equal to the lesser of (a) five percent of the shares
of stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (b) such smaller number of
shares of stock as determined by our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of April 1, 2026, under our 2020 Equity Incentive
Plan, there were (i) 17,421 outstanding common stock options with a weighted average exercise price of $37.94 and (ii) 20,472 shares
remaining available for future grant.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_011"></span><span style="text-transform: uppercase"><b>DESCRIPTION
of securities we are offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering up to 2,201,834 shares of Common
Stock, together with 2,201,834 Warrants to purchase up to 2,201,834 shares of Common Stock. We are also offering Pre-Funded Warrants to
purchase 2,201,834 shares of Common Stock to those purchasers, whose purchase of shares of Common Stock in this offering would result
in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of
the purchaser, 9.99%) of our outstanding Common Stock following the consummation of this offering in lieu of the shares of our Common
Stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%). Each Pre-Funded Warrant will be
exercisable for one (1) share of Common Stock. Each Pre-Funded Warrant is being issued together with the same Common Warrant described
above being issued with each share of Common Stock. The shares of Common Stock or Pre-Funded Warrants, as the case may be, and the accompanying
Common Warrants, can only be purchased together in this offering, but the shares of Common Stock and Pre-Funded Warrants and accompanying
Common Warrants are immediately separable and will be issued separately in this offering. We are also registering the shares of Common
Stock issuable from time to time upon exercise of the Pre-Funded Warrants and Common Warrants offered hereby.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="s_018"></span><b>Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The material terms and provisions of our common stock are described
under the caption &#8220;<a href="#s_010">Description of Capital Stock</a>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="s_019"></span><b>Pre-Funded Warrants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following summary of certain terms and
conditions of the Pre-Funded Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the Pre-Funded
Warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors
should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description of the terms and conditions
of the Pre-Funded Warrants.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercisability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants will be exercisable, at the option of the holder,
in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our
common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). The holder (together with its
affiliates) may not exercise any portion of such holder&#8217;s Pre-Funded Warrants to the extent that the holder would own more than
4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise, as such percentage ownership
is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this offering may also elect
prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding Common Stock,
except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may decrease or increase such percentage ownership
of outstanding stock after exercising the holder&#8217;s Pre-Funded Warrants but such percentage shall not exceed 9.99% of the number
of shares of our common stock outstanding immediately after giving effect to the exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Duration and Exercise Price</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise price per whole share of our common
stock purchasable upon the exercise of the Pre-Funded Warrants is $0.001 per share of common stock. The Pre-Funded Warrants will be
immediately exercisable and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price of the
Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash,
stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cashless Exercise</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In lieu of making the cash payment otherwise contemplated to be made
to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) a number of Pre-Funded Warrant Shares net of a number of shares of common stock with market value equal to the total
exercise price, as determined according to a formula set forth in the Pre-Funded Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Transferability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws, the Pre-Funded Warrants
may be offered for sale, sold, transferred or assigned at the option of the holder upon surrender of the Pre-Funded Warrants to us together
with the appropriate instruments of transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fractional Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fractional shares of common stock will be issued
upon the exercise of the Pre-Funded Warrants. Rather, the number of shares of common stock to be issued will, at our election, either
be rounded up to the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exchange Listing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established trading market for the
Pre-Funded Warrants and we do not plan on applying to list the Pre-Funded Warrants on The Nasdaq Capital Market, any other national securities
exchange or any other nationally recognized trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fundamental Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a fundamental transaction, as described in the Pre-Funded
Warrants and generally including (i) our merger or consolidation with or into another person (other than a reincorporation in a different
state), (ii) the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by us or another person) completed pursuant to
which holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of more than 50% of the voting power of our common equity, (iv) any reclassification, reorganization or recapitalization
of our common stock or any compulsory share exchange pursuant to which our common stock is effectively converted into or exchanged for
other securities, cash or property, or (iv) the consummation, directly or indirectly, of a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) whereby
another person or group acquires more than 50% of the voting power of the common equity of the Company, the holder will have the right
to receive as alternative consideration, for each share of our common stock that would have been issuable upon such exercise immediately
prior to the occurrence of such fundamental transaction, at the option of the holder, the number of shares of common stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result
of such transaction by a holder of the number of shares of our common stock for which the Pre-Funded Warrant is exercisable immediately
prior to such event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rights as a Stockholder</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except by virtue of such holder&#8217;s ownership
of shares of our common stock, the holder of a Pre-Funded Warrant does not have the rights or privileges of a holder of our common stock,
including any voting rights, until the holder exercises the Pre-Funded Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Warrants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following summary of certain terms and
conditions of the Common Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the Common Warrants,
the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should
carefully review the terms and provisions of the form of Common Warrant for a complete description of the terms and conditions of the
Common Warrants.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exercisability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants will be exercisable, at the
option of the holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the
number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). The
holder (together with its affiliates) may not exercise any portion of such holder&#8217;s Common Warrants to the extent that the holder
would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise, as such
percentage ownership is determined in accordance with the terms of the Common Warrants, except that upon at least 61 days&#8217; prior
notice from the holder to us, the holder may decrease or increase such percentage ownership of outstanding stock after exercising the
holder&#8217;s Common Warrants but such percentage shall not exceed 9.99% of the number of shares of our common stock outstanding immediately
after giving effect to the exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Term </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Common Warrant will be immediately exercisable and will expire upon
the earlier of: (i) the 5-year anniversary of the date of the date of issuance; or (ii) the consummation of the Merger.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exercise Price</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants offered hereby will have
an assumed exercise price of $5.45 per share. The exercise prices and numbers of shares of common stock issuable upon exercise are
subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our
common stock. In addition, subject to the rules and regulations of the Nasdaq, the Company may at any time during the term of the
Common Warrant reduce the then current exercise price to any amount and for any period of time deemed appropriate by the board of
directors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cashless Exercise</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, at the time a holder exercises its Common
Warrants, a registration statement registering the issuance of the shares of common stock underlying the Common Warrants under the Securities
Act, is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise(either
in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Common Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Transferability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws, the Common Warrants
may be offered for sale, sold, transferred or assigned at the option of the holder upon surrender of the Common Warrants to us together
with the appropriate instruments of transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fractional Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fractional shares of common stock will be issued
upon the exercise of the Common Warrants. Rather, the number of shares of common stock to be issued will, at our election, either be rounded
up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the exercise price.<i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Trading Market</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established trading market for any
of the Common Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Common Warrants
on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Common
Warrants will be limited.<i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fundamental Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a fundamental transaction, as described in the Common
Warrants and generally including (i) our merger or consolidation with or into another person (other than a reincorporation in a different
state), (ii) the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by us or another person) completed pursuant to
which holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of more than 50% of the voting power of our common equity, (iv) any reclassification, reorganization or recapitalization
of our common stock or any compulsory share exchange pursuant to which our common stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the consummation, directly or indirectly, of a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) whereby another
person or group acquires more than 50% of the voting power of the common equity of the Company, the holder will have the right to receive
as alternative consideration, for each share of our common stock that would have been issuable upon such exercise immediately prior to
the occurrence of such fundamental transaction, at the option of the holder, the number of shares of common stock of the successor or
acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of
such transaction by a holder of the number of shares of our common stock for which the Common Warrant is exercisable immediately prior
to such event. Additionally, as more fully described in the Common Warrants, in the event of certain fundamental transactions, the holders
of those Common Warrants will be entitled, at the holder&#8217;s option, to receive consideration in an amount equal to the Black Scholes
Value (as defined in the Common Warrants) of the remaining unexercised portion of the Common Warrants within the later of five (5) days
of the holder&#8217;s election or on the date of consummation of such transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rights as a Stockholder</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in the Common Warrants
or by virtue of the holders&#8217; ownership of shares of our common stock, the holders of Common Warrants do not have the rights or privileges
of holders of our common stock, including any voting rights, until such warrant holders exercise their Common Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Waivers and Amendments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No term of the Common Warrants may be amended
or waived without the written consent of the holder of such Common Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span id="s_012"></span><b>Plan
of Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dawson James Securities, Inc., the Placement Agent, has agreed to act
as our exclusive placement agent in connection with this offering, subject to the terms and conditions of the engagement letter, dated
March 4, 2026. This is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this
offering. The Placement Agent is not purchasing or selling any of the securities offered by this prospectus, nor is the Placement Agent
required to arrange the purchase or sale of any specific number or dollar amount of securities, but has agreed to use reasonable best
efforts to arrange for the sale of all of the securities offered pursuant to this prospectus. Therefore, we will enter into a securities
purchase agreement directly with the institutional investors, at the investor&#8217;s option, who purchase our securities in this offering.
Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of
our securities in this offering. In addition to rights and remedies available to all investors in this offering under federal securities
and state law, the investors which enter into a securities purchase agreement will also be able to bring claims of breach of contract
against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will deliver the securities being issued to
the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver
the securities being offered pursuant to this prospectus on or about&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities will be offered at a fixed price and
are expected to be issued in a single closing. We expect this offering to be completed not later than one business day following the commencement
of this offering, which will be the date that we enter into a securities purchase agreement to sell the securities offered hereby. We
expect to close the offering on or before , 2026. We will deliver all securities to be issued in connection with this offering delivery
versus payment/receipt versus payment upon receipt of investor funds received by us. Accordingly, neither we nor the Placement Agent have
made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent will not receive investor
funds in connection with the sale of the securities offered hereunder.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the Placement Agent
and specified other persons against specified liabilities, including liabilities under the Securities Act, and to contribute to payments
the Placement Agent may be required to make in respect thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees and Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering is being conducted on a &#8220;reasonable
best efforts&#8221; basis and the Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase
or sale of any specific number or dollar amount of securities. We have agreed to pay the Placement Agent fees set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Share of Common Stock and Accompanying Common Warrant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Pre-Funded<br/> Warrant and Accompanying Common Warrant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">Public offering price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent fees<b><sup>(1)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before expenses)<sup>(2)(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">We have agreed to pay the Placement Agent a cash fee equal to&#8239;7.0% of the aggregate gross proceeds raised in this offering. We also have agreed to reimburse the Placement Agent for up to $125,000 in &#8220;road show&#8221; expenses, diligence expenses and legal fees of Placement Agent&#8217;s counsel, and $5,000 in legal fees of &#8220;blue sky&#8221; counsel. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We estimate the total expenses of this offering payable by us, excluding the Placement Agent fees, will be approximately $250,000. Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include proceeds from the cash exercise of the Pre-Funded Warrants or Common Warrants, if any.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulation M</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent may be deemed to be an underwriter
within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale
of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act.
As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including,
without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations
may limit the timing of purchases and sales of securities by the Placement Agent acting as principal. Under these rules and regulations,
the Placement Agent:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not engage in any stabilization activity in connection with our securities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Lock-Up Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed with the Placement Agent to be
subject to a lock-up period of&#8239;120&#8239;days following the date of closing of the offering pursuant to this prospectus. This means
that, during the applicable lock-up period, subject to certain limited exceptions, we may not, without the prior written consent of the
Placement Agent: (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock
or common stock equivalents or (ii) file any registration statement or amendment or supplement thereto, other than a registration statement,
in each case, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Determination of Offering Price</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined public offering price per share of Common Stock and accompanying
Common Warrant and the combined public offering price per Pre-Funded Warrant and accompanying Common Warrant we are offering, and the
exercise prices and other terms of the Warrants were negotiated between us and the investors, in consultation with the Placement Agent
based on the trading of our Common Stock prior to this offering, among other things. Other factors considered in determining the offering
prices of the securities we are offering and the exercise prices and other terms of the Common Warrants include the history and prospects
of our company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented,
an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were
deemed relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on Nasdaq under the
symbol &#8220;AUUD.&#8221; We do not plan to list the Pre-Funded Warrants or the Common Warrants on Nasdaq or any other securities exchange
or trading market. There is no established public trading market for the Common Warrants and we do not expect a market to develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other Activities and Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Placement Agent and certain of its affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The Placement Agent and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial
and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees
and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of their various business
activities, the Placement Agent and certain of its affiliates may make or hold a broad array of investments and actively trade debt and
equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the
accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and
our affiliates. If the Placement Agent or its affiliates enter into a lending relationship with us, they will routinely hedge their credit
exposure to us consistent with their customary risk management policies. The Placement Agent and its affiliates may hedge such exposure
by entering into transactions that consist of either the purchase of credit default swaps or the creation of short positions in our securities
or the securities of our affiliates, including potentially the shares of common stock offered hereby. Any such short positions could adversely
affect future trading prices of the shares of common stock offered hereby. The Placement Agent and certain of its affiliates may also
communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views
with respect to such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Electronic Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may be made
available on a website maintained by the Placement Agent and the Placement Agent may distribute prospectuses electronically. Other than
the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of
which this prospectus forms a part, has not been approved and/or endorsed by us or the Placement Agent and should not be relied upon by
investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span id="s_013"></span><b>MATERIAL
UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a discussion of certain material
U.S. federal income tax consequences of the acquisition, ownership and disposition of our shares of common stock and the acquisition,
ownership, exercise, expiration or disposition of the Pre-Funded Warrants and Common Warrants, which, together with our shares of common
stock, we refer to in this section as our securities. This discussion applies only to our securities that are held as capital assets for
U.S. federal income tax purposes and is applicable only to holders who are receiving our securities in this offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion is a summary only and does not
describe all of the tax consequences that may be relevant to you in light of your particular circumstances, including but not limited
to the alternative minimum tax, the Medicare tax on certain investment income and the different consequences (such as the effects of Section
451 of the Internal Code of 1986, as amended (the &#8220;Code&#8221;)) that may apply if you are subject to special rules that apply to
certain types of investors, including but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions or financial services entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies or instrumentalities thereof; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expatriates or former long-term residents of the United States; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or constructively own five percent or more of our voting shares; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers or traders subject to a mark-to-market method of accounting with respect to our securities; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our securities as part of a &#8220;straddle,&#8221; hedge, integrated transaction or similar transaction; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. holders (as defined below) whose functional currency is not the U.S. dollar; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of such entities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion is based on the Code, and administrative
pronouncements, judicial decisions and final, temporary and proposed Treasury regulations as of the date hereof, which are subject to
change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences
described herein. This discussion does not address any aspect of state, local or non-U.S. taxation, or any U.S. federal taxes other than
income taxes (such as gift and estate taxes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not sought, and will not seek, a ruling
from the Internal Revenue Service (&#8220;IRS&#8221;) as to any U.S. federal income tax consequence described herein. The IRS may disagree
with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation,
regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. You
are urged to consult your tax advisor with respect to the application of U.S. federal tax laws to your particular situation, as well as
any tax consequences arising under the laws of any state, local or foreign jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This discussion does not consider the tax treatment
of partnerships or other pass-through entities or persons who hold our securities through such entities. If a partnership (or other entity
or arrangement classified as a partnership or other pass-through entity for U.S. federal income tax purposes) is the beneficial owner
of our securities, the U.S. federal income tax treatment of a partner or member in the partnership or other pass-through entity generally
will depend on the status of the partner or member and the activities of the partnership or other pass-through entity. If you are a partner
or member of a partnership or other pass-through entity holding our securities, we urge you to consult your tax advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN U.S.
FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES. EACH PROSPECTIVE INVESTOR
IN OUR SECURITIES IS URGED TO CONSULT ITS TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION,
OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY UNITED STATES FEDERAL NON-INCOME, STATE, LOCAL,
AND NON-U.S. TAX LAWS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Treatment of Pre-Funded Warrants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although it is not entirely free from doubt, a Pre-Funded
Warrant should be treated as a share of our common stock for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should
generally be taxed in the same manner as a holder of such shares, as described below. Accordingly, no gain or loss should be recognized
upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the share
received. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the share received upon exercise, increased by the exercise
price of $0.001 per share. If a Pre-Funded Warrant expires without being exercised, the holder should recognize a capital loss in an amount
equal to such holder&#8217;s tax basis in the Pre-Funded Warrant. This loss will be long-term capital loss if, at the time of the expiration,
the holder&#8217;s holding period in the Pre-Funded Warrant is more than one year. The deductibility of capital losses is subject to limitations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our characterization is not binding on the IRS,
and the IRS may treat our Pre-Funded Warrants as warrants to acquire shares of our common stock. In that case, the amount and character
of your gain with respect to an investment in our Pre-Funded Warrants could be materially different than the discussion set forth below.
Accordingly, each holder should consult such holder&#8217;s tax advisor regarding the risks associated with the acquisition of Pre-Funded
Warrants pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes
that a Pre-Funded Warrant is treated as a share of our common stock for U.S. federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Allocation of Purchase Price</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share or Pre-funded Warrant and Common Warrant is expected to be treated
for U.S. federal income tax purposes as an investment unit consisting of one share or one Pre-funded Warrant and one Common Warrant. In
determining the tax basis of each share or Pre-funded Warrant and Common Warrant constituting a unit, holders should allocate their purchase
price for the unit between the share or Pre-Funded Warrant and Common Warrant on the basis of their relative fair market values at the
time of issuance. We do not intend to advise holders of the shares, the Pre-Funded Warrants, or the Common Warrants with respect to this
determination. A holder&#8217;s allocation of the purchase price between the shares or Pre-Funded Warrant and Common Warrants is not binding
on the IRS or the courts, and no assurance can be given that the IRS or the courts will agree with a holder&#8217;s allocation. All holders
are advised to consult their tax and financial advisors with respect to the relative fair market values of the shares or Pre-Funded Warrants
and Common Warrants for U.S. federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section applies to you if you are a &#8220;U.S.
holder.&#8221; A U.S. holder is a beneficial owner of our shares of common stock who or that is, for U.S. federal income tax purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify; width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia; </span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust, if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under Treasury Regulations to be treated as a U.S. person. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Taxation of Distributions.</i> If we pay distributions
in cash or other property (other than certain distributions of our stock or rights to acquire our stock) to U.S. holders of shares of
our common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from
our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current
and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce the U.S. holder&#8217;s
adjusted tax basis in our common stock, or common stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants (the &#8220;Warrant
Shares&#8221;), as applicable (but not below zero). Any remaining excess will be treated as gain realized on the sale or other disposition
of the common stock and will be treated as described under &#8220;<i>U.S. holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable
Disposition of our securities</i>&#8221; below.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends we pay to a U.S. holder that is a taxable
corporation generally will qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions
(including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and
provided certain holding period requirements are met, dividends we pay to a non-corporate U.S. holder may constitute &#8220;qualified
dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the holding period requirements
are not satisfied, then a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal
to the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at regular ordinary income tax rates instead
of the preferential rate that applies to qualified dividend income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Gain or Loss on Sale, Taxable Exchange or Other
Taxable Disposition of our Securities</i>. Upon a sale or other taxable disposition of our common stock, Warrant Shares or Pre-Funded
Warrants, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized
and the U.S. holder&#8217;s adjusted tax basis in the common stock, Warrant Shares or Pre-Funded Warrants. Any such capital gain or loss
generally will be long-term capital gain or loss if the U.S. holder&#8217;s holding period for the common stock, Warrant Shares or Pre-Funded
Warrants so disposed of exceeds one year. If the holding period requirements are not satisfied, any gain on a sale or taxable disposition
of the shares would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. Long-term
capital gains recognized by non-corporate U.S. holders will be eligible to be taxed at reduced rates. The deductibility of capital losses
is subject to limitations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sale or other disposition or exercise of Common
Warrants. </i>Upon the sale, exchange or other disposition of a Common Warrant (other than by exercise), a U.S. Holder will generally
recognize capital gain or loss equal to the difference between the amount realized on the sale, exchange or other disposition and the
U.S. Holder&#8217;s tax basis in the Common Warrant. This capital gain or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s
holding period in such Common Warrant is more than one year at the time of the sale, exchange or other disposition. The deductibility
of capital losses is subject to certain limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, a U.S. Holder will not be required to
recognize income, gain or loss upon exercise of a Common Warrant for its exercise price. A U.S. Holder&#8217;s tax basis in Warrant Shares
received upon exercise of Common Warrants will be equal to the sum of (i)&#160;the U.S. Holder&#8217;s tax basis in the Common Warrants
exchanged therefor and (ii)&#160;the exercise price of such Common Warrants. A U.S. Holder&#8217;s holding period in the Warrant Shares
received upon exercise will commence on the day after such U.S. Holder exercises the Common Warrants. Although there is no direct legal
authority as to the U.S. federal income tax treatment of an exercise of a warrant on a cashless basis, we intend to take the position
that such exercise will not be taxable, either because the exercise is not a gain realization event or because it qualifies as a tax-free
recapitalization. In the former case, the holding period of Warrant Shares received upon exercise of Common Warrants should commence on
the day after the Common Warrants are exercised. In the latter case, the holding period of the Warrant Shares received upon exercise of
Common Warrants would include the holding period of the exercised Common Warrants. However, our position is not binding on the IRS and
the IRS may treat a cashless exercise of a warrant as a taxable exchange. U.S. Holders are urged to consult their tax advisors as to the
consequences of an exercise of a Common Warrant on a cashless basis, including with respect to their holding period and tax basis in the
Warrant Shares receive</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Lapse of common warrants<b>. </b></i>If a Common
Warrant expires without being exercised, a U.S. Holder will recognize a capital loss in an amount equal to such U.S. Holder&#8217;s tax
basis in the warrant. Such loss will be long-term capital loss if, at the time of the expiration, the U.S. Holder&#8217;s holding period
in such warrant is more than one year. The deductibility of capital losses is subject to certain limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Certain adjustments to and distributions on Pre-funded
warrants and common warrants. </i>Under Section&#160;305 of the Code, an adjustment to the number of Warrant Shares that will be issued
on the exercise of the Pre-funded Warrants and Common Warrants, or an adjustment to the exercise price of the Pre-funded Warrants and
Common Warrants (or in certain circumstances, a failure to make adjustments), may be treated as a constructive distribution to a U.S.
Holder of the Pre-funded Warrants and Common Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S.
Holder&#8217;s proportionate interest in our earnings and profits as determined under U.S. federal income tax principles or our assets,
depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other
property to our shareholders). Such distributions will constitute dividends to the extent deemed paid out of our current or accumulated
earnings and profits, as discussed above under &#8220;Taxation of Distributions.&#8221; U.S. Holders should consult their tax advisors
regarding the proper treatment of any adjustments to the number of Warrant Shares that will be issued on the exercise of the Pre-funded
Warrants or Common Warrants or the exercise price of the Pre-funded Warrants or Common Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if we were to make a distribution in cash or other property
with respect to its common stock after the issuance of the Common Warrants, then we may, in certain circumstances, make a corresponding
distribution to holders of Common Warrants. The taxation of a distribution received with respect to a Common Warrant is unclear. It is
possible such a distribution would be treated as a distribution (or constructive distribution), although other treatments are possible.
U.S. Holders should consult their tax advisors regarding the proper treatment of distributions received with respect to Common Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Information Reporting and Backup Withholding</i>.
In general, information reporting requirements may apply to dividends paid to a U.S. holder and to the proceeds of the sale or other disposition
of our shares of common stock, unless the U.S. holder is an exempt recipient. Backup withholding may apply to such payments if the U.S.
holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is
subject to backup withholding (and such notification has not been withdrawn). Any amounts withheld under the backup withholding rules
generally should be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required
information is timely furnished to the IRS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-U.S. Holders </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section applies to you if you are a &#8220;Non-U.S.
holder.&#8221; As used herein, the term &#8220;Non-U.S. holder&#8221; means a beneficial owner of our common stock who or that is for
U.S. federal income tax purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a non-resident alien individual (other than certain former citizens and residents of the U.S. subject to U.S. tax as expatriates); </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a foreign corporation; or </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate or trust that is not a U.S. holder; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">but generally does not include an individual who
is present in the U.S. for 183 days or more in the taxable year of disposition. If you are such an individual, you should consult your
tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Taxation of Distributions</i>. In general,
any distributions we make to a Non-U.S. holder of shares of our common stock, to the extent paid out of our current or accumulated earnings
and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and,
provided such dividends are not effectively connected with the Non-U.S. holder&#8217;s conduct of a trade or business within the United
States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. holder is eligible
for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such
reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E). Any distribution not constituting a dividend will be treated first as reducing
(but not below zero) the Non-U.S. holder&#8217;s adjusted tax basis in its shares of our common stock, and, to the extent such distribution
exceeds the Non-U.S. holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the common stock, which
will be treated as described under &#8220;<i>Non-U.S. holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of our securities</i>&#8221;
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The withholding tax does not apply to dividends
paid to a Non-U.S. holder who provides a Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. holder&#8217;s
conduct of a trade or business within the United States. Instead, such effectively connected dividends will be subject to regular U.S.
income tax as if the Non-U.S. holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise. A Non-U.S.
corporation receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax&#8221; imposed at
a rate of 30% (or a lower treaty rate).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Gain on Sale, Taxable Exchange or Other Taxable
Disposition of our securities</i>. A Non-U.S. holder generally will not be subject to U.S. federal income or withholding tax in respect
of gain recognized on a sale, taxable exchange or other taxable disposition of our common stock, unless:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively connected with the conduct of a trade or business by the Non-U.S. holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. holder); or </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are or have been a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. holder held our common stock and, in the case where shares of our common stock are regularly traded on an established securities market, the Non-U.S. holder has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. holder&#8217;s holding period for the shares of our common stock. There can be no assurance that our common stock will be treated as regularly traded on an established securities market for this purpose. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless an applicable treaty provides otherwise,
gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the
Non-U.S. holder were a U.S. resident. Any gains described in the first bullet point above of a Non-U.S. holder that is a foreign corporation
may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower treaty rate).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the second bullet point above applies to a
Non-U.S. holder, gain recognized by such holder on the sale, exchange or other disposition of shares of our securities will be subject
to tax at generally applicable U.S. federal income tax rates, and a buyer of such securities may be required to withhold U.S. federal
income tax at a rate of 15% of the amount realized upon the disposition. We expect not to be classified as a &#8220;U.S. real property
holding corporation&#8221; for U.S. federal income tax purposes. However, such determination is factual in nature and subject to change
and no assurance can be provided as to whether we will be a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income
tax purposes in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Information Reporting and Backup Withholding</i>.
Information returns will be filed with the IRS in connection with payments of dividends on our securities and the proceeds from a sale
or other disposition of our shares of common stock. A Non-U.S. holder may have to comply with certification procedures to establish that
it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures
required to claim a reduced rate of withholding under a treaty will generally satisfy the certification requirements necessary to avoid
the backup withholding as well. The amount of any backup withholding from a payment to a Non-U.S. holder will be allowed as a credit against
such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information
is timely furnished to the IRS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>FATCA Withholding Taxes</i>. Sections 1471
through 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred as the &#8220;Foreign
Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) generally impose withholding at a rate of 30% in certain circumstances on dividends
in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of,
securities (including shares of our common stock) which are held by or through certain foreign financial institutions (including investment
funds), unless any such institution (i) enters into, and complies with, an agreement with the IRS to report, on an annual basis, information
with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain non-U.S.
entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii) if required under an intergovernmental
agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will
exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign
country may modify these requirements. Accordingly, the entity through which shares of our common stock are held will affect the determination
of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed
below) gross proceeds from the sale or other disposition of, our securities held by an investor that is a non-financial non-U.S. entity
that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)
certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)
provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided
to the U.S. Department of Treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the applicable Treasury Regulations and
administrative guidance, withholding under FATCA generally applies to payments of dividends in respect of our securities. While withholding
under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including shares
of our common stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally
may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors
regarding the possible implications of FATCA on their investment in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s_014"></span><span style="text-transform: uppercase"><b>Legal
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Carroll Legal LLC, Denver, CO will pass upon the
validity of the shares of common stock offered hereby. The Placement Agent is being represented by Haynes and Boone, LLP, New York, New
York, in connection with this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="s_015"></span>Experts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our balance sheets as of December 31, 2025 and
2024 and the related statement of operations, changes in stockholders&#8217; equity and cash flows for the years ended December 31, 2025
and 2024, incorporated in this prospectus by reference, have been audited by Haynie &amp; Company, independent registered public accounting
firm, with respect thereto, and has been so included in reliance upon the report of such firm given on their authority as experts in accounting
and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audited historical financial statements
of Thramann Holding LLC and subsidiaries included in Exhibit 99.1 of our Current Report on Form 8-K, dated March 6, 2026, have been so
incorporated in reliance on the report (which contains an explanatory paragraph relating to the Thramann Holding LLC&#8217;s ability to
continue as a going concern as described in Note 2 to the financial statements) of Haynie &amp; Company, independent auditors, given on
the authority of said firm as experts in auditing and accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b></b></span></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="s_016"></span>Where
You Can Find More Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration statement
on Form S-1 under the Securities Act with respect to the shares of our common stock being offered by this prospectus. This prospectus,
which constitutes part of that registration statement, does not contain all of the information set forth in the registration statement
or the exhibits and schedules that are part of the registration statement. Some items included in the registration statement are omitted
from the prospectus in accordance with the rules and regulations of the SEC. For further information with respect to us and the common
stock offered in this prospectus, we refer you to the registration statement and the accompanying exhibits and schedules filed therewith.
Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the
registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text
of such contract or other document filed as an exhibit to the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the information and periodic
reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the SEC. Our SEC
filings are available to the public on a website maintained by the SEC located at www.sec.gov<i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may access our annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a)
or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. Our website address containing such reports is investors.auddiainc.com. The reference to our website
address does not constitute incorporation by reference of the information contained on our website, and you should not consider information
on our website to be part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also request a copy of these filings,
at no cost to you, by writing us at the following address or calling us at the following phone number:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Auddia Inc.<br/>
Attn: Investor Relations<br/>
1680 38<sup>th</sup> Street, Suite 130<br/>
Boulder, CO 80301<br/>
Telephone: (303) 219-9771</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span id="s_017"></span><b>Incorporation
of Certain Information by Reference</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of the registration statement
and does not contain all of the information included in the registration statement. Whenever a reference is made in this prospectus to
any contract or other document, the reference may not be complete and you should refer to the exhibits that are a part of the registration
statement for a copy of the contract or document.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We disclose important information to you by referring
you to documents that we have previously filed with the SEC or documents that we will file with the SEC in the future. The information
incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC (including any
prospectus supplement) will automatically update and supersede this information. We incorporate by reference the documents listed below
(other than documents or information deemed to have been furnished and not filed in accordance with SEC rules, unless otherwise expressly
incorporated by reference herein):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual
    Report on <a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316826001587/auddia_i10k-123125.htm" style="-sec-extract: exhibit">Form
    10-K</a> for the year ended December 31, 2025, which does not reflect the reverse stock split that was effectuated
on March 31, 2026;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on
    Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316826000391/auddia_8k.htm" style="-sec-extract: exhibit">January
    20, 2026</a>, <a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316826000661/auddia_8k.htm" style="-sec-extract: exhibit">February
    2, 2026</a>, <a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316826001114/auddia_8k.htm" style="-sec-extract: exhibit">February
    17, 2026</a>, <a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316826001589/auddia_8k.htm" style="-sec-extract: exhibit">March
    6, 2026</a> (the audited historical financial statements of Thramann Holding LLC and subsidiaries are included in Exhibit 99.1
    thereto) and <a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316826002594/auddia_8k.htm">April 2, 2026</a>;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our
    securities registered pursuant to Section 12 of the Exchange Act our Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316821000566/clip_8a.htm" style="-sec-extract: exhibit">Form 8-A</a> (File No. 001-40071), filed
    with the SEC under Section 12(b) of the Exchange Act, on February 16, 2021, including any amendment or report filed for the purpose
    of updating such description.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference all documents
that we subsequently file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial
registration statement and prior to effectiveness of the registration statement and (ii) on or after the date of this prospectus and prior
to the termination of the offering of the shares hereunder. Nothing in this prospectus shall be deemed to incorporate information furnished
but not filed with the SEC, unless specifically noted otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any statement made in this prospectus or in a
document incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to
the extent that a statement contained in this prospectus or in any other subsequently filed document that also is incorporated by reference
modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded,
to constitute a part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may request a copy of the filings incorporated
herein by reference, including exhibits to such documents that are specifically incorporated by reference, at no cost, by writing or calling
us at the following address or telephone number:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Auddia Inc.<br/>
Attn: Investor Relations<br/>
1680 38<sup>th </sup>Street, Suite 130<br/>
Boulder, CO 80301<br/>
Telephone: (303) 219-9771</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, you may access the documents incorporated
by reference herein free of charge on the SEC&#8217;s website. See also &#8220;<a href="#s_016">Where You Can Find More Information.</a>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to 2,201,834 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to 2,201,834 Pre-Funded Warrants to Purchase
Shares of Up to 2,201,834 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to 2,201,834 Common Warrants to Purchase Up to
2,201,834 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Up to 4,403,668 Shares of Common Stock underlying
Pre-Funded Warrants and Common Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AUDDIA INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 14pt"><b>Dawson
James Securities, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Placement Agent</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II<br/>
INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 13.</b></span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Expenses of Issuance and Distribution.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the costs and expenses
payable in connection with the sale of common stock being registered. All amounts shown are estimates, except the Securities and Exchange
Commission registration fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">Securities and Exchange Commission registration fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">3,314.40</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FINRA filing fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accountants&#8217; fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Printing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer agent and registrar fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Miscellaneous</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,685.60</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,000.00</td><td style="padding-bottom: 2.5pt; text-align: left"/></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 14.</b></span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification of Directors and Officers.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporated under the laws of the state
of Delaware. Section 145 of the DGCL provides that a Delaware corporation may indemnify any persons who are, or are threatened to be made,
parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other
than an action by or in the right of such corporation), by reason of the fact that such person was an officer, director, employee or agent
of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation
or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually
and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith
and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any
criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify
any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of
the corporation by reason of the fact that such person was a director, officer, employee or agent of such corporation, or is or was serving
at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include
expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement
of such action or suit provided such person acted in good faith and in a manner such person reasonably believed to be in or not opposed
to the corporation&#8217;s best interests except that no indemnification is permitted without judicial approval if the officer or director
is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any
action referred to above, the corporation must indemnify him or her against the expenses that such officer or director has actually and
reasonably incurred. Our charter and bylaws provide for the indemnification of our directors and officers to the fullest extent permitted
under the DGCL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 102(b)(7) of the DGCL permits a corporation
to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or
its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction from which the director derived an improper personal benefit.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 52; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These limitations of liability do not affect the
availability of equitable remedies such as injunctive relief or rescission. Our charter also authorizes us to indemnify our officers,
directors and other agents to the fullest extent permitted under Delaware law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As permitted by Section 145 of the DGCL, our bylaws
provide that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="width: 98%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may indemnify our directors, officers and employees to the fullest extent permitted by the DGCL, subject to limited exceptions;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to limited exceptions; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rights provided in our bylaws are not exclusive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 174 of the DGCL provides, among other
things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption
may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time,
may avoid liability by causing such director&#8217;s dissent to such actions to be entered in the books containing minutes of the meetings
of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As permitted by the DGCL, we have entered and
expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board
of directors. Under the terms of our indemnification agreements, we are required to indemnify each of our directors and officers, to the
fullest extent permitted by the laws of the state of Delaware, if the basis of the indemnitee&#8217;s involvement was by reason of the
fact that the indemnitee is or was a director or officer of the Company or any of its subsidiaries or was serving at our request in an
official capacity for another entity. We must indemnify our officers and directors against (1) attorneys&#8217; fees and (2) all other
costs of any type or nature whatsoever, including any and all expenses and obligations paid or incurred in connection with investigating,
defending, being a witness in, participating in (including on appeal) or preparing to defend, be a witness or participate in any completed,
actual, pending or threatened action, suit, claim or proceeding, whether civil, criminal, administrative or investigative, or establishing
or enforcing a right to indemnification under the indemnification agreement. The indemnification agreements also set forth certain procedures
that will apply in the event of a claim for indemnification thereunder. These indemnification provisions and the indemnification agreements
may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses
incurred, arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have purchased a policy of directors&#8217;
and officers&#8217; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of
a judgment in some circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 15.</b></span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Sales of Unregistered Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three years preceding the filing of this
registration statement, we issued the following securities that were not registered under the Securities Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2023, we entered into an additional
Secured Bridge Note (&#8220;New Note&#8221;) financing with Mr. Minicozzi. We received $750,000 of gross proceeds from the New Note financing.
The New Note was issued with a principal amount of $825,000, 10% interest rate and a maturity date on July 31, 2023. The New Note is secured
by a lien on substantially all of our assets. At maturity of the New Note, Mr. Minicozzi has the option to convert any original issue
discount and accrued but unpaid interest into shares of our common stock at a fixed conversion price of $1,996.23 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the New Note financing, we
issued 199 common stock warrants to Mr. Minicozzi with a five-year term and a fixed $1,996.23 per share exercise price, from which 100
of these common stock warrants are exercisable immediately. The remaining 99 common stock warrants would only become exercisable if the
maturity date of the New Note is extended in accordance with the terms of the New Note. As of July 31, 2023, we extended the maturity
date of the New Note to November 30, 2023. Upon the July 31, 2023 extension, the interest rate on the New Note increased to 20% from 10%,
and the remaining portion of the 99 common stock warrants became exercisable. The accredited investor did not exercise the common stock
warrants as of December 31, 2023 or subsequent to December 31, 2023 and as of the date of this filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, in connection with the New Note financing,
we agreed with Mr. Minicozzi to make certain amendments to the Prior Note financing. Specifically, we agreed with Mr. Minicozzi to cancel
the 92 common stock warrants issued as part of the prior financing and, in lieu of the cancelled warrants, we issued to Mr. Minicozzi
common stock warrants for 184 common shares with an exercise price of $1,996.23 per common share and a five-year term. From the newly
issued 184 common stock warrants, 706 common stock warrants were exercisable immediately, while the other 706 common stock warrants became
exercisable at the time of extension of the maturity date of the Prior Note during May of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 10, 2023, we entered into a securities
purchase agreement with Jeffrey Thramann, our Executive Chairman pursuant to which we issued and sold one share of the Company&#8217;s
newly designated Series A Preferred Stock for an aggregate purchase price of $1,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2024, we entered into an Amendment
and Waiver Agreement relating to the bridge notes with Mr. Minicozzi. Mr. Minicozzi converted $911,384 (the &#8220;Rollover Amount&#8221;)
which is equal to the (i) unpaid accrued interest on the bridge notes plus (ii) the original issue discount (&#8220;OID&#8221;) on the
bridge notes, into equity securities of the Company (the &#8220;Rollover Securities&#8221;). The Rollover Securities consist of (i) 3,540
prefunded common stock warrants with a per share exercise price of $0.001 per share (the &#8220;Prefunded Warrants&#8221;) and (ii) 3,540
non-prefunded warrants (the &#8220;Non-Prefunded Warrants&#8221;) with an initial per share exercise price equal to $257.48. We also issued
Mr. Minicozzi 383 new common stock warrants with a five year term as a loan extension fee (&#8220;Fee Warrants&#8221;). The initial exercise
price of these additional Fee Warrants is $3257.48. We agreed to adjust the exercise price of Mr. Minicozzi&#8217;s existing warrants
from $1,996.23 (after adjustment for the recent reverse stock) to $257.48 per share. The current exercise price has been adjusted to $9.0976.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 23, 2024, we entered into a securities
purchase agreement with accredited investors for a convertible preferred stock and warrants financing. We received $2,314,000 of gross
proceeds in connection with the closing of this financing. At the closing, we issued 2,314 shares of Series B convertible preferred stock
(&#8220;Series B Preferred Stock&#8221;) at a purchase price of $1,000 per share of Series B Preferred Stock. The Series B Preferred Stock
is convertible into common stock at an initial conversion price of $242.30 per share of common stock. We also issued warrants exercisable
for 9,552 shares of common stock with a five year term and an initial exercise price of $242.30 per share. The current exercise price
has been adjusted to $9.0976.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2025, we entered into a securities
purchase agreement with accredited investors for a convertible preferred stock and warrants financing. We received $750,000 of gross proceeds
in connection with the closing of this financing. At the closing, we issued 750 shares of Series C Convertible Preferred Stock at a purchase
price of $1,000 per share of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock is convertible into common
stock at an initial conversion price of $36.73 per share of common stock. We also issued warrants exercisable for 40,839 shares of common
stock with a five year term and an initial exercise price of $36.73 per share. The current exercise price has been adjusted to $9.0976.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These sales and issuances were made in reliance
upon Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D, Rule 506(d), and did not involve any underwriters, underwriting
discounts or commissions, or any public offering. The persons and entities who received such securities have represented their intention
to acquire these securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate
legends are be affixed to all share certificates issued. All recipients have adequate access through their relationship with us to information
about us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the foregoing securities are deemed restricted
securities for purposes of the Securities Act. All certificates representing the restricted shares of capital stock described above included
appropriate legends setting forth that the securities have not been registered and the applicable restrictions on transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 16.</b></span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits and Financial Statement Schedules.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Exhibits</b>. The following exhibits are
filed as part of this Registration Statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%"><span style="font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 54%; text-align: center"><span style="font-size: 10pt"><b>Description of Document</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Incorporated by reference from<br/>
Form</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Filing<br/>
Date</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-size: 10pt"><b>Filed<br/>
Herewith</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316824006384/auddia_ex0101.htm"><span style="font-size: 10pt">At-The-Market Issuance Sales Agreement, dated September 13, 2024, by and between Auddia Inc. and Ascendiant Capital Markets, LLC.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09-13-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">2.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316826001114/auddia_ex0201.htm">Agreement and Plan of Merger, dated as of February 17, by and among New Holdco, Inc., Auddia Merger Sub, Inc., Thramann Merger Sub LC, Auddia Inc. and Thramann Holdings, LLC</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-17-2026</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">2.2</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821000655/auddia_ex0201.htm"><span style="font-size: 10pt">Form of Plan of Conversion</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-22-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821000655/auddia_ex0301.htm"><span style="font-size: 10pt">Certificate of Incorporation of Auddia Inc.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-22-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.2</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316824001185/auddia_ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment to the Certificate of Incorporation of the Company dated February 23, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-27-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.3</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825002176/auddia_ex0301.htm">Certificate of Amendment to the Certificate of Incorporation of the Company dated March 27, 2025</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04-01-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">3.4</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316826002594/auddia_ex0301.htm">Certificate of Amendment to the Certificate of Incorporation of the Company dated March 30, 2026</a></td>
    <td>&#160;</td>
    <td style="text-align: center">8-K</td>
    <td>&#160;</td>
    <td style="text-align: center">04-02-2026</td>
    <td>&#160;</td>
    <td style="text-align: center">3.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.5</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316824002767/auddia_ex0301.htm"><span style="font-size: 10pt">Series B Convertible Preferred Stock Certificate of Designations dated April 23, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04-29-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.6</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825004838/auddia_ex0301.htm">Series C Convertible Preferred Stock Certificate of Designations dated June 30, 2025</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">06-30-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.7</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821000655/auddia_ex0302.htm"><span style="font-size: 10pt">Bylaws of Auddia Inc.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-22-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.8</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316824006330/auddia_ex0301.htm"><span style="font-size: 10pt">Amendment to Bylaws dated September 6, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09-12-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">3.9</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316820000275/clip_ex0305.htm"><span style="font-size: 10pt">Form of Warrant after Conversion from an LLC to a Corporation</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">01-28-2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316820003404/clip_ex0401.htm"><span style="font-size: 10pt">Form of Common Stock Certificate</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-08-2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821000655/auddia_ex0401.htm"><span style="font-size: 10pt">Form of IPO Representative&#8217;s Common Stock Purchase Warrant</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-22-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.3</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821001165/auddia_ex0403.htm"><span style="font-size: 10pt">Description of Securities</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">03-31-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.4</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9903.htm">Form of Merger Holding Company Senior Note</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center">02-17-2026</td>
    <td>&#160;</td>
    <td style="text-align: center">4.1</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">4.5</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="auddia_ex0405.htm">Form of Pre-Funded Warrant</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top">4.6</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="auddia_ex0406.htm">Form of Common Stock Warrant</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top">5.1</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="auddia_ex0501.htm">Opinion of Caroll Legal LLC</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316820003503/clip_ex1003.htm"><span style="font-size: 10pt">Form of Auddia Inc. 2020 Equity Incentive Plan</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-22-2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">**</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316820000275/clip_ex1008.htm"><span style="font-size: 10pt">Agreement with Major United States Broadcast Company</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">01-28-2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.3</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9902.htm"><span style="font-size: 10pt">First Amendment to 2020 Equity Incentive Plan</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-10-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825001357/auddia_ex1005.htm">Second Amendment to 2020 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">03-05-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.5</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9903.htm"><span style="font-size: 10pt">Form of Stock Option Grant Notice and Stock Option Agreement under 2020 Equity Incentive Plan</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-10-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.6</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9904.htm"><span style="font-size: 10pt">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2020 Equity Incentive Plan</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-10-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.7</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9905.htm"><span style="font-size: 10pt">Form of Inducement Stock Option Grant Notice and Inducement Stock Option Agreement</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-10-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.5</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%"><span style="font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 54%"><span style="font-size: 10pt"><b>Description of Document</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-size: 10pt"><b>Incorporated by reference from<br/>
Form</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-size: 10pt"><b>Filing<br/>
Date</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 7%"><span style="font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 6%"><span style="font-size: 10pt"><b>Filed<br/>
Herewith</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.8</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9906.htm"><span style="font-size: 10pt">Clip Interactive, LLC 2013 Equity Incentive Plan</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-10-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.6</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.9</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821003389/auddia_ex9907.htm"><span style="font-size: 10pt">Form of Stock Option Grant Notice and Stock Option Agreement under 2013 Equity Incentive Plan</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-10-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.7</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.10</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821004863/auddia_ex1001.htm"><span style="font-size: 10pt">Executive Officer Employment Agreement for Michael Lawless dated October 13, 2021</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-15-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.11</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316821004863/auddia_ex1002.htm"><span style="font-size: 10pt">Executive Officer Employment Agreement for Peter Shoebridge dated October 13, 2021</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-15-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.13</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316822007731/auddia_ex1002.htm"><span style="font-size: 10pt">Common Stock Warrant dated November 14, 2022</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11-14-2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.14</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316823002585/auddia_ex1002.htm"><span style="font-size: 10pt">Common Stock Warrant for 600,000 shares dated April 17, 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04-21-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.15</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316823002585/auddia_ex1003.htm"><span style="font-size: 10pt">Common Stock Warrant for 650,000 shares dated April 17, 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04-21-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.16</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">#</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316823008909/auddia_ex1001.htm"><span style="font-size: 10pt">Employment Agreement, effective as of November 27, 2023, between Auddia Inc. and John E. Mahoney</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">12-18-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.17</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316824002767/auddia_ex1002.htm"><span style="font-size: 10pt">Form of Common Stock Warrant dated April 23, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04-29-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.18</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1554818/000168316824002767/auddia_ex1003.htm"><span style="font-size: 10pt">Form of Registration Rights Agreement dated April 23, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04-29-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.19</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316823007655/auddia_ex1001.htm"><span style="font-size: 10pt">Common Stock Purchase Agreement, dated as of November 25, 2024, by and between White Lion Capital, LLC and Auddia Inc.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11-25-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.20</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316823007655/auddia_ex1002.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated as of November 25, 2024, by and between White Lion Capital, LLC and Auddia Inc.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11-25-2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.21</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825004838/auddia_ex1001.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement dated June 30, 2025</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">06-30-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.22</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825004838/auddia_ex1002.htm"><span style="font-size: 10pt">Form of Common Stock Warrant dated June 30, 2025</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">06-30-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825004838/auddia_ex1004.htm"><span style="font-size: 10pt">Form of Registration Rights Agreement dated June 30, 2025</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">06-30-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.24</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825005525/auddia_ex1001.htm"><span style="font-size: 10pt">Amendment 1, dated July 30, 2025, to Equity Line Common Stock Purchase Agreement, dated as of November 25, 2024, by and between White Lion Capital, LLC and Auddia Inc.</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">07-30-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.25</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825005802/auddia_ex1035.htm"><span style="font-size: 10pt">Form of Exchange Agreement dated August 5, 2025</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08-08-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.35</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.26</span></td>
    <td style="vertical-align: top">#</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316825006925/auddia_ex1002.htm"><span style="font-size: 10pt">Employment Agreement, effective as of July 1, 2025, between Auddia Inc. and Jeffrey Thramann</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09-12-2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.27</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316826001114/auddia_ex1001.htm"><span style="font-size: 10pt">Form of Merger Support Agreement</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-17-2026</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">10.28</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1554818/000168316826001114/auddia_ex1002.htm"><span style="font-size: 10pt">Form of Merger Lock-Up Agreement</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02-17-2026</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">10.29</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="auddia_ex1029.htm">Form of Securities Purchase Agreement</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="auddia_ex2301.htm">Consent of Haynie &amp; Company, Independent Registered Public Accounting Firm</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">23.2</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">Consent of Carroll Legal LLC (included in <a href="auddia_ex0501.htm">Exhibit 5.1</a>)</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">23.3</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="auddia_ex2303.htm">Consent of Haynie &amp; Company, Independent Registered Public Accounting Firm</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">24.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="#poa"><span style="font-size: 10pt">Power of Attorney</span></a> <span style="font-size: 10pt">(included on signature page)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">107</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="auddia_ex107.htm">Calculation of Filing Fee Table</a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________________________</p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain information contained in this Exhibit has been redacted and appears as &#8220;XXXXX&#8221; as the disclosure of same would be a disadvantage to the Registrant in the marketplace.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates management contract or compensatory plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Financial statement schedules.</b> Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the Financial
Statements or notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 17.</b></span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Undertakings.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The undersigned registrant hereby undertakes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) To file, during any period in which offers
or sales are being made, a post-effective amendment to this registration statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">i. To include any prospectus
required by Section 10(a)(3) of the Securities Act of 1933;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ii. To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table
in the effective registration statement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">iii. To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to
such information in the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) To remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) That for the purpose of determining any liability
under the Securities Act of 1933 in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to
offer or sell such securities to such purchaser:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">i. Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ii. Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">iii. The portion of any other
free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">iv. Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) That for the purpose of determining liability
under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) That for purposes of determining any liability
under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section
15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) The
undersigned registrant hereby undertakes that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) For purposes of determining any liability under the Securities
Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A
and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall
be deemed to be part of this registration statement as of the time it was declared effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="sig"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned,
thereunto duly authorized, in the city of Boulder, in the State of Colorado, on this 3rd day of April, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDDIA INC.</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td>
    <td style="width: 50%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">/s/ John Mahoney</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Mahoney</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="poa"></span><b>POWER OF ATTORNEY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KNOW ALL BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Jeffrey Thramann and John Mahoney such person&#8217;s true and lawful attorneys-in-fact
and agents, with full power to act separately and full power of substitution and re-substitution, for such person and in such person&#8217;s
name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration
statement and all additional registration statements pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the
same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming
all that said attorneys-in-fact and agents or such persons&#8217; substitute or substitutes may lawfully do or cause to be done by virtue
hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the
dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey Thramann, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer, Executive Chairman and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Thramann, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
John Mahoney</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Mahoney</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Nick Balletta</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nick Balletta</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Emmanuel. de Boucaud</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emmanuel &#160;de Boucaud</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Joshua Sroge</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Sroge</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 59; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LVs3f5BdOlTEKWOIeFtclOLWjLROfSTf0rohhkBIzvlyhBiJNa10jQynRZnDAZu2Vg6hxAsymjN6R7bZpuBniVdtHSvj+vUHZuQZ9MwsnCp/752dtlilIMfROI6SGch5OpFQ7ETw1TMyF12hcVrVoEwFBVPLGp3i1/DhoJ5kqHn1SUdkq8mkEIdykN+QyDiBPXXqQXyzkOeZCEZ9BWLNdG+9a/l0aL4kLGtsfJwd6H8HH81uSl8= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>auddia_ex0405.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AUDDIA
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 65%">Warrant Shares: _______</TD>
  <TD STYLE="width: 35%">Issue Date: _______, 2026</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Initial Exercise Date: _______, 2026</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;), to subscribe for and purchase from Auddia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______
shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="background-color: white">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on the OTCQB or the OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on the OTCQB or the OTCQX and if prices for the Common Stock are then reported on The Pink Open Market operated by the OTC
Markets, Inc. (the &ldquo;<U>Pink Market</U>&rdquo;) (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Registration Statement</U>&rdquo;
means the effective registration statement on Form S-1 (File No. 333-[ ]) filed with the Commission, including all information, documents
and exhibits filed with or incorporated by reference into such registration statement, as amended from time to time, which registers the
sale of the Warrants and the Warrant Shares, among others, and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Subsidiary</U>&rdquo;
means the subsidiaries of the Company set forth on <U>Schedule 3.1(a)</U> and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Trading Market on which the Common Stock is then listed is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
Pink Market, the OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transfer Agent</U>&rdquo;
means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place, Woodmere, NY 11598,
and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB or the OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="background-color: white">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as
reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased
as set forth in the applicable Notice(s) of Exercise. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant
Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than
the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise
of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise
price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to
the Termination Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = &nbsp;&nbsp;&nbsp;as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including
until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = &nbsp;&nbsp;&nbsp;the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = &nbsp;&nbsp;&nbsp;the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a
certificate or by electronic delivery through books and records maintained by the Company&rsquo;s transfer agent (at the election of the
Holder), representing the Warrant Shares, registered in the Company&rsquo;s share register in the name of the Holder or its designee,
for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard
Settlement Period, in each case following the delivery of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case after the delivery
to the Company of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a
Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as
a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant
Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds
such exercise. The Company agrees to maintain a transfer agent (which may be the Transfer Agent) that is a participant in the FAST program
so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common
Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of
Exercise delivered on or prior to 4:00 p.m. (New York City time) on the Trading Day immediately prior to the Initial Exercise Date, which
may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share
Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
is received by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares
of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise
of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this
Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) Holder&rsquo;s Affiliates and
(ii) any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made,
but shall exclude the number of Warrant Shares that which would be issuable upon (i) exercise of the remaining, nonexercised portion of
this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall not
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>.&nbsp;In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to
the record holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a reincorporation
in a different state), (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of the Company&rsquo;s assets in one or a series of related transactions,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed
pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of more than 50% of the voting power of the common equity of the Company, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power of the common equity
of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other
Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that
from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other
Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor
Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall
be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares
of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. The Company and, by accepting this Warrant, the Holder each agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company or
the Holder or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. The Company and, by accepting this Warrant, the Holder each
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
The Company and, by accepting this Warrant, the Holder each hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to it at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. If the Company or the Holder shall commence an action, suit or proceeding to enforce any
provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 1680 38<SUP>th</SUP> Street, Suite 130, Boulder, CO 80301, Attention: John Mahoney, Chief
Financial Officer, email address: jmahoney@auddia.com, or such other email address or address as the Company may specify for such purposes
by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in
writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to the Holder at the
e-mail address or address of the Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder
shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via
e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day
after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given. To the extent that any notice provided by the Company hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Auddia Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: __________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;<B>auddia,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><U>______________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U></U>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature: ___________________________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address: ____________________________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>3
<FILENAME>auddia_ex0406.htm
<DESCRIPTION>FORM OF COMMON STOCK WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Auddia
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 65%">Warrant Shares: _______</TD>
  <TD STYLE="width: 35%">Issue Date: _______, 2026</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date set forth above (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on earlier
of (i) five (5) year anniversary following the Initial Exercise Date and (ii) the consummation of the transactions contemplated by the
Merger Agreement, provided that, if such date is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Auddia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock.
The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="background-color: white">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (the &ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (the &ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on the OTCQB or the OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on the OTCQB or the OTCQX and if prices for the Common Stock are then reported on The Pink Open Market operated by the OTC
Markets, Inc. (the &ldquo;<U>Pink Market</U>&rdquo;) (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the </FONT>Warrants
<FONT STYLE="background-color: white">then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Registration Statement</U>&rdquo;
means the effective registration statement on Form S-1 (File No. 333-[ ]) filed with the Commission, including all information, documents
and exhibits filed with or incorporated by reference into such registration statement, as amended from time to time, which registers the
sale of the Warrants and the Warrant Shares, among others, and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Subsidiary</U>&rdquo; means
the subsidiaries of the Company set forth on <U>Schedule 3.1(a)</U> and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Trading Market on which the Common Stock is then listed is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
Pink Market, the OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transfer Agent</U>&rdquo;
means VStock Transfer, LLC,, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place, Woodmere, NY 11598,
and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="background-color: white">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB or the OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="background-color: white">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as
reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased
as set forth in the applicable Notice(s) of Exercise. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$[ ]</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = &nbsp;&nbsp;&nbsp;as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including
until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = &nbsp;&nbsp;&nbsp;&nbsp;the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = &nbsp;&nbsp;&nbsp;the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"> i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate or by electronic delivery through books and records maintained by the Company&rsquo;s transfer agent (at the election of the Holder), representing the Warrant Shares, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day, and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case following the delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">Notwithstanding the
foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 4:00 p.m. (New York City time) on the Trading Day immediately
prior to the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company
agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the
Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares
of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses
shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of
the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form, attached hereto as Exhibit B, duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all
fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner that prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) Holder&rsquo;s Affiliates and
(ii) any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made,
but shall exclude the number of Warrant Shares that which would be issuable upon (i) exercise of the remaining, nonexercised portion of
this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall not
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a reincorporation
in a different state), (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of the Company&rsquo;s assets in one or a series of related transactions,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed
pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of more than 50% of the voting power of the common equity of the Company, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power of the common equity
of the Company, (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder
shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor
Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of
the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however,
that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the
Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same
proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common
Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination
thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection
with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo;
means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of (1) the 30
day volatility, (2) the 100 day volatility or (3) the 365 day volatility, each of clauses (1)-(3) as obtained from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the highest
VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental
Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&rsquo;s
request pursuant to this Section 3(d), (D) a remaining option time equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes
Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five (5) Business
Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions
of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental
Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall
refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity
or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the
Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other
Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had
been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section
3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or
(ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. The Company and, by accepting this Warrant, the Holder each agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against the Company or
the Holder or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. The Company and, by accepting this Warrant, the Holder each
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
The Company and, by accepting this Warrant, the Holder each hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with
evidence of delivery) to it at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. If the Company or the Holder shall commence an action, suit or proceeding to enforce any
provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact
that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 1680 38<SUP>th</SUP> Street, Suite 130, Boulder, CO 80301, Attention: John Mahoney, Chief
Financial Officer, email address: jmahoney@auddia.com , or such other email address or address as the Company may specify for such purposes
by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in
writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to the Holder at the
e-mail address or address of the Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder
shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via
e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day
after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given. To the extent that any notice provided by the Company hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AUDDIA INC.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: __________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;<B>AUDDIA
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><U></U>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U></U>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature: __________________________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address: ___________________________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>auddia_ex0501.htm
<DESCRIPTION>OPINION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Carroll Legal LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1449 Wynkoop Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Suite 507</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Denver, CO 80202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">April 3, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Auddia Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1680 38th Street, Suite 130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boulder, Colorado 80301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Re:&nbsp;<U>Registration Statement on Form S-1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as special counsel to Auddia Inc., a Delaware corporation
(the &ldquo;Company&rdquo;), in connection with the filing of the Registration Statement, including a preliminary prospectus forming a
part thereof (as amended, the &ldquo;Registration Statement&rdquo;), on Form S-1 with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registration Statement relates to the proposed offering and sale
of up to $12,000,000 of the Company&rsquo;s securities to the public consisting of (i) shares of the Company&rsquo;s common stock (the
&ldquo;Common Stock&rdquo;), $0.001 par value per share (the &ldquo;Common Shares&rdquo;); (ii) warrants to purchase shares of Common
Stock (the &ldquo;Non-Prefunded Warrants&rdquo;); (iii) shares of Common Stock issuable upon exercise of the Non-Prefunded Warrants (the
&ldquo;Non-Prefunded Warrant Shares&rdquo;); (iv) prefunded warrants to purchase shares of Common Stock (the &ldquo;Prefunded Warrants&rdquo;);
and (v) shares of Common Stock issuable upon exercise of the Prefunded Warrants (the &ldquo;Prefunded Warrant Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Non-Prefunded Warrants and the Prefunded Warrants are collectively
referred to herein as the &ldquo;Warrants.&rdquo; The Non-Prefunded Warrant Shares and the Prefunded Warrant Shares are collectively referred
to herein as the &ldquo;Warrant Shares.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities are to be offered and sold in the manner described in
the Registration Statement and the related prospectus included therein (the &ldquo;Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection herewith, we have examined the Registration Statement
and the Prospectus. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of the Company&rsquo;s
Certificate of Incorporation and Bylaws (both as amended to date), and such other records, agreements and instruments of the Company,
certificates of public officials and officers of the Company, and such other documents, records and instruments, and we have made such
legal and factual inquiries, as we have deemed necessary or appropriate as a basis for us to render the opinions hereinafter expressed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our examination of the foregoing, we have assumed the genuineness
of all signatures, the legal competence and capacity of natural persons, the authenticity of documents submitted to us as originals and
the conformity with authentic original documents of all documents submitted to us as copies or by facsimile or other means of electronic
transmission, or which we obtained from the Commission&rsquo;s Electronic Data Gathering, Analysis and Retrieval system (&ldquo;Edgar&rdquo;)
or other sites maintained by a court or governmental authority or regulatory body and the authenticity of the originals of such latter
documents. If any documents we examined in printed, word processed or similar form has been filed with the Commission on Edgar or such
court or governmental authority or regulatory body, we have assumed that the document so filed is identical to the document we examined
except for formatting changes. When relevant facts were not independently established, we have relied without independent investigation
as to matters of fact upon statements of governmental officials and certificates and statements of appropriate representatives of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing and in reliance thereon, and subject to the
assumptions, comments, qualifications, limitations and exceptions set forth herein, we are of the opinion, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Common Shares, when issued against payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and
non-assessable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Warrants, when issued as set forth in the Registration Statement, will be legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Warrant Shares, when issued upon exercise of the Warrants against payment therefor as set forth in the Registration Statement, will be
validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our opinions herein reflect only the application of the General Corporation
Law of the State of Delaware. The opinions set forth herein are made as of the date hereof and are subject to, and may be limited by,
future changes in factual matters, and we undertake no duty to advise you of the same. The opinions expressed herein are based upon the
law in effect (and published or otherwise generally available) on the date hereof, and we assume no obligation to revise or supplement
these opinions should such law be changed by legislative action, judicial decision or otherwise. In rendering our opinions, we have not
considered, and hereby disclaim any opinion as to, the application or impact of any laws, cases, decisions, rules or regulations of any
other jurisdiction, court or administrative agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not render any opinions except as set forth above. We hereby
consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the use of our name under the caption
&ldquo;Legal Matters&rdquo; in the prospectus filed as a part thereof. We also consent to your filing copies of this opinion letter as
an exhibit to the Registration Statement with agencies of such states as you deem necessary in the course of complying with the laws of
such states regarding the offering and sale of the Company&rsquo;s securities. In giving such consent, we do not thereby concede that
we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARROLL LEGAL LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James H. Carroll</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James H. Carroll</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>5
<FILENAME>auddia_ex1029.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.29</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of April [ ], 2026, between Auddia Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below),
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>BHCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(mm).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares and the Warrants pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Shares and the Warrants, in each case, have been satisfied or waived, but in no event later than the first
(1<SUP>st</SUP>) Trading Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement
is signed on a day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading
Day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, in the form of <U>Exhibit B</U> attached hereto, which shall be exercisable immediately and have a term of exercise
that expires on the earlier of (i) five (5) year anniversary following the initial exercise date and (ii) the consummation of the transactions
contemplated by the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Carroll Legal LLC, with offices located at 1449 Wynkoop Street, Suite 507, Denver, CO 80202.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) warrants
to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of the warrants
to the Placement Agent, if applicable, and/or securities upon the exercise or exchange of or conversion of any Securities issued hereunder
and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date
of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such
securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock
splits, adjustments or combinations as set forth in such securities) or to extend the term of such securities, (c) securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the prohibition period set forth in the Placement Agent Engagement
Letter, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and
(d) the Shares and Warrants issued to other purchasers pursuant to the Prospectus concurrently with the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Federal
Reserve</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(mm).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GDPR</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(oo).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Merger
Agreement</U>&rdquo; means that certain Agreement and Plan of Merger, as may be amended, dated as of February 17, 2026, by and among,
McCarthy Finney, Inc., Auddia Merger Sub, Inc., Thramann Merger Sub LLC, and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $[ ], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date, provided
that the purchase price per Pre-Funded Warrant shall be the Per Share Purchase Price minus $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Personal
Data</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(oo).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Dawson James Securities Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent Engagement Letter</U>&rdquo; means that certain letter agreement between the Placement Agent and Company, dated as March 4, 2026,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Policies</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(oo).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in full, in the
form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any amendment
thereto, or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Securities Act,
including all information, documents and exhibits filed with or incorporated by reference into such preliminary prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pricing
Prospectus</U>&rdquo; means (i) the Preliminary Prospectus relating to the Securities that was included in the Registration Statement
immediately prior to [ ] [a.m. / p.m.] (New York City time) on the date hereof and (ii) any free writing prospectus (as defined in the
Securities Act) identified on <U>Schedule A</U> hereto, taken together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Privacy
Laws</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(oo).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed pursuant to the Registration Statement, including all information, documents and exhibits filed with
or incorporated by reference into such final prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form S-1 (File No. 333-[ ]) filed with the Commission, including all
information, documents and exhibits filed with or incorporated by reference into such registration statement, as amended from time to
time, which registers the issuance and sale of the Securities to the Purchasers, and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 462(b)
Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities, which was
filed with the Commission on or prior to the time at which sales of the Shares and the Warrants were confirmed and became automatically
effective pursuant to Rule 462(b) promulgated by the Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sanctions</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(kk).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement, but excluding the Warrant Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Shares, the Pre-Funded Warrants (if applicable)
and the Common Warrants purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and
next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds (excluding for the
avoidance of doubt, if applicable, a Purchaser&rsquo;s aggregate exercise price of the Pre-Funded Warrants, which amounts shall be paid
as and when such Pre-Funded Warrants are exercised for cash).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company, as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, NY 11598, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $[ ] of Shares and Common Warrants; provided,
however, that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s
Affiliates, and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially
own in excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser
may elect, by so indicating such election prior to their issuance, to purchase Pre-Funded Warrants in lieu of Shares in such manner to
result in the same aggregate purchase price being paid by such Purchaser to the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, with respect to each Purchaser, at the election of such Purchaser at Closing, 9.99%) of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of the Shares on the Closing Date. In each case, the election
to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser&rsquo;s Subscription Amount as set forth on the
signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and Common Warrants (and,
if applicable, Pre-Funded Warrants) as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other
items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2
and 2.3, the Closing shall take place remotely by electronic transmission of the Closing documentation. Each Purchaser acknowledges that,
concurrently with the Closing and pursuant to the Prospectus, the Company may sell up to $[ ] of additional Shares and Warrants to purchasers
not party to this Agreement, and will issue to each such purchaser such additional Shares and Common Warrants and/or Pre-Funded Warrants
and Common Warrants in the same form and at the same Per Share Purchase Price. Unless otherwise directed by the Placement Agent, settlement
of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names
and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon
receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment
therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything herein
to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through,
and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any
Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement
Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company),
be deemed to be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement
Shares to such Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such
Purchaser prior to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that
the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to
whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision
to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if
any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
with respect to any Notice(s) of Exercise (as defined in the Warrants) delivered on or prior to 4:00 p.m. (New York City time) on the
Trading Day immediately prior to the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the
Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing
Date shall be the Warrant Share Delivery Date (as defined in the Warrants) for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable
to the Placement Agent and Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by
the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver
on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system Shares equal to such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable upon exercise of such
Purchaser&rsquo;s Pre-Funded Warrants, if applicable), registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of
such Purchaser&rsquo;s Shares and Pre-Funded Warrant Shares, if applicable, with an exercise price equal to $[ ] per share, subject to
adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if applicable, for each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of
such Purchaser to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount
applicable to Pre-Funded Warrants divided by the Per Share Purchase Price minus $0.001, with an exercise price equal to $0.001 per share,
subject to adjustment therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>this Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>such Purchaser&rsquo;s Subscription Amount (minus, if applicable, a Purchaser&rsquo;s aggregate exercise price of the Pre-Funded
Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash), which shall be made available for
DVP settlement with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless such representation or warranty is as of a specific date therein in which case they shall be accurate in all material respects
(or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such
date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless such representation or warranty is as of a specific date therein in which case they shall be accurate in all material respects
(or to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Warranties of the Company</U>. Except as set forth in the SEC Reports and Disclosure Schedules, which SEC Reports
and Disclosure Schedules shall be deemed a part hereof and shall qualify all representations made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties
to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>. All of the Subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not
have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and
the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection
herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms
hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with
its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filings, Consents and Approvals</U>. Except as set forth in <U>Schedule 3.1(e)</U>, the Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state,
local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the
Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission
of the Pricing Prospectus and the Prospectus, (iii) the notice and/or application(s) to each applicable Trading Market for the issuance
and sale of the Securities and the listing of the Shares and the Warrant Shares for trading thereon in the time and manner required thereby,
(iv) any filings with FINRA, and (v) such filings as are required to be made under applicable state securities laws (collectively, the
&ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Issuance of the Securities; Registration</U>. The Shares and the Warrants are duly authorized and, when issued and paid for
in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear
of all Liens imposed by the Company. The Warrants, when paid for and issued in accordance with this Agreement, will constitute valid and
binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general
principles of equity. The Pre-Funded Warrant Shares are duly authorized, and when issued in accordance with the terms of the Pre-Funded
Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Common Warrant
Shares are duly authorized, and when issued in accordance with the terms of the Common Warrants, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the
maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on&nbsp;[ ], 2026, including
the Pricing Prospectus and the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.
The Company was at the time of the filing of the Registration Statement eligible to use Form S-1. The Registration Statement is effective
under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing
the use of the Pricing Prospectus or the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission,
shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;
and the Pricing Prospectus and the Prospectus and any amendments or supplements thereto, at the time the Pricing Prospectus or the Prospectus,
as applicable, or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which
<U>Schedule 3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the
Company as of the date hereof. Except as set forth on <U>Schedule 3.1(g)</U>, the Company has not issued any capital stock since its most
recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s
stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities
and as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are
no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange
or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the
Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements
or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully
paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares
was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two (2) years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Pricing Prospectus
and the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a
valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
The Company has never been an issuer subject to Rule 144(i) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed
in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or
made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate,
except pursuant to existing Company equity compensation plans. The Company does not have pending before the Commission any request for
confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule
3.1(i)</U>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur
or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or
financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation
is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is
made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge
of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an
&ldquo;<U>Action</U>&rdquo;). There is no Action that adversely affects or challenges the legality, validity or enforceability of any
of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to
result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject
of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and
foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under),
nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Environmental Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each of clause
(i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Property; Title to Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) The Company and each of
its Subsidiaries, as applicable, has legal, valid and marketable title to, or a valid leasehold interest in, all assets and properties
reflected as owned or leased by it, as described in the Registration Statement and Prospectus, in each case free and clear of all liens,
security interests, pledges, charges, encumbrances, encroachments, restrictions, mortgages and defects, except such as (i) are disclosed
in the each of the Registration Statement and Prospectus or (ii) could not reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect. Any real property, buildings, improvements, equipment or personal property held or to be held under lease
by the Company or any Subsidiary is held under a lease that is valid, existing and enforceable by the Company or such Subsidiary, with
such exceptions as (i) are disclosed in the Registration Statement and Prospectus or (ii) could not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect, and neither the Company nor any Subsidiary has received any written notice of
any claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any such lease, except
as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81.6pt"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) No tenant under any lease
of the Company or any Subsidiary holds the lessor&rsquo;s interest (collectively, the &ldquo;Leases&rdquo;) has an option, right of first
offer or right of first refusal to purchase the premises demised under such Lease, except as such options, rights of first offer or rights
of first refusal which, if exercised, would not reasonably be expected to have a Material Adverse Effect; neither the Company, any Subsidiary
nor, to the Company&rsquo;s knowledge, any other party to any Lease is in breach of or default under any such Lease, except such as are
disclosed in each of the Registration Statement and Prospectus or as could not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect; to the Company&rsquo;s knowledge, no event has occurred, which with or without the passage of time
or the giving of notice, or both, would, individually or together with all such other events, constitute a default under any Lease, or
would permit termination, modification or acceleration under such Lease, except such as are disclosed in each of the Registration Statement
and Prospectus or as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) None of the Company
or any Subsidiary has actual knowledge that any real property owned or leased by the Company or any Subsidiary fails to comply in all
material respects with all applicable codes, laws and regulations (including, without limitation, building and zoning codes, laws and
regulations and laws relating to access to such property), except as are disclosed in each of the Registration Statement and Prospectus
or as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) The Company and the Subsidiaries
have good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of
this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of
the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license
rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any
rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage of $5 million. Neither the Company nor any Subsidiary has any
reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transactions With Affiliates and Employees</U>. Except as described in the SEC Reports, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof and as of the Closing Date, and any
and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the
Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed
by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time
periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the &ldquo;Evaluation Date&rdquo;). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal
control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Fees</U>. Except as set forth in the Pricing Prospectus or the Prospectus, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights</U>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any
Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. Except as set forth on <U>Schedule 3.1(w)</U>, the Company is, and
has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance
requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their
agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not
otherwise disclosed in the Pricing Prospectus or the Prospectus. The Company understands and confirms that the Purchasers will rely on
the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of
the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated
hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this
Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made,
not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect
to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the
Securities to be integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets
exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking
into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws
of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases
required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, subject
to permitted extensions, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for
the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accountants</U>. The Company&rsquo;s current independent registered public accounting firm is set forth on <U>Schedule 3.1(dd)</U>
of the Disclosure Schedules. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm
as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s
Annual Report for the fiscal year ending December 31, 2026.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each
Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based solely on
the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-decoration: none double">Acknowledgment Regarding Purchaser&rsquo;s Trading Activity. Anything in this Agreement
or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by
the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing
or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company
or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically
including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private
placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser,
and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with
or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. </FONT>The Company further understands
and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities
are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities
are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in
the Company at and after the time that the hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned
hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulation M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with
the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>[Reserved.]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)
in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cybersecurity</U>.&nbsp; (i) (x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s
or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and have no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data;
(ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules
and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to
the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times were, in compliance with all
applicable state, federal and foreign data privacy and security laws and regulations, including, without limitation and to the extent
applicable to the Company and the Subsidiaries, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU
2016/679) (collectively, &ldquo;<U>Privacy Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take
appropriate steps reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and
the collection, storage, use, disclosure, handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;);
(iii) the Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives
as required by Privacy Laws; and (iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy
practices relating to its subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices,
as required by Privacy Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number,
email address, photograph, social security number, bank information, or customer or account number; (ii) &ldquo;personal data&rdquo; as
defined by GDPR; and (iii) any other piece of information that allows the identification of such natural person, or his or her family,
or permits the collection or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. None
of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy
Laws and the Company does not have any reason to believe that the execution, delivery and performance of the Transaction Documents will
result in a breach of any Privacy Laws or Policies. Neither the Company nor the Subsidiaries, (i) has, to the knowledge of the Company,
received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation
by the Company or the Subsidiaries of, any of the Privacy Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation,
remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to
any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that imposed any obligation
or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which
it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will
constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on
each date on which it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1),
(a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo;
as defined in Rule 144A(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the
Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser
has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed
any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.
Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Shares and Warrant Shares</U>. The Shares shall be issued free of legends. If all or any portion of a Warrant is exercised at
a time when there is an effective registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised
via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following
the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares)
is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify the
holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders
when the registration statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and
agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in
compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including
the Registration Statement) registering the issuance or resale of the Warrant Shares effective while the Warrants are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Furnishing of Information.</U> Until the earlier of the time that (i) no Purchaser owns Securities and (ii) the Common Warrants
have expired or are no longer outstanding, the Company covenants to timely file (or obtain extensions in respect thereof and file within
the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if
the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes
of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other
transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of
the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents,
including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In
addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar
obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers
or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission
and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stockholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing
to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To
the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates
delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and
agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any
of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the
Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject
to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder as set forth in the Pricing
Prospectus and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of
trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) for the settlement of any outstanding litigation, or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, stockholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, stockholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against
any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify
the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and
keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the
Company to issue the Shares pursuant to this Agreement and the Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common
Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall submit the appropriate
notification relating to the Shares and the Warrant Shares to such Trading Market. The Company further agrees, if the Company applies
to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and the Warrant
Shares, and will take such other action as is necessary to cause all of the Shares and the Warrant Shares to be listed or quoted on such
other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading
of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also
offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class
and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting
of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure
Schedules (other than as disclosed to its legal and other representatives).&nbsp; Notwithstanding the foregoing and notwithstanding anything
contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty
not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors,
employees, Affiliates or agent, including, without limitation, the Placement Agent, after the issuance of the initial press release as
described in Section 4.4.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge
of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set
forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capital Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward
stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest
of the Shares[, other than a reverse stock split that is required, in the good faith determination of the Board of Directors, to maintain
the listing of the Common Stock on the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver the Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>.&nbsp; This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder
only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>,
<U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise
notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Pricing Prospectus and
the Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all
prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into
such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to
be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares
and the Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser)
or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment,
modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in
interest of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any
party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred
Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties
of the Company in Section 3.1, the covenants of the Company in Article 4 and the representations and warranties of the Purchasers in Section
3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not
for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this
Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for
its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
or a &ldquo;.pdf&rdquo; format data file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic
Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method,
such signature shall be deemed to have been duly and validly delivered and shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by
such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the
defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in
any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and
Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the
Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and
other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AUDDIA INC.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: __________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 42%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for Notice:</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>1680 38<SUP>th</SUP> Street, Suite 130</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Boulder, CO 80301</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Attention: John Mahoney, Chief Financial Officer</U></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With a copy to (which shall not constitute notice):</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E-Mail: jmahoney@auddia.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">AUUD</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings">o</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">o</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Warrant Shares: _____________ Beneficial Ownership Blocker <FONT STYLE="font-family: Wingdings">o</FONT>
4.99% or <FONT STYLE="font-family: Wingdings">o</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 24pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">o</FONT>
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company
to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing
shall occur by the first (1<SUP>st</SUP>) Trading Day following the date of this Agreement (or the second (2nd) Trading Day following
the date hereof if this Agreement is signed on a day that is not Trading Day or after 4:00 p.m. (New York City time) and before midnight
(New York City time) on a Trading Day) and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded
by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or
purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed
(as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on
the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>auddia_ex2301.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
We consent to the incorporation by reference in this Registration Statement on Form S-1 of Auddia Inc. of our report dated March 6, 2025,
relating to the financial statements of Auddia Inc, which appears in Auddia Inc&rsquo;s Annual Form 10-K for the years ended December
31, 2025 and 2024. Our audit report includes an explanatory paragraph relating to Auddia Inc.&rsquo;s ability to continue as a going concern.
Our audit also did not include any adjustments for the reverse-stock-split which was effectuated on March 31, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
We also consent to the reference to our firm under the caption &quot;Experts&quot; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
<BR>
/s/ Haynie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Salt Lake City, Utah</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 3, 2026</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>7
<FILENAME>auddia_ex2303.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
We consent to the incorporation by reference in this Registration Statement on Form S-1 of Auddia Inc. of our report dated March 5, 2026,
relating to the financial statements of Thramann Holdings, LLC, which appears in Auddia Inc&rsquo;s Current Report Form 8-K, Exhbit 99.1
for the years ended December 31, 2025 and 2024. Our audit report includes an explanatory paragraph relating to Auddia Inc.&rsquo;s ability
to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
We also consent to the reference to our firm under the caption &quot;Experts&quot; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
<BR>
<BR>
<BR>
/s/ Haynie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Salt Lake City, Utah</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 3, 2026</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>auddia_ex107.htm
<DESCRIPTION>FILING FEE TABLES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.4a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: d149969d4ca4dcc78f3d113c08487173 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">S-1</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0001554818</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-04-01</xbrli:startDate>
          <xbrli:endDate>2026-04-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_2">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>2</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-04-01</xbrli:startDate>
          <xbrli:endDate>2026-04-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_3">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>3</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-04-01</xbrli:startDate>
          <xbrli:endDate>2026-04-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_4">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>4</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-04-01</xbrli:startDate>
          <xbrli:endDate>2026-04-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_5">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>5</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-04-01</xbrli:startDate>
          <xbrli:endDate>2026-04-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0001554818</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-04-01</xbrli:startDate>
          <xbrli:endDate>2026-04-01</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">S-1</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">AUDDIA INC.</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457oFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">457(o)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">12,000,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">1,657.20</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_2" format="ixt:booleanfalse" id="fee_016">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_2" id="fee_017">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_2" id="fee_018">Common Warrants accompanying the Common Stock or Pre-Funded Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(2)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_2" format="ixt:booleantrue" id="fee_019">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_2" id="fee_020">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_2" id="fee_021">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_3" format="ixt:booleanfalse" id="fee_022">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_3" id="fee_023">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_3" id="fee_024">Pre-Funded Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(3)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_3" format="ixt:booleantrue" id="fee_025">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_3" id="fee_026">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_3" id="fee_027">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_4" format="ixt:booleanfalse" id="fee_028">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_4" id="fee_029">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_4" id="fee_030">Common Stock underlying the Pre-Funded Warrants (3)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(4)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457oFlg" contextRef="c_offering_4" format="ixt:booleantrue" id="fee_031">457(o)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_4" id="fee_032">0.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_4" id="fee_033">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_4" id="fee_034">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_5" format="ixt:booleanfalse" id="fee_035">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_5" id="fee_036">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_5" id="fee_037">Common Stock underlying the Common Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">&#160;</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457oFlg" contextRef="c_offering_5" format="ixt:booleantrue" id="fee_038">457(o)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_5" id="fee_039">12,000,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_5" id="fee_040">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_5" id="fee_041">1,657.20</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_042">24,000,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_043">3,314.40</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_044">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_045">3,314.40</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_046">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(2)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_2" id="fee_047">Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(3)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_3" id="fee_048">The proposed maximum aggregate offering price of the Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants sold in the offering and the proposed maximum aggregate offering price of the Pre-Funded Warrants proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Stock sold in the offering, and, as such, the proposed maximum aggregate offering price of the Common Shares and Pre-Funded Warrants (including the Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $12,000,000.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(4)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_4" id="fee_049">Pursuant to Rule 457(g) of the Securities Act, no separate registration fee is required for the Pre-Funded Warrants because the Pre-Funded Warrants are being registered in the same registration statement as the Common Stock issuable upon exercise of the Pre-Funded Warrants.</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>auud-20260402.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaCLCaPty552qYkxvmR3fbkKHycoKCetSCQgrQbWcZAI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:AUUD="http://auddia.com/20260402" elementFormDefault="qualified" targetNamespace="http://auddia.com/20260402">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://auddia.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="auud-20260402_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="auud-20260402_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>auud-20260402_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>auud-20260402_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="auud-20260402.xsd#Cover" roleURI="http://auddia.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://auddia.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 02, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Auddia Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001554818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4257218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1680 38th Street, Suite 130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">219-9771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Apr. 01, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001554818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">AUDDIA INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 12,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,657.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Warrants accompanying the Common Stock or Pre-Funded Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Pre-Funded Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">The proposed maximum aggregate offering price of the Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants sold in the offering and the proposed maximum aggregate offering price of the Pre-Funded Warrants proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Stock sold in the offering, and, as such, the proposed maximum aggregate offering price of the Common Shares and Pre-Funded Warrants (including the Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $12,000,000.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock underlying the Pre-Funded Warrants (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 457(g) of the Securities Act, no separate registration fee is required for the Pre-Funded Warrants because the Pre-Funded Warrants are being registered in the same registration statement as the Common Stock issuable upon exercise of the Pre-Funded Warrants.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock underlying the Common Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 12,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,657.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 24,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">3,314.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 3,314.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>7</ContextCount>
  <ElementCount>37</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="auddia_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://auddia.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="auddia_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="auddia_ex107.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="auddia_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" isOnlyDei="true" isUsgaap="true" original="auddia_s1.htm">auddia_s1.htm</File>
    <File>auud-20260402.xsd</File>
    <File>auud-20260402_lab.xml</File>
    <File>auud-20260402_pre.xml</File>
    <File doctype="EX-FILING FEES" original="auddia_ex107.htm">auddia_ex107.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>24
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "auddia_s1.htm": {
   "nsprefix": "AUUD",
   "nsuri": "http://auddia.com/20260402",
   "dts": {
    "inline": {
     "local": [
      "auddia_s1.htm"
     ]
    },
    "schema": {
     "local": [
      "auud-20260402.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "auud-20260402_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "auud-20260402_pre.xml"
     ]
    }
   },
   "keyStandard": 16,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 16
   },
   "report": {
    "R1": {
     "role": "http://auddia.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-04-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_s1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-04-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_s1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://auddia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    }
   }
  },
  "auddia_ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "auddia_ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/ffd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 6,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 47,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "auddia_ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001683168-26-002663-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-26-002663-xbrl.zip
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MN2YY'N7**U,F$NA0#D*;-RE%+$1+Q<JEKR'ZP(;#6RQ04UW#]V!WP _0P8Z
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MX&U4U>L@WVT$^9Y_TR#?K7)_M1^+)_OO#WY#[>+)F]-W;W?_/U!+ P04
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M;V&QP-3R&<<[7?=%[_ME<HT1J)@8(_]P:OP2?X?W7/9./*FX22:TVL>^=K@
MP=[O4WM$-/QM K6T=JP"J;$2I$PF8'M@48G=Y]:\AH/FQ,QKE9&3[]!L%,_
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M<4URJZ#)MRQ7ABQ:M-EGVK*L V6>ZAK(@/9\TQRGR ORXUYY9NL-:CNF"0.
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MS!\#>3SAR6NZ0R/P33'VS@M%'A'_1@57NE!MSP58M^4LRM/?G0BB^%_,9^U
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M0Z%1#LI^4VH;4<P1XLI2/M7&,J9I%QW<C6'!>QG&!OC@B'S=!1 >K,4'_P3
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M"SU!U^*"DQ*V,.\X? 2AY!B%XO&('-6GL*8"]Y06_*,?BF%YG'I\>[7!0#N
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MQ,J%HH9"X99R66#RP2? 0*)%.)XSC<DF^T^0BG4'!MP&(URN9:!J-/Z?NF7
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M6,, F]/]=.]1W)T4<:#AYQ9C/*CE<NF]K769V.]F@+;^8]G;^S'\S@"EK_<
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M9+R$!HJ,VNBKKC#(S0/IP-X#PXF3)T)R1_#-*9,+,Y$3G^?>NKM/R+4[FK&
M+?"FO2CJ\I]L>N)B_G\<XYP5E@H\W!&._CBUY3!F"^8A:%"0>0)D@[O2M"LT
MMMDU\'RT#3^8:/*M.)I?R\[V%,83X*)!IC\KX[XPHRJNW?[^!<2IFY?N8"B)
M-]<^59RI1KUE[G,L%*;K2B17;ZZQ.I<V@ICSQ!^+1/7X(58*X)U7;;/"9*AE
M1H0-8AM2-;#UVI9:2>*5TW6'3/X4Q?:,QYBP62/=RC&L>"D\C'YV:S;.N3I7
M]FM)/,!792/^ 5XS-XL"F>)%5UAZ2"R%[VS"*>+-GN&P:5W)WBXPHUNQR@BF
M"RGP>7Y;V_9.SQ[['["7VUXWQ!/NYUCG"G=,+"0D&CZ8CE/'\Z)F#26@LT(
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MP>V /GGC+'<X?-?+);4,)_KET8;-E!,("D]CCXB-T-3YS5:M=X&\R[#N8U,
M[#N'$!,KQC(@T^M[8FC\UN6AAST5/F9XP_X+/!UN>O!RMH#E;ML[6T\W?NS3
MC<ZTH ,@:_)/GE7*"UGK.;,];]CHPJACTK8#^\72V<LORLZ#+\+7X<C@CTW1
MSG'TSRF*@]W7T\DV#J" >3A'N%X TN.U(2^2?VO_$'^NJ,= ?>=V:*<K=-:*
MJL/5'%FOT85"P2$O!CL,D=,M/6R< 8?@)N);<H)!?6S< AQMI7+E9"(APK92
M)I  8.\^GA )"??\[YP?J1H#X.7D6-!ETY+].2_SL??H' \,/UT4:)0&WP]'
MA//1\9"<_T6>3V=SDOBFDNCDV!S=7=*JE?7J/=L)Y@O;]:J?88.3&JR%*SC^
M-D@_%8845#Z1=@TOGHU3V"?*C7G;DD5.?<J\>J, 7HO48(WO@R-A-9>?M5Y6
M\%+TJ-9@C !)R!HFAY<:8^>Y.22=^"K<NZZL?UG7'"6 .R")71B_I)EH,0-@
MXQ[L+.&$+(I6R*'-LO9^L/2FZMMRNN8MHX(30L>A1J]F'%[D'AGZD_F=/83!
M_GO6U M8E[[SQZX[=W*O6ZB]B!>H)!AJH.-N.(O(9^103:#C<A<&IT=1^+FH
M?%<_E2J6A_RVPTL:+L$?\X9P"ZXI&/Z!RF4FDY39 X%#=88[ %FICY2;.V4D
M&^_C?>Z;,& '>WF'B%VV<\#.QCRB\><2:/'-7&RH<4(C/3PP5\;V+J47YA82
M!/M %XC>$_$G\ &8Y9>N_>>L6:K;'7&H(_<Q*EXK,/KM46"3('R0A6%.B<%2
M0D9BL-'A,9A7>K,+U'$8UL5IZN@*T:[X<VH'*%,*;E ]MVW@^O+!O*S6-LQH
M\QV>?ZK#-E2SF:F,#T;.4$ K"=I.K'#8GDH\;7EZTA 7R"B,PG?[X',A6Q2S
MDH-T<S/M_9HS!R5W.9H8).."(PWCI7I*5%@Y^#5%S_R]:&U\"Y9&Q4Q'YU?;
M(?@:&^SI0WP:O TDBBKK=>-RX>VXH1-U$5M04%,%ZJ*2B*%AE3O!EJ8Q%"JU
MPE:H@+K(&FPA$,<UA@-;<[&N"MMTEN34PEK\:<DJ<$8Y,3MQF.-K?2Z"$?!@
MH)+L-: L:^J66(&T:(<D/;W1;-@WGOA>9PLS9[NBIKAQK]-K;!%PNSS[-MU1
MSFN3N:6A@_GFM;EI99Y:<\MNY(*EVGH>LPK)ECJQ7*P%(4VZ,$."6H) 93EE
M6$%^UX1%X\@XU4]83I<\^XC0-PQ]!*EYGZP,<V>MC!<4+(;'@:W1.1_9[>*M
MH)<X@V\H@Q\B0$!8\:#6@/QFBA@3%OX9/Q6<E:*D1MV%#CUPZG!.A<,Y'QZ<
MI:,CKV\8X8@=5!DQ9^/>S.@H1P$?JX$J8&4ANS?GK0LG2-7,5$8C4!AA6)R_
MES9F(Z[FIQIJW-QJ:)#ERKWE?!+EM'CY_/RFJ"^?'#])M:\B7>!O$E >"1#6
M.?U('HG7*&X_UYA"]8?ELX%R>[Q&TG%5.5[8[,IB>Y3;$8)&";:@#4T!.FRW
M-"O)7H?='NVW42LN>H(\E%WFVFHZ,@7P9](:W LOFZ(@*HB15T+7\>2]>/GZ
M_)0Q(Y.K(U:N]H+"(FB#RA1"9TF4R4]&^BP9MI\\// YI^$)K+--]TC9[I][
M=W)&W^YS1K>0,_IVGS/Z@^ZYR>).&9)#<_*E#0P-3NFGX"-ZJ\P'M-*G-!^6
M<9K"Q\45<)+H(8G"<21$'EH9*<N*XDE3^SRX9XC/S!4P4](>M8=FYA& E&PF
MS*80@A0K+9IN$.+G=]?4ETAM)&\BX"MZP^0[A79<'.=W,?[#@V&0/P[4Y)\0
MYL>ORU:#V\*0?R'0K!"YA%4Q<=QYM_"^COFP5^UB]Y1Y=!$D%[K7Q53<(\T&
M*^0+5\HE 3W&"?.JC#8?2,ED[FE)MZV83-$-_*<BAK]%^K*=A2]L N%:<W^V
M=PSOO_/K81#B<[V?2U!CI4%[A9RP;;-D'M=(M82P;;*ME\6O5#JW>XL5[7R-
MA-SM= S'N&K-JFA%J8'7P/[&X8%6FUSQ1C=DMQ-=271*0TAM&U;%ASSJM@1E
M:F;8YH#A=4284K,^_^_L?_+LT<-'7^&>E% 7YZ%W] )YRQ&5KP1Q._D,-+$,
MC5PI! !P.LJGIK6#U-NZSR$=&'C):OZNBRYH]"TO;B,""XE1)B<2G/.+4LK>
M$&;\ C&$[QZ<\ J-S7[G)^[P8(RRWN;(0:A6$LB 5<8 O@7H<=FFU63NEH2#
MW3[L\->-OC,OUKI3=,N#=1/_6GWBT8>\QX=5L?(V*X=8%"\:<Q'2*5HMI <Q
M8IK $:NXWO:#@Z@@G"YF($R=>GZP98B&.D8:M&N;0E8Q5ZV/^$;8Q8+JIG"7
MQ=.0B(($^YKZ%#QY]&0R/3K.3I7,;5DK2FIC-L'O!Y%_)#4,MV%N!3DM^'RO
MH K35A5_RO.M#K$U+=:6$"#M"%&.+.7-NH;!,>5\F+F32C,:UKKNV[5$/3B!
M0K0S[KF+8L9A.T2N8G5+;]-[X251;(4NDZ!-24:$Q[? %10WQ"&[YW;N6APA
M+#X<."CF3WEN=M: J?FF[3I0?WF@M7;=JICLZ@(.=DG?N.>%CW.+C6I2EQRE
MQ,@)1+:S/+@>LY]'( ;RD.TD#NZ"PP.ZPB\V+?Z<^_=L675735VA0>D*R\H6
M_ 1NL6L!XBY?!"</5A=@%"^/A.8>1=PF%W?**PU(V]FL$T?">YVSX/-!W8R3
M7LTZP8Q86VL8+R0#(NBP]->6#*'J&C&P6")OM#.I! 8T6VT6)19?4 ED36BZ
MUJ UCDB$['2!9@]S)4A"8>M[I=,[6UY.SQ0:#2CW3JML(DN:*5?0XEXV'6AV
M&"A78K&%NP(I:.;E3)@E5(T9#(H)$<AD5="^T,@V04M#!) T&V-L]>5*EW4D
MX!]8U^0OS%9547<1PF5\.3"+(<_K!J.*<2;1R%P])CV2SY?X%J 1,5\JEA>F
M4?2K!D,Y [T+;A7K7566&BVX_!M7(AM9"%RA+2MQG+UN;.+KLE (#KSWHFSI
MQHMUAVDU7Z;*E^3^RA6!:<J5R_%SD8NN8Z5#Q5]G7')F.S1X),:CA;RPV6F+
M9[%K,9YBDLK$W3<(' IHSH*UK)=#Y#&WA>[P+^JRDJS<1>M@!IM<:J_ &.T%
MF661#2"6\)YT'A5]UY@KRE4Y"&+.)4#V'7(7*&F#>!"+65]RKU7,SSI!L^0@
M1B3 =DO)"1!U45YQK>C&2H27AE0-<C$CZX!SL6,JKA7X0E1$G< 2$;P1WA_-
M(34]>8B>8807SO:%<2#K'>$TE%S>6.P48R[@Q4C79<6<B^%PE/9=2-,&+S.^
M2]N;7I(/JEV0=LZ&DF45$/WXN[F7&%\%5K@J!4E@?;?2$Z60R3AUS*I'-&Z6
M?XSEA&7R_GZ-ADS=#!^SK0HUI(\<3P:!=<%1D"O=F3OI);0:1H)ZWXR(PA0R
MJDTX)HM["X\"_P)Q\CX>L9J'2 \@:](GSP.]M/:>P.$A-1O&23W<-_>H<#N6
M6]LZ.%:S1$I1-^61B4*.2T"8$$;*YHWI/'\5:1(26?"&X$0KV9SSBD[RXRL0
M@+Y9\K62$^>CEX;O>"09T*B.(KPFN"3@N]B1 2(P+5/AU61$]/!@+.*K8BPN
M' OS#.Z@#\=2>.,F>%IN[^[WPO"5#@^4VQA4PHO*BL_Y3LOA1W)2H'GA*DH$
MR$#SKV%![@14)2+;JDL$;:I+4V)\R1;U&NUC798"9H$3'5C%AKD3%"NITZ,6
ML>J_V\)3Z"'(85 Z!51$IP0EA0&$.T39IJ:_1M'!206-?Z&1O=M*<.Z1/WO?
MGKL+DN/DX1[*<0M0CI.'>RS''W3732[O;-1,L=,]A=6Q7!\NH="ERX YDB D
M=/AC=&\=+QR&D+M<QUU=-:XOBW$G-+G_4R/WC&SMK?FV8?#( _93Z-B3QT0$
MW68G7T[F1X(%7>361("!7#?9Y-%1MC%%2VG:F7$9.QT?G%C;M;MLJ-B'8RJ6
M1T;G*G7B"@PQP2Q+Q@H'1YDINIF-:A\='DPHIPG[\:(A#E7YIM-OR&[093DM
M=9(5@^YNB@-.J"DZ$ NX3)B1.1#>-Q>&%L9EPX9Y"9T4\;E?;L.HD:I\?TG+
M2'Y%IL2C5Y7$!20I0\H6F"K.Z,],B1G]0NBKF-70EGK1U-E4L*2!<;A*3"VK
MBJ9M#$A[S:^KL@TL74:UV.> *V#]M0 -PZWL)(ZH[\XVNL GDHFUCTCCC\AZ
MF!CB-;(&?C0>01W1=.2J4T0J);<E!2,5'W$6)DS)V>V\+2?WKTG3,'.RRM.0
M&O.$1NJ!D>LFL7K'C3E8VBVM1=@G\T T1,^L)5D?K+5=U1U3V9$;X4$5R+[%
MQ$D1+H(WPS$XV 1.'[ZV,%MQLSV+24D ?D):9@6XFF&@%>7(O6-0X+WB/4 [
M&U%K94=LI+R[YR#AK,6H]0*H3WR5*P2&S;.)UQ=_/3U]JQ6%QIX)S,SS/$C5
M-;]&-_;>-O8(XF$"U7EX(/>FT,NZ+D#3XOLE;X(/#]*9Z(<W3<]WU7H?7X$=
M\$51MA7YT9T@>\;2K(&DKIJN3&:O$#U(,EF3?4T[+J" D\8NM?>#26/9L\\+
M88HGC'4*-M;.%E5SW;E[V/7J4:L0&7END7=NS]JZ-#^+?N[(>:VQ-J:"ZY?V
M_7,Z>!\88A'!"DQ5]AG!@"@;16%PDEZ)W:'_[0& A-\X>?($*VC&[(A[Y.O>
MR:Y-0XO4U1 ^H[,.S-*?:R$N!ADZNV+Y>54RUE3BJL]!%*IFI2S6=V$#"-DX
MF#[J^FS;OD9PL6A_5'[#$R  OVY+$I62))(*+J*H[UQ7"X)PY9:PON;"[KE_
M#]0!14\_N2SFF45?,2WA;RK'5/5@@^1NK>CS*S_'8)&BF@.%+9 37<OL\P.3
MTR/N(0!>Y 9//P'(S&8MAA1QG#76IKK'R.S":0,KT7+='JL-S1%I#PXF'ED5
M'8;UB=.>HWF3'X_T8 =EB%/4;XN*YZA,LPLF5;QV(E")TQ)96204NJWYHNJN
M!*!,%\K%DUU4/?.]X&$"1GA#\4Q_EN)OK](_=?T3,#LGO<0V&17S&BX7GB,Z
M3"A!.%3=7?HHI:M$QOQ0'S'PJ(#M/)= /C-GNB>IZ*9J(2!I%P[\!YD_.J2"
M$*>MG+L!8B"LSL/L5+-8P/*WEC*:X\P.$)&[DUPOH2.]=;PW?'<TZ4 P"X\,
MV):)L$!,#IC$5EHA/:E0S5"I D*J<%5ZE*T>,8_6RBX):\6$BS9I/8A6#SV"
M&TBRJ+9\5#$='FC-Y-60W3Z;G*SY/+"RMV@I6C/7=(,2R&7'%A8%X9V:TCJ*
MKB=AH:NW-O+!&\']0K[Q=N").7UA-)=IKA@L\@0!*FT?O_,][2F3;@B?1JQ+
M_&F4#%;HZLZ8(R"  -($:6I\T"BB26B2:=?1G^XD0"%D<WT]A8=4&S48N 0<
MG0[)3TTV.3ERA;;/BTWH[DIS/QK-8!"P;JQ2[I-I],N_A6GT"D3I(H2WM8;K
M[H64#<WPDFQPE-A-[CAC%CZ9ERM8-^>DKT!9668P#S,?9IAB8CB,>S@0MRTH
M<E05-D;E4=]A[ECRKXFPBN;^%BW+7!JNM!_#'>VT[(D*+ _K]_&^<VR&Q/!H
MS!U?8*V1"KTU[4:5^4\B>H",#F 8L&,)$!+LH[@P&UEZO*=Z.K-+XVJQ@R7B
M[RV6@2PR=*)ILCJA#H*[H]'+QNKN)-%N9=)L@\W ]6D<)1'H.$+8LX5*T1,"
MYBZ*JZ8E+0;&1LFVS(UL(!CBN)D.9!LA>X#]L9_I,UX.?A^]]9%"THP42F(G
MT&6/3RTE.887F*H'[*=R&>P+\GU;?Q**.K>I=0SY)HOUB;3%W0Z3*4S$ J?^
M>H;O<7@P7_<.)*+5N  V;DKD]EZ(>K5! TN MU>XEP=U%6BRVBE( #N$/%\D
M?HG1^L3$AZ/S%69B "6,.%448RU0//WGYN:R&#:G5*F#CU,F\P5#B$H:W9C9
MD/^]#0?LGWN'4NXG^Y3[;:3<3_8I]S_HKIM\N%,6?6#%%[#'LG,CF1XVY4$@
M*_H<_+D5EO8[/WH'H!>VMX#SM[8Q,NU+*\R7*V$8VO'2WOVWQQ;Q3>IXA)J"
M,W;FY;O# U]@0?2&2V-+9 HXPIW=3*!W(RA#3-'*K]PC6CNOE^4J",B-8$X%
M&.D-4@]0K;V',@A!* I&G&25!L^F(+#@"@4 08?,':1N@KM.D1/XBGUSR@&5
M;?!"G29E\!.&>$7L: .VV$VB@A$?IBM#2SYIT0UMJ!P#$[G$=.#6@5!,N3?I
M "OJDEI(%6 _Y#&3^6:1R5R':"-D3+?INPTV'*N$V>G)DE8Q,S^[E%QNZ@<4
MQ^O+\$M7<\*13_O8 .IK+W&DDMC%21K0X\N1+V3?H;\LV[D ,?VZ<GB<HMS^
M'2TMHZ )XGEW<467M!JN0DKX9%L[3T5H-].[/D"1] CO''09&SP !6H$:?SS
M\;OCF$]/'&5*H-I^42E.S( U6TT3$;'[/VUL'].$1#,A%-<<F^M\]9?[\75Q
M(:F&2TP@^.CO6$NH\.5<JZ==&#''U2/CU >:\?#@_K%@5G?J]!TM&74B((?P
M3F$)IF3DCFF6LIF=3):70!-.A$F!N9QUL%SE]UQ4EZ@QYZ3^\YTXGW,)4NN3
MV8YI-\_X*.=.VI<1=FUXN<-A^9BBC7O0FS!Y>&I2PJ_U_-BH!<H.[$YBYN0R
M#.%@'JAHUN+!QZJ0)\UD+M%#]TVH6E6PT?+M'AY,0'/T3/ M&AI^ZGH!MNHE
M7.")%\^V"QN^*SW3DQLK0F/A/57AS<Q'-RE/<A--J70)""-AJ>>CPEZ3&ELS
MF\"<LA\FPB7*U2-$RAJ%:%FVB>I)SF4"PM QD$='!>EH/BV&;12*7U$-F/JJ
M;!O[EK XO9'0-NX<KB/%T5R:HJ(Z,:SF6!@<%5Q,K0VIEUF_4=_%1PP-@^QM
M.11SQ:KLFJX[NF2?_(N#GWC2[+F01TZ!Y:V? EK;GP6"]0K$C[3^7_[WMT]O
M-(BHM<FX431J#]E] 'HM%O<5> R.Y]Z+.6Z]RS7,2"8"+K%[M2TT+WFQG)8D
MT&6+N9]V4>"X4/3R[*)%729_5$S+1!>02L$B+;F>@JO%D=[6@^$:B>]V;)Y?
M@D10H;'!G*/-R;IDD/]XD<TNX;<S B_S.W,Y-,'FL L <_I3=O+7<L8:[)]%
M.V_6Q,1N@9[P^771H>\7)6%\ N9O[G=V\X408ZIYCB8S#] LF+\(&KL@,? :
M,^)X.G'BK.L(FZ$!%CE2,.4^NX^"T+1@E-)EJX:*Y*F<G0KNZ17KN66L2@R;
M>5^N#9)'="1B05D<3=\<YY]/$?H'C'3.7AK_.ZN,J#;/H]]Y>OT.D_XSPN/8
M-&$GIQV>[O;'$JC'Q<.F#913M]64RK3/744CQ>/P'S!9RW5U8?L1<XV?102S
M;:!@GNG=:9?N*?(PPQXD'>P!X3 O,BKW+A[C8HL*%1:37:+E,%$_?+INE3N$
M?7NTP=/,=^G9HB'&'!F'->?W<&OB9PS&PUZ,/9D:R_&/<V+-#47T'WD[76,A
MRS./9TC",G!R=_& ]BX.'F[UK1]N8P?=N4]RO^7=D6XN3BEA?<J!HNJH(S0R
M0?F>.%W$U<]R;#=>P"$':FO%\1HT]M+'HL^GI]+QA-_3Y%UCFU A?E!'@C:D
MDF,+\#L\2$$VD_$ ^]IJ'VJ[[S?%0V&/#IL%ZV7QL/8H#KG% XW*8GR?!.1;
M491]ZBQC1#EV!IXYHM5E,_=MQ$0714.\3QNZN;,;^JV@-9_"8WNFKSPE_!KM
MZ_NQ1,=?"H9]H,;D4.2.A&'[\8@[#[<-@6IRU1UQ26THR KH978Y9"S7D"&+
MT%@T'PU&B#.L3"*;C$&$I U5IRR/-<9P#S%Y8?P&[S/GMFAY2F-MHW34=7>!
MAYJFS*V0,C=WY",;-W2RWC Q@!:DM>%-/5LOIRV9V?17V\#]Q494?98Z:K[8
M7[A@Z]PL&&4IVM6V&++>4@B5)L-;M4?=Z75#H-(6?;R+X8)J<"1(Z])7IY0&
MX,@#;;H<#IJRFG/KG'))1JS,#9J5*QN%6A%=COHA.' 5X_8IY$Q_L>%)H@!&
MY$T!NK+3ORKX=Q)-ZU@\<P]JIKV@&+Z'MQ^DOAA0+]D)7$(^W1,K^%$R^HF+
M1DY@:M7&(NNNGN&W')W7+18VUOX(Q:JGC0=TD86.7IL+UW+%$>S]UO;4K#>8
M]!1,G^-,]>WN=@ H.4> %MEN*7(#/X_HWS")_]ICY)N3XZ]"W,+^T?^21^^$
M1GJT1R/=!AKIT1Z-](?<>\YVA1,1EKIG6(%7^V(.W'A0H!%JD>$='$D.\^(,
MTV'?,!L=?47A6!<)94)/8:G,(UY/',J"4U]IPD]=\\7UP"V&APW:M/A?:['0
M>?9*GV>N88CCQ_2G)#\B?#1#E<*'4QJ/(.N6!'!NTZ#;W?7M!^#3E 41%RU0
MKM0ALF)XDX/=Y"I5Z4%"\!%-AN0&/5*<0K8Z9^J,@7#RK'U-?(N!:?9)=O7G
M,2V([^&FJ;UYPI(Y<@M,BUOZDLR!!59<N(PX9Q#@<^$JA8]MX]\P5SY\I9 "
M!?TG%E'ZS$C!<;)3LU\M62A,U[(H<API['0<!ES:+.AC/+IEU*IG'[GH7,#_
M>ZSZ73,H1<?>JG8G]3X /SJBR<@)P9P23)J'ZG%=4.Q^I@((VX\)C&Q*^D(Q
ME6!-7YJJ! ,9/A,B>:4D?,OG'?-$WM\[RO3#?S8U\P,%]\/HB+\AI^&C3"/N
MBLXC/.U$!,0?G[ 7(@4H#<WW>^%WV0M7PS!=G&V04 SB5M-Q."%'&<95A!Q_
MP[D\&P[Q>%,^:QR!0((S)1Y+3@&JFZ)JU(C*2>&"@AQ'TIX*XWD-]X60<;C2
M/GK:55&M/?6J>Q6FZXI^AX.!?R^H'L\BF+''CY3?<[21)%^UEAW<.U(4R8R/
MI WM6SA^EV+CNK-$ !Z77A6X#OY$6IRKS(]TX>H4@:T4,L-++7@3Q2Q#1+!
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M&<Y3WT;C&6JRIMJU<FNL\E"N#W/\41\2RS =C(HY$A?9HX</'W$=Q5+Z/+A
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M1S*W?^X=0A,\V:,);@--\&2/)OB#[KK)]1TY4<-V?KY0Z"<,A!NF8CY7V9G
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M]FPS19 K>XS:+T9G%@N,WDOO$R?DWK^T@9#6E?$LL>%8R2X2N966*K+1KMX
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M!\K-18ND[DVOZ6^8/(TD#SU%RF@*\8,YV2S+&=V% ^$X$'N/;# F?&2>28+
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M0Q*C?C#;BM81SF[+#Y;J%S%4XPKDT9C'QX>P;&C#Q3["=H78#(!";%P\=V-
M#AW"J/07'881R+R(0KB9I(0JV%,AJ#\I6P']_7S-4*TX"A56R7[2-+KVRQ\7
M"ORTV!%:'_0NB8&3M_=)0:_//.Y!V7C..5PT4,AXY.TQ+;A;@Y09W21*N:I-
MMN(?KWF++3-<HIB42,2."3LIBS<2QVW(ZW*/B!&IR6J)6(]*<8'2D?IEPF+M
MD$QQK*=>F<9U@JVYKD ]F6;=V4(YBFTH&F!NK,&O1=D%]8$XG)'G'[SSEE3$
M;C'#G50ER.SGUI7WQXJ\;\_=!2[XZ.$>+G@+<,%'#_=PP3_HKGMR_/7>5W6\
MSIS.D-:^W1B>8&U#]:;GOG5PK:=,&,'L*$:#3A7'2Y+^;5O.Z,!\*^1':Z&U
M\NF3SMCD$C_Q.PJQ^^J(ONP6A>NS$%47J2/4F>-S,\6:F-Y5N:^*C3"M$YIG
MCE3[&[2M7&5B@MTX=>> >9,=1=>%#?EDIW[<K9F#3:I'+1A*"EM2KD5_D)W]
M8UU>P0R3L3J9J0DP?5\YIGBRME0;>G ';),DHJB='PWZ;KUX]O84OWOSXO29
M#OO?(Y/CR?$W]U49A,#"D+$?54+4!NA="%8-P[%!D3G,:6CC4[#'-@7@2"E&
MYR-;6IJL@+^GO#?OTBED'?HC!MO]!;P0WL'G. J%CR8.C-!K,@L.)64+ZG2
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M$]!R2-FR+&&QOF:E)*HC&$!,Z.=O^Y">R*0#YBO.$D+IYRK$!/\2@04I'T5
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M';>=E?-1@'!ZF%Z E-,HAKTM*._@55X5[L7A'WN^@L=D%@DB/?9(@];K=P(
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MKC_#*9I1, '-NX:BCK"#TT(R,;,&B]1*F0YK=44U'=ZEZ(48L-HE_T:X]K
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M_R"Y$F^SV*#=7,KGP.I%3A:4<T>!)F30;70QJW0';7LK 9>-&%@"W$=]'WY
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M'8D)_T"NQ9(1*4TEN9ZH*P[E]B:,NVWS+3?D]GKH;B.945BMX+D?8]IK/?)
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M0IV4\31QYJ';9&Z3E)"-=?=7GM7S;<!8%$/2\O-I4*-!PJ>/7X>KFG1:03(
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M?;V9^F9:]J>B/06;IV2X_?W1MUQ7%QZFW^$.O?G(_$YV<>L4VGWQ)_WC?SJ
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MZL!.:_<'VM>M5F?'_2T>1.YIT_T=Y)WR)RYJ*.K&2_S[;O%6"U[;^Z+Z</\
MD\!!_<=KN)U78,Z?AG'\PTF\8Q7=D"9V#CI8!W-_?IB-^30(0L]7X6@0  D_
M';KM_79K^[X;@N_[5YQ\:;CZ;S!\N]WYT3:"]=V]O;W-[;V=_1]H&]:WMW=
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MS8VU&:/[==B&PJ1P'/8DI5*ZJ#H<%A(DEJJ)7!?%4N++KHEEU0;K9OJ0 ^-
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MKSD,+JCU(#D)$;#$,$^#'N6"Q8C^U@25Q$6#T@ =5B9&,V\(A<QU*:>3=YE
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M%TD/T4C%ED.N='$9(6]W$YXY8Q06SB7'JWN2!IO.7:&>ZB".>6G8/H("'9'
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MG\H"K 0Q1/IONH=AJ1<]YY-1_KS]:=\%2F5Q@A*7\@K3N4:L00JKWP?GMGU
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M%<9RXDE\0#<::I@9()]R07Z&I_>:8&_@L/[%X#:4 ZNYUG>QO9)47&4)\KT
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MX2$=YJ%G%=/+69E>) @:_5M)NKN5FV;QD',W'EHNWC&'D$RD;A)[%"(%K4]
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MX@L]]X6;P)'E],1.2_W*%S$0* W^ATDYH;,I*R48&Y6>>2I2A-G-QZ\<-WH
MJ@%;E6;PP?AJBG0'U%KHYJE+!T+&!96ZC')G_ZC[P48@N2*'8.Y?5$9*#]%J
M-AMPK$\YM_R:%3[8[$GROV4RBDC9&26%MLVY;E&NM.*%NU%.PZ5"*]DMKLC1
M61&!DY0?+)['A;DQ#P=Y7*?10G30"%-=!C,G.*R<^GHF2<@9MA&N8;R6*)W
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M 8YAPNF5Y*![Q[O*Q6IH6^%G(D%RP@X>!??S%T!]UOZDR15_WQ/&Q4#DM1+
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M4"SA<)[+0IS\_DNP=% 11*'U:P*, WE"9.T.0P[5.F4CS^-)X*X$2>!X!;!
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M-LM\H9K$ACUTKI)[%?T5NS UU.VS\1-]R]':>Q=S%M>)OH72 L"2=TBQ\3!
M,*^8L3SB8"65^-0 XDJJ:EKC0+DF&=?.# ;:("I,C=WZW8166C;0(XA$(QV4
MBQ:K"?.S">/18'O(DZ&^RPC"MZ!RI@ ]V33\,6QU+2-EQI:2?B,?TC5\(\?@
M^N-8SX7X WBIEC@-R>_U _NR9J,6OR#Z(><QD>4,LLGHUX G8SQG_:GOH9,6
M85S@7/G'#[M5]V>KQ[6ANR97SR<M-&=--:@IC.)4:ZY$!JK3:YA+PR#:G*9/
M=W$L+=QO@_SG-P8?T"W/FW.HL'$7$P5']#IG#*[<X5\7"!&'4YOEOP3YQ6!K
M=^\PY/]MVW-8\8COO]8G^5.IK^.A?0"FE+W>Z$+?_:EY0?U/]7]JBAC\V-)F
M?ZE;_FG^_[:I-$Y\Z5>Z%>U6] FLXO=<-U\ODUE<OV-6D&;B_3>.KI+)XI=5
M2DDM7MFDF6E=_+>BG+[9ZF__]C/\PXO T+HL$XPUI&%%\'!96_[GNG$\W%MW
MKW*89T##)$G$6^QFBMD4W":!W-W>VC,RV<GCDQ^'R"/C .[>D+>VFVNK56VY
M&W?I83Q:#;E5MMLLF[8JC-5GT'K1:D?*/29T)1O!;VG\]:O;M;Z^ <\ID?JU
M,(!=CCV\VK'H><N7H:^: H,6=,CS2"KU5F)L>@08JZH,(X^3JT&9%\U>4_!C
M4$;GC_W=@[#7ZT'+XF;)HA&0=L[%L2)7"J0YZ-5!J(O\#@VOB1[RA%P4>AZ5
MSDRP$URY13PA=]V/IE?_RSR& >"6B[\6,@3^[D[@76*K+^]&@;J-%.TNE:+;
M24ZL/WA%$0JNCVB7M1K= +DB9\\"B0(1+#&2P$B33A*:2 BR27S#KB:+X,?=
M@QZL_4[P>SR,2I*0&HK!0>P[[G'7CV5%LQW@(."&JMA2C#8:SN @3"M&('41
MMDR*N6*=IP\S'##3 ?PF"(_(8X!4(M2?6%ZJ-;/]Q#&D/,( E-V)J^A;$YS#
M=<)%@^PZ?CR1W+MKD7PKM/_D?X_M.ANV2KS#UBE^GM50S;)-.XWK=6_OW1TX
MVI^D0WTM=.AAAPY]!'3H;H<.??3CT:;-#=Y\-HR'P9_W3Q[_,$&TU@ G,R82
MJ$!?_1A#A<P#9IOB.-)5'*4,0CSC4/GN5K2]U>^;S+"FF"NGZ%XE!1&WN_B!
M9&8^HI^1<0(1>LA'I9@>Y9I!Z$QRPSB5!QBW^.OSRV2"2@*^OJ +ZW<IF<+;
MC(FAU>F9N2$P(BF&]%YGN3?&MBCRCCHJ*BO4"&#E]-%*\!@1+0X2D/]F6;MJ
M_9E I2DQ2DQ_)M57-:7Z?B[UDNSW#V!S]K=;)X.-XV?[O<&+ _K1D7OGBV[W
MB(@L6NA!D24-QT):DOX728P$0^D;L*=%16\<M)A$]:W=";[(R-K&$38%]'^Y
MGT?ZV1K+N^N;L[?U/[6W=+:X&F037,K#O5^-NK?:"#^\_U$;PGM$@1/\: '@
M48"9,$D!$K) IGH#>,C'O/X*POF ^O\3V*L'VI]!0CR,D(]I\'F$U*C CL$H
MG0%/Z8PQ2>4P%O+@@LS0Y2V$@<ML4C@\',VWI&1V)@0JL6!&X) %%M($KC+)
MTT88HI,TLMS\>6IJ%&I,[[/A7R^^3/5-R_C(YX<S>E!HG-$"J@\>ZBD>3W@P
M@;4MIY;IFIV"_=T>_PL2Z"LX6),E[^:..+C3%4D/^A>@\ $R+M+2['!YNVRI
MWL"\#!MA0V#2*:Z 03P(\UAJBH1>MBN19S3GO*KJ8XX\10B!#3W4+H!*78PN
M?H2X8E*M[#%$U#(@$W5+AHY3AQ89;_Q&H@V553@I0(V[UAH-*Y)(9S1&M139
M;IJ+)>64^2L_%*5>51XS>-J@P%.%2ZFI'2B?2'PF0R1-:M@ N_#WC/YZ_C;2
MO9N5;\73*)05'^4T<DF&3;$TB9D(,RP:P#NVRD(C@BUR(%K5:@%B$*W104/-
MTFKKM=HD6*3!\4!S=ZJI#@0?3[?NCV4[ 6=Y&E]D,^"? 4MP-@<:H=)B3YW,
M+U(A@2LG\A'H5;CT (M!L6DL7("LJWC+Z%1:]CSJD?[(A;E8]*_T7?\1?QI'
M5!%!.&0HCB2N<;G[I27%ZU#'Q%:6T$QWS16LU<%C+S.R'B2P7@OQ[N-C53C,
M8)8IJJ":1V/A=A2V>?B@I(Z$WD^0>)#:5*1Q.2OSV!G\+'9IQ/3O%BXYU!7?
MW?$HY"(CNDFW4WV4.)\T%,Z]AJQ39QF)X+'P*A)47W"TI('_(?-V,"+Q4^SW
MR.-)?-W10G1]W-M[N2RX\+H++CQ"<&&O"RX\KX.D[6<B%]X,%?!C \TFL">3
M\D*UHZSC1!7H7Q)8Q]&7+V]W!--A.9GA@887&-I9%E%NTB)LIT+=//-Y/ W-
MI\*T0I=DF1D &HBH6?5LX*-N&L/:/-3/:/M1<DE_/")_:,*JW>>8/?&7R?3Y
M>8*:@F5(%,(V-63%>D52,?49"[P6<7Z-M3NUE9<.$Z1X,(0/!;N44;>^CK22
M#@:!63G)3@;GB"B^;M8O"5I(*<XY-HYUH=&2N"(#(?T+/V*[CT;7"9#CAL[G
M/'W4^35 8H#@)'3B:/;/8:"E_L)MGI7009[]I57:B]B9RXZZ\2*B1ATRC@04
M7K!?]']#,.> R ;),!F?PUY35M3Y Z%95+M$RE^B@)>(2LC55DGVCTP!-M>0
M+-H,,_1)2!<VHIDQ.:WAX]3RI$50MPJP)!R(8+>>TRE?3D>.R=\PQV&&4$*R
M4I+<;(6A*W8%O3'4MU0X8-,Q_5:O,O#? ><.HA#A@EW81'4*IY*ESZS.<' @
M#CS /A13##LG:PLII[&&F?Y8GEQ'R!UL/[%=$1>WWI)E7D;9"B:9MB2WY1W0
M"P%UC25)70H7PK/'OROLDI' Q#E#V-"X<T07?V=';=>33\1U-O%&#5_X&<FF
M[6B9-(#(R6$U?.'>"4['C9L#S?@;XE$E3&*JV)L[]S[Y,;AB,=?AS#-]$::P
M*7"7"+?E,(^U*0P\"5D!QYG0ZNB**&:4P4\>$;-&('!Y4OSEW&3!5!L/0TR9
M;;MZ&D2*AL&$SM2]THN#DR-4(MQ"#HTO447PV&#KF/*@RF!"<P).W0A(D(NY
M-C9$/X$BS8:U]C++8>P%^P) ^+W0D\IJ="M"8._<258(IQDL&8$6'=!$G2[:
MYZDX H<WU0+T!S1$+(.^(+5<4B%FK+W,-Z]H/Q6'T'I]WOR)P!JCDR+#.J9E
M"A3R,7(,3(%&$VG G->,N$!&C D070LS,P)'T4M&<60."VIUQ.FN!2('WY#;
MOCR1P742SPNJQF;8 )A>V@\\NJ=/7B^W3.HEUH\CTGL:+Z%B$^+$X%+I"Z%4
M#_4%0\_7S\@6KS=+>=)3'0*]?V8,&_#R:*7S!&BA\TP+0 /;WCWW+5.\[ZZ.
M*E1;L9TS*#N1 7 !FXJR)%E(AS"/!UHFX&_Z!HO05=Z&L&DA0\#:\K*VL3.6
MN'"& M>,^) A5*4HD+=TW,*^13_A/9@RFH>'71@2NRB?&9R[R\Z4,X2J.;HV
M5J*?^5^#'@& #LV&3/<P(R<N N!!B^.3I<]AEA?FJ6QAL\$G^1)O2&H)7D#@
M*D$6G<%"&3?__9P[<1/=X[%[L@R3W<#^S@.K#VF)'WJ_U_FA'\$/O=_YH;LC
MV\B;O.?R)O]Y='[R^?3HO?KRX?3\Y&UP=JY_<1:\.WE[\OGH?7#ZX?CCGR?!
M^='_'QQ__'!V"K\]/]7_>G)3;%G[^^)GM( OI" &.'N)"':W' UD].7@!_NR
M<[9CB%&A,!MXV*)OA+.BDVGL-[0UR*8(G6H:H.U4BJRAK=IL[8EBZ3:F3&.A
M@03 OZ:)K4U4Z:'-UP_-U]+'4.T+3;5L!X];&:/BZAQST-B@;AOB0DEA+!C,
MRYS3+AD7 N.<A48P'+2;@K6=57&G:+V!;_@RGF#N(Y?<XMIS6%.L;5^F90ZP
M-#;@"A=W)[U)J1"@^(5>R/&(H) 5M+O/@;+P43%,_C;C^<)B0_F"5A^/ N="
M*BD6Y?),UXX6RH+A%"10!FSB(BLQQ1GS5?27%[!W!!$N@15NF.3#\@HR48>^
MHP?8L9$;E2"6BLG"W>IGDJFK!T-&UY_Q2,M03L/3$Y-;PG&;L C*Z37U&OW9
M;*&;(2)><"JA5SBI06K_H"\K<9KB@";ZM([0-=9_??@2ZVUQ\9-@"S[&X3_X
M$$?_MK?MHE$AU@27!V7=@3HBHYYNGU)!Z,SAQV>9D@G.M*92N'2FRY92?[%+
M%JDFBSS17 .;%W*7 VP)WP$EK?F+"16!NQ4S/;XGRZ.)6N2&+#1^>T]RM^XY
M,X0BD2]&<331[^*OWY5VOR[72^UA>O:;=8>CN<CTO-,KP<9#J8YAS2\>341;
M0C;=N]^V;FL:1L/IDK$7'2<8+6:M=9OP()L A"Y4E\+9!F0V[_;@8?9 6Y_1
M+*?X(CSP@#3),<KV @OX:;LQ&;E)VE]25!+/8->Z37J831)6>-+ND12(*FF#
M5:*/BV ] &R!=67!*\/ !2SKR[X*KK])[H!N[QYD[_1+7^:86-<]+P^[\JP(
M"]@!_NEEE@(BXL4L>\'(B*MX=HD)IH)7@J-2A3A4L]N[C7S ZP\\?@W^O:@P
MD7)3"0'BXJ/1) X%2XU0)_!ZS.*+'!4_MR([@$D2/;@H=W_=;>^#;"_Z@,6;
MZY9BQ[(-V^#@+0#LF@ZY;IS>^5R;4@O!2:!: HU0*8ENVQ[=%0'GD4,=>/]R
M<9NH*%[,+O.LO+@T?B-$A*X5!@#0V"!.M7"@!XJ"*:8.M/%#?2_C2.?ZN(/1
MZ,U[$7]#SA'9F!8>R#LC]GA:$1,O6QG<^DP(-H*H!*&VKF,US3/B94 G4:A;
M')%PC^)A0G1<@KV>A %PN&1Y9+. B;GA',K^E/G"Y8#"\-W8<F&0<TER+/P0
M@J+LGQ!@KT4RH&J70+HPRS."D5/E()H!?9@*CA)9#+4)A*$8(#$U9H6$HXI#
MPX@&X6B;8D4FH$10V22M!QXE]@3%,Q&DBL07I*3!?0"V*4!%AW!-Y/J3Z0N\
M8717$8=U*17*NW?T7\$(MF@^>Q&Y,9^+9$S0-_9<X)^W-P!9NBE]K(&(ZG>(
MJ$= 1!UTB*AG=9"$M0ENV@*4-F:U-"4EBSC^*X2GHH3RVLJ0()N@]^?X.DY+
M(%^DQ, M-L]./Y])F!O#Z%G]-FX&Z01-CX/N\/.90+:1_T@9%A'GU: OA"89
M9N01TC XH9PB6F6P0*;N,I_M!']JL8%(3L@\X$.M(PU@50#(PKX=],QQ5L@$
M<-GT#H?*Y66LO/Z\;$S J;MR7GVSQ";UQ'TRHZ$V@:*A+<LGX&\+=K'SW@G^
MG968HUGF%T+&B80KA+: %>8,P)J[PZ&\$D12]<F$BM(%0SD\Z$:1S$I^;9&5
M8P+ 'X69'U5T2)0GA:U?#9UBH\)$57G.X1AK0=5RJK^F]24FC7ONSU:KDB.L
M-$9;FD$&E93XO8FIE=D"HX":PDS"&FB+ON/95)@8%[E=8=8@=84?6D"BEE//
M%@J!ZVE@Y=*HJ'QWR2@7:YF#P'V&JU$U!X40Q^4N--Z!A@;-2I+SB >);O,8
MZ?TYTW;MT3._S62AN(0QI$Z)&0""7!J]O-Z9Q0R:W$;_LRO[QXT2D)"9C[)=
M9-5]7#J;9H<;X@;A+L&>EEPGFW H_S@]"]Z>GAU_.3L[_?@AT#]]_/#^W\%1
M</;ESS^//O\[^/@N.#[Y?'YT^@&E3*T$[@9'9V<?CT^/ .S[]?3\C^#\CY/@
MZ/B_OIR>G<('PN#CUP\GG\_^./T4''UX"[U_^DA_@LX^?OD<G)T<?_FL?W.B
MI?KDZ/B/X-/GCV>?3H[/3_]UHCO^U\G9^<?/2H_(_S",_LOG?^I^SS_BH+Z\
M/P].S\]PD$=O_W5Z]O$S#>GS"38'GX/1?3KZ?'YZ_.7]T6<SGY/_^G+RX5BW
MJ3]R]D4/0;J%,59GI&XPHQ!6[OV7MZ<?_DGM?/KT_O3XZ/?3]Z?G_\:OG[Q[
M!V/3WSSZ\.^@&3;]X>.'%[0#(?TI#-Y_/#YZ'RIH ?Z*5P+,YOW1U[.G7,/X
MW+VCFK# #TF;<A]H[J,)L&#J6R>9B4<7[I\<E)ZQ5N:(%&&4E0/0/YTE4$)=
MQTEH4-,>%DO>',.REU4I6=;W.;)CNFWMJ6=EKGT<0_1-"A%!'?4KR$-,X:;'
M0=GV..$88K&H(EG5ENH55ZK+9\$%I@5#=+XHG#E#ZNQ%"L3Q"A/O/,8YO/";
MV0!#RM.S2'3DF>,KW]"M-G^=>Q_J'[46>AWGHBWB?)2P0NP$9Q16F3 Y'2PP
ME:%N!;>O:-LR3E1&K[<0'&$VUU/^1'Q]T.&/O9U>KV\9&%FO:1@#@O+CPC"T
M4M5M:7%DUPJ;PO&:;<!*5H1TQYU""FVNCJ.DM!7M/K5@"D#9U6'IJ8^,G6'8
ML)0OLF@-O]]QV$2A9_,-B"B^,H:* +0.!(XJ8@N0HS5+M3801SF98_IC@$G
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MRF1PECG#KL'1<17/W,&YRP\92++(WEV%47GG&N2C1:NN5TF9]N00>)>B@Z+
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M][?LWO=Q8;R[3"RG+RW%%I<M.^'(DM?NA3!$>"V9&5!A%GTU\E/EEF+Q999
MWL[C!J=<&>^OC1"ZQJL++Z>NC9&U9H>A]&@/*_I4H!Z%X]P1UG'<J[<QW&22
MX2R2];R<+U],)JBSLVU:CFK1<L(&>YZTKHK?DN2HV?/BG>(J@C_X>IGX(J>:
MNYES!>8BLS@IM[_;G.Q@F;JAFM2-<,6%$P-S$%*?T/C=Y<O290,FNOO)8@<T
M0DQ)=DK+H/<?_LH.Z6+5Q:<?@62"ZLZD9=-S(<_P*A3?G-%#> V2*Y0R4X*'
MYD_#37*_0L/=I7'4S3_?>NHU6$_U@#BVHF4_+>#N^24HIUIC@;!KK>8FQ^?N
MX> :X[4;6#>P;F#=P+J!=0/K!M8-K!M8-[!-'5A]2,L"8R^[P-C#!\;V>UU@
M[&]R9)/1/WXH_KO7W__!=+K^@-]CH8T_L3!#\02OFH=94.-^.X[R7%\* 2Y+
M\/[]<1B\C5-$J1U_)"_D-)+J-  VQ7K4S%'M(Y8]OWN&-9B(.6NP(*S+)WWE
M4<3@Z()Y:XD:/(^9,(1B,7]$BY2#![]G61J'>ER?0ISGO[/\+_R7HG\UP*H0
MJHS=ZZ:_VQ>ZU#W3O-EWXS7M.NXZ[CKN.NXZ[CKN.NXZ[CKN.NXZ[CKN.NXZ
M[CJ^5<=KN&Y?=:[;1W#=]CO7[3U+_E/S/]XF!N/Y?@^,[_?D&R2P=J[<-Q_+
M/!A$$TS/*"[CF$J6 35G/(RQ2-5>/PQV>[L'"*74_]@W:25Y3!R9R'<M@%+(
M#":@7,BYQPB21 <OX_ 8Y0J%&25=$.LLC2?9O#"L%D"9 <A!R ^L#0;SF6$P
M6(F7LX^%FP"YI#,$99;([(/9*C%"/AW>E7*4.+[C) [^O^A*WW60KQ*E6(N)
MRJ[%F"-^D10S=$Y/R\$D&4I& F ZQTE^%5:* H$+6U(F3 F5(A,&[!$!1SDO
MQB2>$U#?Y+U#P\%%<AVG%FOH5?N.28RQWJ4=#P+H879WX<M^_&0HS'CES=)[
M.].SAW0%"T,W\H>PUO/+/-(]I5B=! (%[]\?2U)\D8R2*$]0).T^G'R[3 ;)
M+'C]>J<O*-YCIH/]S#N2$@GAX8O_#)$09Q3\&>5ZBUZB/+YT!:O(5%4FS4[[
M^[Q%L.UAABDM7!AHJ@]CI">Y@(R3Z"*/II=TTA"52D#NICE:(DU.PYUE0&FH
MOU;&E-Q[D5&NOAY(GOKDEWJ,'[)9'.Q*#TVKNPV+L_JLX%YEN=YD$5U,:K:"
M"^(-U(\HWA4I9K%UDW[N38J?[.W<#:P;6#>P;F#=P+J!=0/K!M8-K!M8-[!N
M8-W NH%U ^L&U@WL;SZPFZ66'';QR4>(3^YV\<GNR+9%(E^:2.17B!2I?V=E
M<*S__BY)1\&?0#SO4,4^P=D\<)3R:TSQE0I'[MG),;*)7C"Y"R:2<+1"2<CF
M[$6?R5WP*Y84Y6@X"ZK,8\OI]#GS1-)4L R'%VR$E!7O%Z$R(1XN^5<@D1@E
MPD2SEL&'EH.(@T- TRK9,RZ+4$%<^[-+X5)N6XV<*[1AJ(OR9(KA93PJ)R[=
MF1U;6TL[P1DPOB;Z)S^*UOX5(F2[2F90-=!PUS@A6@Y?YD0^:+8WQ[%1T7%+
M[L*CTWN_ QL,G+#(?E.C)7.VM;2$R+2?RD\XJH>-L:PAQHVQ5C"+1MO\N&V8
M! ;$L%96\U*3"&-\&$:Y0V44B3B'][HYCNU3T\!'A6P'&*K@YSP:4OU*_3,S
M F7#\LIP7"72>\2A1@I[TMS4DKT#.12JX@3+ZUQ-)_$LIO!V' &;&O*TFV_I
MKHC^*Z')@/3R?O@1>1-O+/4GX.PK"7Z[,ZK,IGT6;4+[_*/@7V,N9NTQQ+E"
MCW4KL3)(,E26&MLCG.;#8XJ*Z3N0-G%.EZMI0#@#D1/JV\*) N/'L^8C9PXF
MP$KT/Y1N$ZJGXM"CZRB92 TDO $(28'%PN;QH-!W2E"O<@27/! 48C42?6//
MYSM%/-RYR*Y_2][L !_J\]]<>/ZQ!L80#AF^.\R6*=2-\IKU>R_^,U3Z;$&)
M&21BK?W]OT)3S+;ZU\,7_TF1=;V3(]I-W(NLB,UGZ7#1Q<IDV],R+\J(B,29
M>C;H[VU%V_"L] ^V1MM-@N6_T^,\1OH^_?=<_YUKS\BVZ[-<9%E*Y6:B(DNU
MG$#U%'W^F=TM&L^$9U%+G%Y:X#D%3C(]GCQ+P228+)15$$)_"H#%\:33]#P:
MY;#F?/<B11IT(LN!55")!['8B4IMX^A/#7?T%4CYJ=Y-YDQ)2</N2RYE?RT^
M!);2NP\;WGC[+##//W=!)]<I92^])"/_<"K_>US$PK[UO@ZS0<<)"/7@_HNA
M-JY>FJED(!=XW<'5%*H(*GOH/Q8HWWHY0]B1>4Y E!*K:.$3E0%3/H)3>&NA
M:)06N[:/32^S5#^>)2#7[JIZX<.OJE@'1RC[VBX9[OPVR']^HXYF,_WG4R$)
M_1RSAD9_[;\\[ 5[A[\5Y?3-[%);"?J_P=E,WP+ZQ3DK00S[>SWZ[.\@O9P]
M?MC;Z_7IU^?Z<.,:_A)L[?7VMH/=_NL7KU^]ZM_K/!]@*;LNNBZZ+NZ^BWJ;
M:\'?'\OS<>OA/MHZ_?TZ7L.]_KISKS^">WVO<Z\_[2-WEPYGSW?^ROC.]75\
MZEI2X#LZ9JIUM]3: .BAV<#JG.D5%S58N*O=OIA4LJY3>CVW,-"CQRD4-Z22
M8&P )U#D8Q0WN4!GF:KZ.GW/8,C=25M@!'*)>_%95FUF\O&R1\KX;(U#/&I=
M&V6]G9"RY)F7WA!E<!M@6'_%VIC#"?B+H#Y/#L4)JA5%8''%I0%T6HH=Z+(.
MO+ISCNE,\_@ZR<H"RKO5PSO.^MGO(</86*CUS6?]:I+HG?'*R+E).9[/)2F,
MVX1*R[5[1\CG GEOOOM3AE8?E<.]KX57.>*L36(MDC"U;:XT4NKK-YJ1+TM?
M$EAYFU*7H,I,/(II.$['6)_4F5G%N0XU2\SR32"%C6L8J2TZ.5C?VGXD\V<U
M@F(MN"(VO<GZU*BFJ+CC&X(X,'T,XIB"':8,,B3]@ ]ELEBR+Q D2=+MA_2=
M6(7+5;"J"MB-Q^'I7ZUZV@]8$WNI,O9#K60]-[W[4^7-02WOMH7JVULZ6UP-
ML@FNVN'>K^;!XO]H):IE?*\/?VI9_[L;-?@XC]!OCH.PN7N_1<&E%JM__' Y
MFTU_^?EG)XCP\U$^O$RNX^+G>'01Y3_K,Q?]W#\XV#_L'_[<Z_7Z+P_W]/]V
M7^I_'AR^^IE<P/^=]'M_O>CO[O5W#W8N9U=&)%[H9E_H6<+E_XN\)S^\ >\[
MC@G\][_]'+WQTES;LERE")-Y=_4<)E*+*(>74Q\DBF06TTG"8;XYI-1AS:(2
MCA0X?RE7D9M]^:N[7:84^YIBY^K+3;^[<7M/4F@?0%#]#%.(T> @3)RFZ3&\
M*TGN[;WNBR0?_K6. /]'I(]5OL A[O9(CD".P[L:T<N7-QS1NWB0VR'=_8CZ
M_?[^=XRH_^H>AG1P^/IF0\*#C^-Y:8<3;,W63ZD.UDZIQJH[+6G5. 1.BM_&
MKWHK4MQZ278/7E=WZ<W1-$\FKDC\BMWK7KN+[Y$O/BJB!UGG4Z?H. ["*5?E
ML2TTA)YW&\/-<*E^=BW-,\M+<2<7I];>>@<O7_X\G"33_SZ,UGWW]6U^1,?N
M'1@''[*=0+?Y8K_7>]7?#NF>QQ7P[GJ"K-DI;PT:@^Q87%,NGJ!/I[P?!I[1
M8>/]H. S^0"]+Z*&Z'6&BELX#MT-VAXF%N[LV$[C$6*7V?>KZ ^'I9D0&4>S
MW01^#6,4*;'MX+9#/^.,;55_QQI$M2"81 C_&<)_]H.EB FHN$I !SPH7/&0
MW"L)5 %L16D!]B=/,O1DD/('W MH<BUSZU#92:A("H<Q;^S<]\&8GJ2HH%,1
M4_H2(NT*W;<I)+P#9!.75)&VUH'^\ 0+TUOCT]TGUSPUIJ@:E#/'%'6WQ=:*
MU.TG8[:M]6?CD;5&-\ U<Y0Z(*U6#QK:]T&D#)1NB5,DQ0WVOX]N"F]O] ]8
MBC4AT)#Q5-#5PM=*T21)LTR1SVUF$(J1,X6E8$B>AP$ZUH[FJ()]I/->M,]7
M\2P*;Q;L<W)\EOXZZT9;9H\KQ;Y'6JV0:Y\2V*GE>R$<*P<I%/T-8#J-"!W!
MYW@[IL@C5.%TLF^=]=]F_'+YOD-$4+KW0*LXA(&%!7EX((OY42N@03.!KW00
M((  !80!^IM#@,QVG:8@*UBL-427N8/_]-VVW@%H\(]6H97,,:7?/D,)Q<"_
M'3U 5GVXP+#1BO\/9Z5@.DJP-!UE!Y19+CS\C$3Z?IM; A XZ'4 @4< ".QW
M (';2'4E'OWP?+N2W?K=I[2U_;N;W^/W\F4*NLYNN-OKAX=[^\&925X[IL2U
M,P@///0H/N7QBW<E!C6^1GD><:+!IS+7;U01*SO*ISE^[KMI[#1B]=@COE/I
M6H)BD;79#_=[>^'+EX<M\R5_U00RWU33[H/;H+*J]SYXYX&^CTUXE+OQL>_F
MKO\5_1_>;_]'7]Z^/3T*3C\<[SS2(CP>$_\SV/VN_WOM_]/GCV>?3H[/OYS]
M7=<@,?U_?][K]]8$<,W$?;1@!F_>1O,B2]5_1-"_)5L(R6ET=Q#7Y[AVC]]_
MI9CJO25//Z.<H:Z+KHNNBSO7#Q_W_X?/8&G_;ETL\Y#W.P_YPWK(?PT^(IRG
M^"7X(QF-XA0V@+ONW.9WYSQ[.#?=IZ//Y\'I*85-3S^\^_CYSZ/STX\?@@\?
MSX//)__UY?3SR=O@]$-PMS;4^N?_V696]'MWFUHQ>',ZBZ^"_IYO#RU)G>C=
M?^J$'M5'1-) 9;24$3NG!0#:AI2#]!;@8\F@Y!"P/_+GB@0\]\ ;)*(%%$$C
M3CU*Y2O8?QWSTJAIM,!/)LC-DS)&TZ#.BFA"\?@Z=:!%MNX$1Y#Q=045C@#T
MELU3A*?$>F1 <%08N%"%MA!&(J!!!2[UI"B@>P_@-XX?%--VHS=V_7&L]QJO
M.MOT6NC6M/IPD>OU'D&+6:Y?JHO!UN[>8<C_VVZ] @ZK;QP]X2V[$BS9E99'
M=-=_^=MNHL91_-C29K_E8=X+]_K[._N]MJ\U=G(SH'O[DG^]3&9Q?9WK';X[
M_?#YB$%@L'"%#'?9.BT?=_/G>%5VPUZOM].KK<K]+<5JZ:OW_3Z^@#R-./9O
MI/M>FU[OP5=G;4$YHBIQ$%&4PI(/OCX'ST)X/N4)5M-[J&5Y%1X\5:$Y1RX&
M8!ZX$!2\W-3Y@XO/PZ_3:NGA=]R86GU0$O],"GC3HS3.RJ(ZVL9O+%FP5=;]
MN@MZDW9XP??#EX<'.R]K"]XPA4=X"ZNCV-TY@*4\SV;19-6(^;,W77;\6C#*
M2JW&K:5BW+ 5<T^VO2.-\V@8R<]U2^-A5-QG G)MLQ,[$[S1!-]_8B;X:3J*
MKU+,3I!\JK=)KNW++*<7Z>-8_RW.BXTQP)G6VLO#L&S]DVAN$M@PZ49A97+]
MZRA'-#MG1^X?R*?>_O/X/63)7"<F>2<RWPA<UEW VR>\W@M,)8(<',C9FU]F
M,"AD$(9OS2[S6/>=VH2G:!2'"A)SP/33OX-OVT^% 91"EF01YAV"<L8$]B_*
M!/,P]2B'<0R? YZ'&+TOP^0ZF83!,$\@IT[_*QKI?[ %>1U3WA-D6R07] NB
M<5%(XP+_-Q3"*\J0PLP_N'Q-37%G";9#2GD!OF63=1,-.6,*/TU+@I02$7P&
MI2\,1BR481#KV66+&$>&NI1JZ A7,L&D&&BIB/-KS)41(@M*_Y$O<I_K=TD<
M^)0(YK&! ;'&+,ZG.:3X,1\0;OALP=N/V>I&S_.X>O1#E*?QPC,J](K]3SFZ
MP+P,R-Q-65$4-\X4REHG6)5A-N$$2Z#A &IJTC$-M[7N"0@@,.O(G7:#3PG_
MO$QZ6-Y']8W3WZ($NHLL&^G-U<WA0"!Y+H"4?KUDE[B2!>Z$&=X@GB3QM9'X
M!+-#(9TMFT)"WT@8LYSU-MDF ]C-!%8^9M=96*O( %1((N4BM959749 +V0'
MI3N+RH+9JW%T--]+DBS:_714#HD")9E,P%C>"8[6./_JYN>?4_,6-SS_E.ZG
M][#QC*K*FM[H@#IGQ!R;QL.RWOE4+>?3'=Z-NFTXH\&Z9U2M?T;-D0MN?^2(
MIV#\_]J[UN>VC23_'7\%*IN[DFXIF6^)R255DBS%RLJ6(ME)+E^VAL10A T"
M#!Z2N7_]=?<\," !BI1(B*2Y51O;)#B81S]^_9AN?",=F.9G+=XF3E.SX!/<
M9T]RG_G\ OQGS<]_VHTL;C2Z$Q@#;Y7B%6[LSD*+#Y(8I9Q+A4#8"%>&M?;U
MU6X\8:K+)H_=@A&8@W)13]=SS3X/QARIYA^6U?/S1L*YP'[@';A^XJF+;$-
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MDHQ3C=EJU4+[U+#A+1V)U5Y905&_\GX_Y&/=EEJD2IWK4-;9@+DA?)'IR"H
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M!X D#]ZS\ N/TQZ2XI:33OZH4 X4)M.,8ID5I*.@7>%![/+X$9TQ)S0#&Q3
M(7U^$O7PXBPF]IQ)EY!X&:"7JZNSM%0&^_E%-#![F<<'_\H[Q^6^I-HYJ#4.
M<%=6_ZX"PEP?SJF7P3FSA>\2^*H-?ZW53+ZJ*[Y*,Z.0S&\\JI)NO^?A/77
M('X1:?L7O!LF6!8:KWI)=A&U4Q#0OPL\IQ=4B&,JBGW$,/9=TE5?J/PYXRO[
MZJPRQ6_Z.1Q7U&0!-A/LM6JB+(?+Z@>U(^2R]NK?54#$Z\1E]8W03V"95MNM
M5AX?S5X@&@G(0XJ_SG28=YL41_V@7D>27@JU;3A)-S8$<DV3=&,^DC[+]C.X
MS/0S@ \,B;ZC\6>]JX"$UHG&-T-L-Q'^'+^<QG5JN4K@?HH'S#QJ :4TB%+Y
MEUO&&T<E&0X;P!N-+3 <6E60=$?M/,Y9/F^ 0=T;V'512**U35B_>5"M'8A%
M?0.,T3ALKK<^ '.XWNHTRZ1JF;3;?K&<)X)]P>^1%NO2[GS!,$1F:RIX<[EL
M=43X;$Q2/VH?+8Y)]'6 65G'$V3Z5EXDI.0Q09;96R#;A$*:!_7.#H6H">:Z
MES8/A32/&\=YO#)7#O[3W)"Y6+%-R*-]T*A^.\CCJ0D>;82YFN>2J<^C&D['
MJN#PSOGR<FK.]6VL$S4?;P0U4TRW45T<Z&2PMR3MR?AM>_O@2^>@5M_!%S7!
MSD;0./P5T'SK3<]S1X+"6XM$A>1=>MF1((T-B4IP,,#5U1E=-(+OM+59#LW?
M'=3>G)1 ];6#^C%2?;4,JE\*&%H=U3<W)'0$?VTTJTU-]<W%8J%GX@KK%$3?
M*L*N50^J91%V =VL$V%O1KQH&H O2-J7-]?VK;I?2%T0=(63#-7?J#OZ4@-L
M$XXI$:MO .&7$ Q:#N'7:NTLX3?F(?R):P'IY=MR*!JD;!DDW3AHU$HCZ5R*
M>2K->.ETFVN%;)C[$*BZT3CNI%3=Z2BJ5@);9B/*9$,=P;GCOJJ3N%%.03.Y
M\ 7#-%\QR--$E+YR66D*NE:6)&Y"?G"1J?CV8B&V=M<,GCO$G\\]TW;)9]K.
MGFD&?.U.=3FGVIJ0$JL^U9;"XM<CUY> XXR%@>?95]1U5B>*;_R)O-ZA/H6W
MGN&BF#WD/Q8?;TDNC%:UH5P8B!06L?/,6PMHX]OGHIHJ?("%91XX)7QOFT-#
MV'4E.#2 S.9&P:]CV,$,%W=IS![R?_[GM3C!=&$#)QS/%:3)%A=\SSX#7O[D
M4WE!JLX0V:?8P+#'HEC!ZJWBAS(]UT!MN3&_M>*'Q3T=ZZ@8\FS&N6+P%VX(
ME)Z)7;Z^9E@*U3S!!\<'M6I)SI%.9T7!^>5QP>)^DZ5S01EI6;5&RTAA!*9I
MJ;2L7H"WIN=E@S)\*Z4Y":NMDC*N@,[F?LMJA?[B*;>;(O07L@>$8^%:^,%_
MH9C^AR#&NK=XISGS;0J<1'?0G9)8OI)8?^-A\>S<3>&;YB)\<YN67A5,@A;$
M- /E/W;RR$)GQT\E\--24M)6RD^+)_AN"C\ME%!VZ3M)3]:1G*F2BA[4W+1C
MEN<RRVJ2S*S_554_K9RRLT4%*9?ZP!REDUN[TLFO4CJY^4V73BXBXK6M5KJK
M53IK1=-\8=8OG6.9&U6K=,9J"VIBEURK=-8$UW1+EE6K=*V67A:'K^7BVW,>
M^W-JE;[,\EC\,M:F6![MN2KE>.X(K DX*]9#2YO*]8$17FOLC/#EVA5+J1>X
M4B-\\3M;F\(*1Z4Y@W=\LVR^R74-K17?U')3"#:1<9K'[48F+#C7[9FTF_IU
MOP]\$MKGPY$7C(DQ4A;!;E_OW=Z <<^^8H\>]D\3]X*O>W%@5'6NE<,LI5RG
M 4ZIM4IBEJ+LOO5BENU(0,QCEKGR3!9@EAN.UXKO!@&7_=]WW+)<;EGS2A'(
M+9MQ_ZQ>K1X=-6J+<T->8K\D\P_!@ZSUWR0ZKV\3G=<.:LV#S**^<3HOX;[:
M$NB\@04(S8*T+Z)SE/'MJNB\+3N7FC7>:J*@9F.+Z!YKO-%-S*5D>&P#W9=<
M\W")=#]7@E4QW;=V=+\RNE___*G:=B10 5\<=ZJ=9YC,.9B_8O-^GY,75G9N
MT1!(UE8&P%_4Y^C78.#;YX?V>S8(?%[258URL%+]H'9<'N]L@ 5=<C7$)=7)
MG1<JS;KSNZN!^ZWAHY)K)2Z/UA?*/\\T1[[%5!ZC^]V.Z+\U<+09Q1,!_!QE
MJFW-"W[R2VE-=7N<Q$"M@I:/?V#"EGV%K"-;/(H@-K5_W,IZNC6P)5KE<<SZ
M0Z+\2[P;P3%S8:*9^F''+VO&+ZN!54N\Y)H?7ED[=IEJ'S"O@M&9'+J<78Z:
MR>\@L#4T7V8'@47+RA0G#"Y$:',.LP)ULQGE4//X9UDF^(YM5J<JMI9M-B.8
MG<<V"]Z*?=J:W_'/4OAGH;#QQO//9@3)@7]:K?HS_ )IU9%:1;.)-]9L4L%J
M)#*[]LKU>4%-[IUA-#^W'NU XLJX=3-"^\BMQ]6ZR:V-A>ZLGW\%MO/OIRVK
MD^0^B6*[5::.JU4/?BLE UXTARB';1H+4=+&\\WBJ0'_*)UEVIWZ,]QX\T7]
M2>?5E,HK#/C#ST(^MC\.0C9D?DD73,IMI;6SP9;/79O12K&-#2UJS>>[_F1C
M@+MD- K"N.RZ*&5U:M'- G;@;<ELLAD]&O/89"$/GV23*S"@#CZ-=FRRTR8F
MB>)R.B5P@$&^]4ZV\\/,$,[V=@MX18)92>.!>D'+TN72T\PI3%-;73>T/0M\
M[/B&!/>.C7V7V__-AJ,?5>'S"M9;XR,._X&'A'N78YORFZ3KN3W[I-<+$C_&
M#D07+E9J64Y9W+6ESN4*S3]?5."C3@V?5T52!F&<L3#;J\3><_V>EV"C(=>W
M9S4\D55=;.JXPG[>?^WS6+LAGG/JC3(5$XB*QNI$Q=J<PRL.L1JU4VI+WG^,
M O;4C&Z"1\#;V((&-'"8O:EAS_YI*FX"> C>S^(DY%2U;W^G;I8&>8_*!;RR
M-,T9\WJ)QU3-.U$!S;[@W/Z(51!W<N*%<J)6;:X2)<#'5,[3+*5EOP6K'4^2
MVWL8>720=;&H&:"%>("/>AC$_//T]LIV9(W#_</7WM^U&T(?=4X!W?F+?AIE
M2NUJUO#YG$2QVQ\7U@(%OITHJOO,UW[W\[^+_T=%4TNI>#JCL"DQU$Q2UP<Z
MK:OZ;.AZXQ^>FLR47LOMF[7$\3\&=I?;?2PN2!%_E65P6&!WE+[^F8W#<B@U
M#V,\]^5GL$@& LGU^T$X%/JG!P_!9\*N 7$5V<J &; (]I+[-B!:1O7\,13%
M1B/.P@C#5]@NO5[]\4_\'_V]]B-^C.+.<:.>%T0(64#!17 ,]F.0>)A^83/\
MECD/#%X,0C0.Z!<JCPJ M!29P$Y?>#SR6(^OR^G-O'B\XL,#4P.6B+W:X&G8
M.(HLXNFA!K*#$/X^!%,D8@ UQS9LFY^_:TJR+D'"D:A<QCA=K0.ZRY*_N6*?
M7K77W0=%[3._YX)M'V'_.]K+J#?@3N+QZ!"G8=^I?UI^$-L>FG9 _5W0_L 9
M\!]BC6#HQE3*E_=8$G&B6Y.[0OYWXJ)%&)-<BC@51(@'^&#(D14C&X<'K@*#
MD10"G"1\& V"1U]Q@IZM=:=F&^%S\$L>B:'BX'!IBDN=Q3<QW!R%\MN[0OFO
M4BB_]4T7RE\.@VP.R)PXRX+BX<_5GEA['22G73LZ?*K&MIQ I_I?13IDF;/Z
MA+5D8_8%CB*:FMHJE/92Y6?!#NVQ??LC*"XJE(O>*]" 80KP4&$!.$_DTGGT
MPVJG4\J2:[#D@"R/BNTD(7ITF ] #(8("%R#?=D; !SNPY98H+TC!N#"9B%"
M"7QZR!SX*;-'010?&'EB9GM& NBA>>5 XY>-WT/YH4O>='CPL-YR_>]^=@]Q
M7Z4[5&QI&$0CV)TDLC2^ G*ZPPV#':E5@?SV&OMH>2!Z,J+*)SWRY=<ZC<9K
M+.7U]E!L8LC['FR2@I7&/N*V]L&.(%C)'PA@LM"-B(K[6)D4?Y 2)2;]JOW-
M)T=[+Q _&@(YPS.(!6:0-HJ$H+]O$9-48(:@*%TG89XW)D0L9LSN[^%M\(8*
MC#@*.05GF-T'28)CQ8#G97ZR_(&)Q5/P+;_,G_@A%@!'SQU\XJ.&M/!9Q +W
M ?RK0B0(Y @@(2*T[G#Y=QCV(?"2H;!Y4ZHCE@<:W7/%AL4!3M1!)1G:#\Q+
MBGX@3&:T#_C7'N<.S(3%4HX\,B4(\-%]89O#S!S^X(H584<1>I\7/.(\!P"&
M;-AP=6X<*&9(R=M#]M4=)D/Q7CSRD/9PR,9HM$BJ41X";O5END9*/]+A0MW%
M<6B\J^%&$<YBE(11PH3TN@5SRF[6FVB!N?U*SJGB/\4)1L9VXMI&(19E3T_=
M#ZPAG G\ G1QO8IRED@L>_YJ9?H5Z1K%@%-$(9T:$R[ZS"VO"\Z5NX/4LB5_
MFA)V/F5]8R)G6G CM85HQIIL240#AXJ4I)Q!Z+W ;7=P%]UN0@\B'\#I/[A!
M$H%4D"XF399%<@@HWWRW(I XL**D-\A(B-ER82M/#X!+';$:BRM4JI%V/PE!
M4)-0<K J]=#U%9KQ7##5/#<>6Z('0K%^K=B<P?;2'A>*_6@  AYEC(,Y7LI+
MPFP?%E1PG"%'KH3I"%*Q<L2F]*U42&[@##7/HYC%"1D_8JA\\#^P<07S$8H$
M'@?JZ08^Z!O7,0:5NFNE]%$2*33V!4P8HI>+]$?F% !D#3GSZ>("LPI/%0E%
MZAACHP7(3566U&/P,G1))WX4@*ZCTX =)Z+3TM<\PVW8YJ;@N.4R'$HOAEH-
MIC#.DKS)(C1"@5UFZNH9ED;%0ET:.M34P1SQ$=^"E@R/!V#S))%@H8@#4TU0
M@Q+T,LTS!# P13$LY)JGT5Y" L'A2*2H'UH9HDPIKP_P*GC$V?0 C"0^^LYA
M%5%EU@8\NH+]&<T9MWMBFB12U%,]& XD@7#O6C13FB<N=U+,3,U[B\VU$[+1
MN.<B#X<9>PVVQT"-LZEQ0M(;Z#3K5!?8,P]G?F. 2^Q\/^3<5IR8,94+MA..
M:L2D#0WG@W*>@Q[L/W$\\"@Q./Q)70S5@8QG_.@;.Q!$P"@]P+Z0FHP$% (&
MJ^"8BJE>!FJ%ITAB61.\LFZ0Q$\<F MFO2&4X+5@9(-=N=#)_XA"\)LZR ?!
M671P674B+'+0E&2OH *0-H0^-O3JS6:**26SK9;&MKQCCI#AT2YD^"HAP_8N
M9+B)K+0J0ZLUGZ&U@)$%LII"$%-VBR'/,7TCZ7Z6_BP!1AO5,^D1F?*:%GA(
M+08*FH7T:C:/-T2I(')2"UU%SM'\GQ+2&).%Z.LYGA(,2'^:SI5'EIBMBP/"
MAB%;&;\\J10X3_02?,<VK]#,\-@Q;1E0F,&E'>V[8103XK1$0$)['GPP0P_M
M&XEE*O8@>.0/>#*DF_W &)F4,=G)Q<Y"XWR4<E=KF)RSE?EA.KA*\,4%I^V^
M*51 .^,6=@%W?0D&%IF?530_XX=HLU8H.R] +X&V9\G[RH3W"T9(\\GZ%)]$
M?T(0:NM5'P*<=C("+,,="H$, P<8CJ)(Z2M%L()%>F,66]<C*]YX.W_C\?4P
M32O=_R%LMPN/>N.)E:@ EE[1-OB5VH:XDZ(N6HH7MR]N* 23H@[#(+6C'Q'^
M^@G8(V!)8@$&4Z)%*BK;P*0 <H_(#UI[CHK16L;;TQ)#>AI->P_$1\5^1$^K
MD2LW-3L069S*KG ,JON\#[(#8PGSS],RIV4_,:U]+2%F<?0LZBUP@%OS.\#S
MXH9+<X!;WYH#_&C?OO2CH,]"E)5H) U]MR^-/>(KQ3NP=9:*D#^)&F0D=81<
M2/FBL*^.&P+)!2',,!#-02,Z+Q+! -+)+P ?!GXTS7@FZ6;CT\*HCX2K4VGS
M1S>2P54S"T?E=S,'?D!DPW1N0#"" T^][\:Z<(Z:&=) KXJF97<,+>-[YOH1
MSICN1([ U.F-<7?Y5XSE&@$\W#&""<))&Q*:KL#N<G1S]#BR_"&<CPBV/F@=
MP^R>Q]PA[H$U.0'U=IJ=<7;VG@%S"!HR4:M)FNJFWZ2/4^5^1#%IV ?ICQXQ
M5]PQT$>I3]*B=.S)<\PY1KERF%T/MJ*?>,!X?7R5<A8QDDJH;EVE)3$3  ;=
MI\V%_0NES!%Z;<ZIN)3Y[TM9K /W,^(U4_0C($7B4QA@FFS0UX377R-.SG]K
MR&*$;9KJ(A['\I9&9GZ8*N)0K2P T< N K' 2!)'CF +0)>C_OX,<XT<5ZP!
M7P_F7B06-.!TO'E$B=XN@2D7)TWE^K_'2V"^F#VQG^N#;&3.Y\11E*=$+;!'
MLA7HXIAR^JQY<_J(-Y<5Y5CR$L5_#UNN7[18=]^^F!=%Y<I_*X.B)G.1U+T!
MG:-3F%.30<&%(;F,69:,3,/,4DI%W_)AQ6^;EGX%UBFF.\+^8"@3_FAVCO8&
M^\5ZD&"%560:SEI7:@L2/G&%7>!PD/@HAK41N"P&2RFC?)*3-#=O1#C=;FLF
M>)^1=,=B11E1/E4LGJ Q%6=ZK00-:U7X=&4DLAMN78>;Y>H_WKGZ7\75?[1S
M]:_G74M="*HK;\JXSD_? 6#\3EUMN;O\Y</)QT^WYW<KGT,9P/@FDS7%57J*
MO*4Y:3]G<2%@&=+'.>85&DH.5@>FFZ6.0$F9/.2[U GJVU1#[^Z@IFZ:"H".
MEEX<J;#^=!BZ8I%R3-#M3"]C23P(0A .CD[/[B'6@!F?8C8Z13S$Y_1ZT3G&
M"T+F!!4[D%?(&Z%C.XQ^19TLJ;YQNTPC:(/NO<&OD"U^^JZ^S*ME)Y_>OKT\
ML2\_G!T^52]H5GT5)3NSTKW@J>;17(^UJO\U+75?5@?JN;MT.OYAUE7 "2W>
MG=3B^:46O_OY3?1&-.G6';J?WOJB%:LQ9U576>*.9*<]-^&LR>S/!B[O&[?[
MKX43;.Z%;,8]RVRI152OHAB97&7WYYOK/\YO[>L+^^3CQ^O;#^?_M_K""F5H
MVG]]N/[#/KFZLD__S_[X[OSNW+X!$''^X>.=#/8*>U=X.!\'8$!;:>DT5;BD
MR_$^%.;NQFZ<Q-*C#=\&+BKLR5+[HOZ^P10RCY=>HN-*<9B(:TH>>T0O+I,%
MWZ(#0(%XL8Z\,(#CX!45X6Z%QSRPS1]%EC'&7"/,PQ3!2GS:>(#,XJZ8,'FU
M??2]'9B?B>L;QMQDQ#UONI8/H*-B4VD5>BR*.1,*GWS..%5X=X^AZD300LUX
M<"LSWVM/0J2J8Y(#M\#=$.WGII4;,70]+BAH_(H"=?FY"]->J78=;Y7-O/*9
MA5OD>Q 7=L5%$MH3$0^'27!1!4>7UZCHZ8G @8HQ1Q.N='H<1ZFD7O6GHR<5
M^QY!']XV)"P686QABHCLE(A,ZJ!/!6X#I(9(+A!7YGA(+AWB"OP TR(HI(!S
M%B1148Y;W./^6#B9R%_8=]'K=&\Q2MX'YGIZ3ED"C"2YI:3+Q1-=S7D8%Q,<
M@Q>Z JIB(^JH$(AU@-\0M#ZX89QP:VO"C,NS&.8S"=*8B[ *5-!"7Y%0<4:%
M^#7CT^D*JK8<*C[DRC)$S@[-SZIB\11RE*^NMPN<(DNM,7&GE."<I2_JLV'\
MG&MK31;06,G:/KJQ5^ZZZJ6LZRWP6&$YD 6)\05U&U=7HG6I[+3:XR!S;@(7
M5NSWAV^?-*V?5S#]N?.\"3E>2,/8N3"$SK^"%B$8)@VABO'1V8"!BF<"*+Z5
M>0/KM2!R'MD-X3Y:%2<LT7;> !K9NPD!J[LC -=3U+'LRM+?KKS:_!6\NL2U
M%O%$E<M#S_0R[63GDOR.KR8QTR.G-L%I>X>= -VM8-T$J/W!A3>>,L_C<<S6
MBZ=V<',)TWW6^:X)=VP^?V_^"EY?0IT/X<F$>X>VPS&_H,<29[U$PDY0+6&Z
MZIAML6&+G_6:,,SFL_SFK^#5A1;8I=$@8?9=&-SS]1(+.V&U%$-T\>-=%6^L
M:SK*N@^WYO.:E4[>^=&^'E&ENA_L*Q;%N^SR5\DN/RXSN[R<5A"978C5DK\Z
M7W^T+]_27_Y=/3[]-RR!^W1_F*9!/^._?KWX[%3_]?CYY/W@K\[]T=?3]M7O
M4:/?.G6NO8_G__KC^I)?Q#WO^NJ/SU>WU_V[C_UJ& P&7TXO__/@C0>G[J\?
M6*WZ^;>Q?_N7__;DKZ3^^WU[\/4D&@\_?VC?'G7_&B6GOON[$[^[>_C\SX=/
M[_Y*?ONK\_XQ\L]&;XY:=2?V7._R??_V^K)]]TMOT+H>7?QV=/[QL?;Q_?BB
M5A_T?@]_#\X?+TY_O[GZ9=1P:V_>#H)?6U_^?N?7[CXY7_X^'GXYOW3&7S[\
M\[?Q6_?TYL\___[MS_%_OESSO\[._^J<_G'UP?GEGQWVQJNRJ^:7JU_BJ/_K
MH]-^=_SNW7$MN?..?Q([\J8;.&/\<Q /O9__'U!+ P04    " !*AX-<5K\*
MF2@#  #<"P  $0   &%U=60M,C R-C T,#(N>'-DM5;;<MHP$'WO3/]!]6O'
M-I>0-@22R9"F94*:!$J:]J4C;)EHD"5'DKG\?27;,A>#"[3E2=X]Y^RN=U>F
M=3D/"9@B+C"C;:OJ5"R J,=\3,=M:SBPKP:=;M<"EQ=OWP#U:[VS;7"#$?&;
MX)IY=I<&[!Q\A2%J@L^((@XEX^?@"9)86]@-)HB##@LC@B12CC12$YPZ#0AL
M>P_9)T1]QH?];B[[(F4DFJX[F\T<RJ9PQOA$.!X+]Q,<2"ACD:M5YI7LMQ_]
M#@LO)[^_91'[,._CYS&B'^-/H^?H[AYV>AWX(!>-1NWUQV0^#?OU8#2Y_;+P
MV&T'R4'G<<P?1]^]GU?=-&1+>"\HA$#U@HJVI>O+RIO5'<;';JU2J;K/=[U!
M@K-28'-.,)UL@U?/SL[<Q&N@!>1\Q(F1KKO:/8("Y<K*BTOPF H)J;>&]V5.
M6 4WW-2Y!L5;H:<I%!NHCS9P GG.F$U=Y5#XVJD!QL(>0QCEX "*42*:.=;
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M"-.Y#*O ?:I+UY?2BP<P?B>4_L+X*YL3G')&XN):BNU.4;?>[1,S/;:;#\T
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M_7+O7[5;_@=02P$"% ,4    " !*AX-<Q#UDRNE(  !UR $ $0
M    @ $     875D9&EA7V5X,#0P-2YH=&U02P$"% ,4    " !*AX-<D0#,
M-6A.  ##[0$ $0              @ $820  875D9&EA7V5X,#0P-BYH=&U0
M2P$"% ,4    " !*AX-<GE+Z*OX+  "9.   $0              @ &OEP
M875D9&EA7V5X,#4P,2YH=&U02P$"% ,4    " !*AX-<ECI[QP2=  ",M ,
M$0              @ '<HP  875D9&EA7V5X,3 R.2YH=&U02P$"% ,4
M" !*AX-<<[NLE9(,  !R6P  $               @ $/00$ 875D9&EA7V5X
M,3 W+FAT;5!+ 0(4 Q0    ( $J'@UP58K'D;P(  "@&   1
M  "  <]- 0!A=61D:6%?97@R,S Q+FAT;5!+ 0(4 Q0    ( $J'@US[O^2E
M50(  . %   1              "  6U0 0!A=61D:6%?97@R,S S+FAT;5!+
M 0(4 Q0    ( $J'@UP#F+UQ4 \! &"(!P -              "  ?%2 0!A
M=61D:6%?<S$N:'1M4$L! A0#%     @ 2H>#7%:_"IDH P  W L  !$
M         ( !;&(" &%U=60M,C R-C T,#(N>'-D4$L! A0#%     @ 2H>#
M7-?P#?3]"@  ?X8  !4              ( !PV4" &%U=60M,C R-C T,#)?
M;&%B+GAM;%!+ 0(4 Q0    ( $J'@UQZ#M'H6 <  -!7   5
M  "  ?-P @!A=75D+3(P,C8P-# R7W!R92YX;6Q02P4&      L "P"X @
&?G@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>auddia_s1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="auud-20260402.xsd" xlink:type="simple"/>
    <context id="AsOf2026-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
        </entity>
        <period>
            <startDate>2026-04-02</startDate>
            <endDate>2026-04-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-04-02" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-04-02" id="Fact000004">0001554818</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-04-02" id="Fact000009">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2026-04-02" id="Fact000010">Auddia Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-04-02" id="Fact000011">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-04-02" id="Fact000012">45-4257218</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-04-02" id="Fact000013">1680 38th Street, Suite 130</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-04-02" id="Fact000014">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-04-02" id="Fact000015">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-04-02" id="Fact000016">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-04-02" id="Fact000017">303</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-04-02" id="Fact000018">219-9771</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="AsOf2026-04-02" id="Fact000019">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="AsOf2026-04-02" id="Fact000020">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-04-02" id="Fact000021">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-04-02" id="Fact000022">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>auddia_ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="c_offering_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="c_offering_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="c_offering_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="c_offering_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001554818</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0001554818</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">AUDDIA INC.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Common Stock, $0.001 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="c_offering_1" id="fee_012">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_013"
      unitRef="USD">12000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">1657.20</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_2" id="fee_016">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_2" id="fee_017">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_2" id="fee_018">Common Warrants accompanying the Common Stock or Pre-Funded Warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_2" id="fee_019">true</ffd:FeesOthrRuleFlg>
    <ffd:FeeRate
      contextRef="c_offering_2"
      decimals="INF"
      id="fee_020"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_2"
      decimals="INF"
      id="fee_021"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_3" id="fee_022">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_3" id="fee_023">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_3" id="fee_024">Pre-Funded Warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_3" id="fee_025">true</ffd:FeesOthrRuleFlg>
    <ffd:FeeRate
      contextRef="c_offering_3"
      decimals="INF"
      id="fee_026"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_3"
      decimals="INF"
      id="fee_027"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_4" id="fee_028">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_4" id="fee_029">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_4" id="fee_030">Common Stock underlying the Pre-Funded Warrants (3)</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="c_offering_4" id="fee_031">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_4"
      decimals="INF"
      id="fee_032"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_4"
      decimals="INF"
      id="fee_033"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_4"
      decimals="INF"
      id="fee_034"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_5" id="fee_035">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_5" id="fee_036">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_5" id="fee_037">Common Stock underlying the Common Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="c_offering_5" id="fee_038">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_5"
      decimals="INF"
      id="fee_039"
      unitRef="USD">12000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_5"
      decimals="INF"
      id="fee_040"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_5"
      decimals="INF"
      id="fee_041"
      unitRef="USD">1657.20</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_042"
      unitRef="USD">24000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_043"
      unitRef="USD">3314.40</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_044"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_045"
      unitRef="USD">3314.40</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_046">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_2" id="fee_047">Pursuant to Rule 416(a) under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_3" id="fee_048">The proposed maximum aggregate offering price of the Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants sold in the offering and the proposed maximum aggregate offering price of the Pre-Funded Warrants proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Stock sold in the offering, and, as such, the proposed maximum aggregate offering price of the Common Shares and Pre-Funded Warrants (including the Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $12,000,000.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_4" id="fee_049">Pursuant to Rule 457(g) of the Securities Act, no separate registration fee is required for the Pre-Funded Warrants because the Pre-Funded Warrants are being registered in the same registration statement as the Common Stock issuable upon exercise of the Pre-Funded Warrants.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
